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Abstract 
Adaptation of cellular energetics is an important feature of tumorigenesis as a vast 
supply of nutrients is needed to accommodate increased growth. Essential energy 
pathways includes glucose, fatty acid and amino acid metabolism, where mitochondria 
function as key orchestrators. The main aim of this thesis was to investigate metabolic 
rewiring during cancer cell plasticity. Providing knowledge on central metabolic 
regulators and markers of metabolic reprogramming may present new therapeutic 
strategies to overcome development of resistance to cancer therapy.  
In order to identify metabolic rewiring associated with cancer cell plasticity we focused 
especially on cellular energetics in epithelial to mesenchymal transition (EMT) and 
drug resistance, which are both well-documented examples of cancer cell plasticity. 
EMT is important in cellular functions such as wound healing and embryonal 
development. However, this process is hijacked in cancer development and is known 
to be an important mediator of invasion and metastasis, and associated with poor 
overall survival. We found that altered mitochondrial function contributed to 
development of EMT in breast cancer. This included reduced mitochondrial size and 
network, and reduced mitochondrial Complex II succinate dehydrogenase (SDH) 
activity, which resulted in reduced mitochondrial respiration. Upon analyzing gene 
expression data in breast tumors, we found the SDH subunit C and EMT to be inversely 
correlated, especially in basal-like breast cancer.  
Upon investigating markers of altered response to starvation and fatty acid oxidation, 
we found pyruvate dehydrogenase kinase 4 (PDK4), a central regulator of pyruvate 
metabolism, to be upregulated. We found that PDK4 was a sensitive hallmark of 
cellular plasticity as upregulation of PDK4 marked the metabolic shift from glucose to 
fatty acid oxidation (FAO). This was evident both upon overexpression of central FAO 
regulators and pharmacological FAO inducers.  
Altered PDK expression was also evident in non-small cell lung cancer (NSCLC), with 
PDK1 being upregulated in tissue from NSCLC patients compared to healthy tissue. 
Acquired drug resistance to epidermal growth factor receptor tyrosine kinase inhibitors 
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(EGFR TKIs) in NSCLC remain one of the major contributors to the high mortality 
rate of lung cancer, and is an example of cancer cell plasticity. Therefore, we developed 
cell lines resistant EGFR TKIs to mimic acquired drug resistance. We also found 
evidence of deregulated pyruvate metabolism upon drug resistance through 
upregulation of PDK2. As PDKs was identified as a common denominator both in 
NSCLC patient cohorts and upon acquired drug resistance, we tested the sensitivity 
and effect of the PDK inhibitor dichloroacetate (DCA) with the aim to increase 
therapeutic efficacy. Upon DCA treatment, we found increased pyruvate and lactate 
oxidation, while reducing glucose oxidation and lactate production. We further found 
that DCA reduced growth alone or in synergy with EGFR TKIs in both sensitive and 
resistant cell lines.  
To conclude, we show that metabolic rewiring is an important feature of cancer cell 
plasticity, both through dysregulation of mitochondrial function and altered pyruvate 
metabolism. We found that metabolic rewiring mediates the process of EMT and drug 
resistance. Rewiring of cellular energetics is a common feature in cancer cell plasticity, 
and we show that inducing metabolic stress through targeting pyruvate metabolism, 
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Cellular metabolic pathways involve anabolic and catabolic processes that are 
regulated to support energy homeostasis. Anabolism includes processes where 
precursors from the food we eat are converted into proteins, lipids and nucleic acids, 
which are the essential building blocks of life. Anabolic processes require energy 
produced from catabolism of the energy rich nutrients we eat. In catabolic processes, 
sugar (glucose), fat (fatty acids) and proteins (amino acids) are broken down to fuel 
production of adenosine triphosphate (ATP). When ATP is hydrolyzed it releases 
energy which is rapidly consumed to meet the energy demand of cellular functions and 
processes. The daily turnover of ATP is estimated to be equivalent to our own body 
weight [1, 2]. ATP is mainly produced via oxidative and oxygen dependent (aerobic) 
pathways in the mitochondria or through glycolysis, which occur independently of 
oxygen (anaerobic).  
Cellular energetics is often deregulated in tumorigenesis as cancer cells are highly 
dependent on catabolic and anabolic processes to sustain growth. One of the main 
contributors to why cancer has such a high death toll, is cancer cell plasticity. Cancer 
cell plasticity is defined by the ability of cancerous cells to invade and metastasize to 
form secondary tumors, as well as tolerate therapeutic pressure and develop drug 
resistance [3, 4]. The evolution of drug resistance represents a case of natural selection. 
Within a heterogeneous population such as cancer, there is a lot of genetic and 
epigenetic variation, and this variance is inherited by cell division [5, 6]. As with 
organisms, only the “fittest” cell with the most favorable variation will tolerate therapy. 
The role of energy metabolism in cancer cell plasticity is a reoccurring focus 
throughout this thesis.  
1.1 The mitochondrion 
A crucial component in the ATP producing machinery is the mitochondrion. In popular 
science, the mitochondria are often called “the powerhouse of the cell” as they are the 
main producers of the energy currency ATP. However, these thread-like structures are 
important for other cellular processes such as cell death (apoptosis), aging (senescence) 
and cell signaling (e.g. reactive oxygen species (ROS) production) [7-9].  
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1.1.1 Mitochondrial history 
Cellular organelles later known to be mitochondrial structures were reported as early 
as the 1840s. Richard Altman named them “bioblasts” [10] and proposed that they were 
organisms living inside cells, which were essential for cellular function. The first time 
the term “mitochondrion” was used was in 1898 by Carl Brenda. In Greek 
mitochondrion translates to thread (mitos) little granule (khondrion) [10]. In 1948, 
Friedkin and Lehninger reported that the mitochondria indeed were important for 
cellular function through the discovery that they harbored the process of oxidative 
phosphorylation (OXPHOS) [10, 11]. 
Supporting Altman’s theory, the term endosymbiosis was first made known in the 
1960s by Lynn Sagan [12-14]. Sagan proposed that the mitochondria were aerobic 
prokaryotes ingested into a heterotrophic anaerobe. We now know, through the work 
of genome sequencing done by Andersson et al., that an obligate intracellular 
endoparasite belonging to the Alphaproteobacteria class, namely Rickettsia prowazekii, 
is the closest relative to the mitochondria [15]. This indicates that the mitochondria 
most likely were an Alphaproteobacteria engulfed within an early relative of a 
eukaryotic cell [15]. Further evidence supporting the endosymbiosis theory is the fact 
that the mitochondria have their own mitochondrial DNA (mtDNA), which was first 
described by Nass and Nass in 1963 [16].  
1.1.2 Mitochondrial structure 
In addition to mtDNA, a mitochondrion consists of two membranes, an inner 
membrane and an outer membrane. The inner membrane is densely folded, and this 
structural invagination is referred to as cristae (Figure 1). The space between the inner 
and outer membrane is called the intermembrane space whereas the space inside the 
cristae is named the matrix [1, 9, 10]. The matrix is central for the metabolic machinery 
as it harbors enzymes required for the TCA-cycle (Chapter 1.2.3) and fatty acid 
oxidation (Chapter 1.2.4). The folding of the inner membrane into cristae is important 
for generation of the proton gradient and OXPHOS, as the protein complexes necessary 
for electron transport chain (ETC) reside within (See more on OXPHOS in Chapter 
1.2.5) [9].  
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Figure 1: The mitochondrion. Left: showing a representative transmission electron microscopy 
image of a mitochondrion in HCC827 cells (Image taken by Endy Spriet (MIC, University of Bergen) 
of HCC827 cells) showing the folding of the inner membrane to form cristae and the matrix. Right: a 
simplified cartoon of a mitochondrion with its most important features: outer membrane, inner 
membrane, intermembrane space, matrix, oxidative phosphorylation (OXPHOS), mtDNA, β-oxidation 
and TCA cycle. Abbreviations are listed in the beginning of the thesis. 
 
Despite having several copies of their own mtDNA, the mammalian mitochondria do 
not function independently of the rest of the cellular machinery as the majority of the 
mitochondrial proteins are encoded by genes residing within the nucleus [17, 18]. The 
mtDNA harbors 16,569 base pairs encoding 13 of the 83 respiratory chain proteins, 
along with 2 ribosomal RNA and 22 transfer RNA [17, 18]. During the course of 
evolution, the mtDNA size has decreased and mitochondrial genes have been 
transferred to nuclear DNA (nDNA) [19]. Interestingly, mtDNA is normally only 
maternally inherited as the mitochondria in the sperm are targeted for degradation after 
fertilization, although exceptions do occur [18, 20].  
1.1.3 Mitochondrial dynamics and morphofunction 
The mitochondria are not always single structures. They often form complex networks 
and are motile organelles through microtubule transport [21, 22], and can be transferred 
between cells via nanotubes [22, 23]. The amount and size of the mitochondria is 
dynamic, and dependent on cellular energy state, cell type, disease and stress. 














is a highly controlled process. Important mitochondrial regulatory pathways in that 
respect are mitophagy and mitochondrial biogenesis, which, when combined with 
fission and fusion, are essential for mitochondrial quality control. Together they are 
often referred to as “mitochondrial dynamics” or the mitochondrial life cycle (Figure 
2) [9, 24, 25].  
Mitochondrial activity and function is highly dependent on their structure, networks 
and shape (morphofunction) [22]. As mentioned above, the inner membrane folding 
into cristae is essential for maintaining mitochondrial OXPHOS rates [9]. Fission and 
fusion are major governing pathways regulating mitochondrial structure, function and 
numbers. Fission is important when cells divide, but it may also trigger apoptosis 
through release of apoptotic proteins and initiate mitophagy [26, 27]. Fusion is 
important for compensation for damaged mitochondria, for example in heteroplasmy 
where cells contain both wild type and mutant mtDNA. Mitochondrial fusion allows 
for transfer of proteins and organelle compartments to adjust for stress and increase 
mitochondrial efficiency [22, 26]. Examples of proteins regulating fission are dynamin-
related protein 1 (Drp1) and human fission protein 1 (Fis1), whereas fusion regulators 
are mitofusins (Mfn1 and Mfn2) and optic atrophy 1 (Opa1) [22, 24, 28].  
Mitophagy describes the process where dysfunctional or otherwise damaged 
mitochondria are engulfed and degraded in lysosomes through autophagosome 
delivery [25, 29]. Essential proteins regulating mitophagy include PTEN-induced 
kinase 1 (PINK1) and parkin (PARK2) [22, 30]. In healthy mitochondria, PINK1 is 
transported through the inner membrane, before it is cleaved by presenilin-associated 
rhomboid-like protein and thus targeted for degradation within the mitochondrion [22, 
25]. In dysfunctional mitochondria, especially uncoupled or otherwise membrane 
compromised mitochondria, PINK1 is not able to cross the inner membrane and 
accumulates in its un-cleaved form. PINK1 accumulation activates PARK2 via 
phosphorylation. PARK2 targets the mitochondria for degradation by ubiquitination of 
mitochondrial membrane proteins like Mfn1 and Mfn2 [25, 29, 31]. Evidence suggest 
that fission is an important regulator of mitophagy, as inhibition of fission through 
Drp1 mutation results in a decrease in mitophagy [27, 30]. 
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As mitochondria are broken down, new ones must be formed to sustain metabolic 
capacity, a process which is termed mitochondrial biogenesis. Mitochondrial 
biogenesis is complementary linked to mitophagy and involve the cellular 
transcriptional and translational machinery [25, 31]. A master regulator in that respect 
is peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC1α) 
which activates many downstream regulators of biogenesis. Examples include nuclear 
respiratory factors (NRFs) and peroxisome proliferator-activated receptor gamma 
(PPARγ) [25, 29]. NRF1 and 2 are known to activate transcription of mitochondrial 
encoding nuclear DNA in addition to mtDNA regulating mitochondrial transcription 
factor A (TFAM) expression [24]. However, the numerous processes involved in 
mitochondrial morphofunction and dynamics is still not fully understood. Disruption 
in this complex machinery is known to be involved in a range of diseases such as 
neurodegeneration, aging, cardiovascular disease, muscle atrophy and cancer [22, 25, 
28, 32].  
Figure 2: Mitochondrial dynamics. Mitochondrial quality control is a highly regulated process 
which involves fission, fusion, biogenesis and mitophagy. Master regulators of fission include: Drp1 




















biogenesis. Upon stress induced by ROS or altered membrane potential (ΔΨm), PINK1 accumulates 
in the mitochondria leading to PARK2 recruitment which ubiquitinates the mitochondria and leads to 
mitophagy. Abbreviations are listed in the beginning of the thesis. Figure based on [26]. 
1.2 Cellular energy metabolism 
Mitochondria are the headquarters of cellular energy metabolism, however, 
mitochondrial function depends on a range of different cellular processes which takes 
place both in the cytoplasm and within the mitochondrial organelles. The metabolic 
pathways associated with maintaining cellular homeostasis consists of a vast network 
of biochemical processes, where most are crucial for survival. Essential parts in this 
respect are glycolysis, the TCA-cycle, fatty acid and amino acid oxidation, and the 
OXPHOS.  
1.2.1 Glucose uptake and glycolysis  
Glucose transport into the cytoplasm is dependent on glucose transporters (GLUTs). 
There are 14 GLUT isoforms known to date, which are categorized into classes 
depending on their gene sequences. Class I consists of GLUT 1 to 4 and 14, class II 5, 
7, 9 and 11, and finally class III 6, 8, 1, 12 and 13 [33, 34]. As an example of the 
complexity and importance of these transporters, muscle cells contain as many as six 
different GLUT isoforms (GLUT 3-5, GLUT 10-11) to facilitate their high energy 
demand [33]. Brain cells display high levels of GLUT1 and GLUT3, which is 
orchestrated by the glucose dependence of the brain, as GLUT1–3 are reported to be 
the isoforms with the highest affinity for glucose [33, 34]. The GLUT expression 
profile is an important determinant of contextual glucose uptake in the cell. For 
example, GLUT4 is known as the major insulin-regulated GLUT and is central in 
facilitating glucose uptake in muscle and adipose tissue [35]. GLUT3 and GLUT4 are 
both reported to be translocated to the plasma membrane upon insulin stimulation in 
white blood cells [34, 36]. Further, GLUT4 is also a marker of insulin sensitivity, as 
GLUT4 reduction is found in insulin resistance, pre-diabetes and type 2 diabetes [35, 
37]. Upregulation of GLUT has been linked to many different cancer types such as 
lung, breast and ovarian cancers to name a few [34, 38, 39].  
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A central pathway in the breakdown of glucose to form ATP is the glycolysis, which 
has a net gain of 2 ATP. This ten-step enzymatic process converts glucose to its end 
product, pyruvate (Figure 3). The two pyruvate molecules produced from one glucose 
molecule in glycolysis can be converted to lactate via lactate dehydrogenase (LDH) or 
transported into the mitochondria where it is converted into acetyl coenzyme A (acetyl-
CoA) via the pyruvate dehydrogenase complex (PDH) (See more in Chapter 1.2.2) [40, 
41]. Master regulators of glycolysis include hexokinase (HK), phosphofructokinase 
(PFK) and pyruvate kinase (PK). In essence, these enzymes regulates glycolysis 
through allosteric mechanisms, when the energy charge of the cell, i.e. ATP level, is 
high. HK consists of four isoforms (HK1–4) and is responsible for phosphorylating 
glucose to glucose-6-phosphate thereby using ATP. PFK is dependent on ATP to 
phosphorylate fructose-6-phosphate, which forms fructose 1.6-bisphosphate. This step 
is irreversible, and is inhibited by decreased pH, and elevated cellular ATP and citrate 
levels [42, 43]. PK includes four isoenzymes namely PK muscle (PKM1 and 2), PK 
liver (PKL) and PK red blood cells (PKR) [44]. PK completes the glycolysis through 
the irreversible conversion of phosphoenol pyruvate to pyruvate, a process which 
generates ATP [44].  
 21 




































































Figure 3: Glycolysis. Glucose is taken up through the plasma membrane by glucose transporters 
(GLUTs). In total, two ATP molecules are used, the first where hexokinase phosphorylate glucose and 
the second where phosphofructokinase-1 forms fructose 1.6-bisphosphate from fructose 6-phosphate. 
The net production is two NADH generated from the conversion of glyceraldehyde-3-phosphate to 1,3 
biphosphoglycerate. Two ATP are formed from the subsequent phosphoglycerate kinase step. The 
pyruvate kinase completes the glycolysis by converting phosphoenol pyruvate to pyruvate, while 
generating two ATP. In the pentose phosphate pathway, NADPH is generated through glucose-6 
phosphate dehydrogenase and 6-Phosphogluco-natedehydrogenase dependent steps. Abbreviations are 
listed in the beginning of the thesis. Figure based on [2, 45].  
 
Glucose can also fuel the pentose phosphate pathway (PPP) by glucose-6-phosphate 
conversion to 6-phosphogluconolactone by glucose-6-phosphate dehydrogenase. The 
PPP pathway is mainly anabolic and yields NADPH and ribulose-5-phosophate which 
is a precursor for nucleotide production. Ribulose-5-phosphate can also enter the 
glycolytic pathway through fructose-1,6-biphosphate or glyceraldehyde-3-phosphate 
[1, 46]. 
Depending on the cellular need, pyruvate can either be transferred to the mitochondria 
and be broken down to acetyl-CoA, or it can be converted to lactate in a fermentative 
process generating NAD+. The conversion of pyruvate to lactate is not irreversible, as 
lactate can also be reconverted into pyruvate via LDH, which facilitates the use of 
lactate as an energy substrate. LDH is built up of four subunits, thus forming a tetramer, 
and may include a varying composition of LDHA, LDHB or LDHC [47, 48]. The most 
common complex consists of LDHA and/or LDHB subunits which either alone or 
combined form the tetramer [49]. The subunit composition influences the enzyme 
functions of the complex. For example, a tetramer consisting of a majority of LDHA 
subunits (LDHA4 or LDHA3B1) is associated with lactate production whereas the 
LDHB dominated tetramer (LDHB4 or LDHA1B3) is associated with pyruvate 
production from lactate [49]. 
Monocarboxylate transporters (MCT1–4) are proteins facilitating pyruvate and lactate 
transport across membranes [50]. They are mainly located in the plasma membrane, 
however they have also been found in the peroxisomal and mitochondrial membrane 
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[51-53]. Thus, MCT is hypothesized to be important for pyruvate transport into the 
mitochondria [52, 53]. Lactate and pyruvate flux is largely dependent on pH and tissue 
specific settings. For instance, MCT2 reduction in brain is known to lead to brain 
impairment, and MCT11 reduction in liver is a causal factor in type 2 diabetes [54, 55]. 
MCT1 and MCT4 upregulation is found to be important for adipocyte differentiation 
[56]. Further, MCT1 is known to be involved in increased migration and invasion in 
cancer through activation of nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-KB) [57], and has been proposed as a possible prognostic marker in NSCLC 
[52, 53].  
1.2.2  Acetyl-CoA production via pyruvate dehydrogenase 
The pyruvate produced in the cytoplasm by glycolysis diffuses through the 
mitochondrial outer membrane via porins to the intermembrane space, before it is 
transported through the inner membrane to the matrix via mitochondrial pyruvate 
carriers (MPCs) [40, 58, 59]. In the mitochondrial matrix, pyruvate is converted into 
acetyl-CoA, CO2 and NADH by the pyruvate dehydrogenase (PDH) complex. The 
complex consists of several copies of pyruvate dehydrogenase (E1), dihydrolopoyl 
transacetylase (E2) and E3 binding protein (E3BP), and dihydrolipoyl dehydrogenase 
(E3) (Figure 4) [40, 41, 46]. The reaction requires five cofactors which are bound to 
the enzyme complex, these include thiamine pyrophosphate (TPP), flavin adenine 
dinucleotide (FAD), coenzyme A (CoA), nicotinamide adenine dinucleotide (NAD+) 




Figure 4. The pyruvate dehydrogenase (PDH) complex. A cartoon of the PDH complex consisting 
of pyruvate dehydrogenase (α2β2) E1, dihydrolipoyl transacetylase E2 and E3-binding protein, and 
dihydrolipoamide dehydrogenase E3. Pyruvate is decarboxylated into acetyl-CoA, CO2, NADH and 
H+. First, E1 decarboxylases pyruvate to form a hydroxyetyl-TPP group and oxidizes it to an acyl 
group, with the release of a CO2 molecule. The acyl group is reached by the lipoamide arm from E2, 
forming acyl lipoamide. In E2, acetyl-CoA is formed by transfer of acetyl to coenzyme A (COA). The 
E3 complex aids in the regeneration of the oxidized lipoamide, which fuels electron to FAD and NAD+ 
which generates FADH2 and NADH and H+. Abbreviations can be found in the beginning of the thesis. 
Based on [1, 46, 60, 61]. 
 
During fasting when blood glucose is low, in resting states with low energy charge or 
when ATP, NADH and/or acetyl-CoA levels are high, PDH is inactivated via 
phosphorylation of the alpha-E1 subunit by serine specific pyruvate dehydrogenase 
kinases (PDKs) (Figure 5) [60-62]. Dysregulation of PDH through either mutations or 
phosphorylation by PDKs can lead to quite severe metabolic dysfunctions like diabetes 
and insulin resistance, lactic acidosis and late-onset neurodegenerative disease [40, 61, 
63]. Moreover, changes in PDH activity has also been linked to myalgic 
encephalomyelitis (ME) / chronic fatigue syndrome (CFS) [64].  
There are four PDK isoforms known to date (PDK1–4), all of which are commonly 
found highly expressed in heart, pancreatic islet and skeletal muscle. PDK2 and PDK4 
are the most ubiquitously expressed as they additionally can be found in tissue such as 
liver, kidney and brain [40, 65, 66]. The PDKs have differing responses to NADH and 
acetyl-CoA levels as PDK1 and PDK2 were found to increase activity both upon 
stimulation by NADH alone, and an NADH and acetyl-CoA combination, whereas 
PDK4 was stimulated by NADH alone and PDK3 remained unresponsive to both 





















The pyruvate dehydrogenase complex (PDH)
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69], and PDK4 upregulation is associated with increased mitochondrial fatty acid 
oxidation [65, 70, 71]. Although starvation increases both PDK2 and PDK4, they 
appear to be regulated in different manners [72, 73]. Insulin is found to decrease both 
expression of PDK2 and PDK4, however, insulin has a stronger effect on PDK4 
expression [72-74]. Further, PPARα expression was found to increase PDK4 levels as 
opposed to PDK2 in hepatic cells [72]. PPARα, which is a part of a family of PPARs 
consisting of PPARα, PPARβ/δ, and PPARγ, has been found to be essential in PDK4 
upregulation in starvation and diabetes [65, 73, 75]. PPARs are known to be regulated 
in diabetes, lipid metabolism, inflammation, proliferation and cancer to name a few 
[76], and long chain fatty acids (LCFA) are known to act as PPAR agonistic ligands 
[77]  
The inactivating phosphorylation of PDH can be removed by pyruvate dehydrogenase 
phosphatases (PDP) (Figure 5). The activity of PDPs can be increased through Ca2+ 
signaling (PDP1) and insulin, and decreased by starving (PDP2) [40, 69, 78]. 
Moreover, increased PDK4 expression is associated with a decrease in PDP2 
expression [66, 69]. 
  
Figure 5: Pyruvate dehydrogenase regulation. PDH activity is induced by high levels of ADP, 
pyruvate, NAD+, insulin, COA and Ca2+ when energy levels are high. During fasting or heavy exercise, 
PDH is inhibited by PDKs via phosphorylation of the E1 subunit. PDH activity can be restored through 
de-phosphorylation by PDPs. Abbreviations are listed in the beginning of the thesis. Based on [1, 60, 
62].  
An example of a PDH inducing chemical is dichloroacetic acid (dichloroacetate or 
DCA), which inhibits PDKs. It is a pyruvate analogue found to reduce plasma glucose 
and lactate levels in humans, and increase cellular lactate oxidation [63, 66, 79-81]. 
Research suggest that DCA treatment reduce fatty acid oxidation, increase ROS 



















production (Chapter 1.2.6) and induce mitochondrial calcium signaling [61, 79, 81, 
82]. Interestingly, according to Bowker et al., [67] DCA appears to be more efficient 
decreasing PDK2 levels than the other isoenzymes (DCA effect: 
PDK2<PDK4<PDK1<PDK3) [66, 67]. Due to the effect of DCA on glucose 
metabolism, DCA has been suggested and used as a therapy in diabetes type 2, lactic 
acidosis (lactate build up) and cancer (DCA is further discussed in Chapter 5.2) [61, 
79, 82, 83]. 
1.2.3 Tricarboxylic acid cycle 
The acetyl-CoA derived from glycolysis, β-oxidation of fatty acids or amino acid 
oxidation enters the tricarboxylic acid cycle (TCA-cycle) which is also known as the 
citric acid cycle or Krebs cycle [84]. It is normally presented as an eight-step process 
(Figure 6). The NADH and FADH2 produced from the acetyl-CoA, are essential 
electron donors which fuel the mitochondrial ETC.  
The TCA-cycle is initiated by the conversion of acetyl-CoA and oxaloacetate into 
citrate by citrate synthase, and comes full cycle by the conversion of malate into 
oxaloacetate by malate dehydrogenase [46, 85]. It is considered an open-ended 
pathway as compounds such as anaplerotic amino acids and odd chained fatty acids 
may re-fuel the cycle (anaplerosis), whereas some intermediates may exit the cycle and 
supply biosynthetic pathways such as gluconeogenesis and fatty acid synthesis 
(cataplerosis) [2, 17, 86, 87]. Cataplerosis and anaplerosis are equally as important to 
maintain carbon flux [86]. An example of an anaplerotic enzyme is pyruvate 
carboxylase which converts pyruvate to oxaloacetate and thereby fuel the TCA-cycle. 
Glutamate dehydrogenase (GLDH) is mainly considered a cataplerotic enzyme 
although it also functions as an anaplerotic enzyme through its involvement in 
glutamate metabolism [86]. Glutamate can be converted from glutamine by 
glutaminase before glutamate is converted into α-ketoglutaric acid via GLDH 
(anaplerotic). However, the α-ketoglutaric can also be converted back to glutamate 
aided by the same enzyme (cataplerotic). Thus, glutamate is an amino acid that can be 
both anaplerotic and cataplerotic [86, 87].  
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Figure 6: The TCA-cycle. The TCA-cycle initiates with the formation of citrate from acetyl-CoA and 
oxaloacetate, which is driven by citrate synthase. The citrate is thereby converted to isocitrate by 
aconitase. NADH and CO2 is produced in the two following steps: isocitrate formation to α-ketoglutaric 
acid by isocitrate dehydrogenase, and its α-ketoglutarate dehydrogenase driven conversion to form 
succinyl-CoA. Succinyl-CoA is thereby converted into succinate by succinyl-CoA synthetase, 
releasing GTP, before the succinate dehydrogenase converts succinate to fumarate while creating 
FADH2. Fumarate is from there converted into malate by fumarase. In the final step, NADH is created 
from the conversion of malate to oxaloacetate by malate dehydrogenase. Oxaloacetate may re-enter 
the cycle or be used in a range of processes such as gluconeogenesis and as a precursor for amino acid 
synthesis. Anaplerotic amino acids (orange boxes) are able to replenish the intermediates in the TCA-
cycle. Abbreviations are listed in the beginning of the thesis. Based on [2, 64, 88]. 
1.2.4 Acetyl-CoA production via β-oxidation of fatty acids 
Acetyl-CoA can also be produced via β-oxidation (fatty acid oxidation, FAO) of free-
fatty acids (FFA). Upon lipolysis FFAs are hydrolyzed from triacylglycerols in white 

























































If we are to follow palmitate through the oxidation process as an example, it is first 
transported into the cytosol via fatty acid transport proteins (FATPs) and converted 
into palmitoyl-CoA by acyl-CoA synthase (Figure 7) [89-91]. From there it is 
transported through the mitochondrial membranes via the carnitine shuttle. Two 
important enzymes which facilitate the transport of palmitoyl-CoA are the carnitine 
palmitoyltransferases (CPTs) [91]. CPT1 sits in the outer mitochondrial membrane and 
converts the acyl-CoA to acylcarnitine. Carnitine acylcarnitine translocase (CACT) 
transports the carnitine linked fatty acid from the intermembrane space to the inner 
membrane, and translocates carnitine between the outer membrane to the inner 
membrane [92]. CPT2 localized in the inner membrane, transports acylcarnitine into 
the matrix, removes the carnitine and re-forms the acyl-CoA [91-93]. Carnitine reenters 
the intermembrane space whereas palmitoyl-CoA is further broken down in the matrix 
through β-oxidation where four enzyme reactions breaks down the acyl-CoAs to acetyl-
CoA, producing NADH, FADH2, acetyl-CoA and an acyl-CoA (now with two carbons 




Figure 7: β-oxidation of palmitate. Palmitate is converted into palmitoyl-CoA by acyl-CoA 
synthetase, before it enters the mitochondria through the carnitine shuttle. Inside the matrix it is 
converted into acetyl-CoA and acyl-CoA with FADH2 and NADH being formed in the process. Acetyl-
CoA enter the TCA-cycle whereas the acyl-CoA re-enter the pathway. Abbreviations are listed in the 
beginning of the thesis. Based on [2, 91]. 
 
The mitochondria oxidize both short and long chain fatty acids for energy production 
when glucose is limiting. For example during fasting, there is a switch towards FAO 
[89]. This switch is also named “the Randle cycle“ after Philip Randle who first 
described the “glucose fatty-acid cycle” [94]. Most tissues can use FFA for acetyl-CoA 
production, but FAO is especially important in the heart whereas the brain mostly relies 
on glucose and ketone bodies for energy production. Whether the brain can use FFAs 
or not is debated, but research suggest the brain use FFAs and ketone bodies during 
fasting and diabetes [95, 96]. Although albumin bound FFAs are able to diffuse through 
the cell membrane, FATPs are important enablers of long chain and very long chain 
fatty acid (VLCFA) transport [90, 91, 97, 98]. There are several associated proteins 





































binding proteins, cytoplasmic fatty acid binding proteins and fatty acid translocases 
[90, 91, 97, 98].  
The mitochondria are not the only organelle able to oxidize fatty acids. The 
peroxisomes are structures which play additional roles in amino acid catabolism, ROS 
production and inflammation to name a few [99]. Research suggest that the two 
organelles complement each other as the mitochondria oxide the short and long chained 
fatty acids whereas the peroxisomes oxidize VLCFAs and branched chain fatty acids 
[99, 100]. However, peroxisomes have been observed to be able to oxidize smaller 
chained fatty acids during mitochondrial FAO dysfunction [100]. While the 
mitochondria can utilize the products of FAO for energy production, the peroxisomes 
reduce the carbon chain to six to eight carbons before it is exported and taken up by the 
mitochondria for further oxidation to acetyl-CoA [91, 100].  
1.2.4.1 Ketone bodies 
The low carb diet and the ketogenic diet are currently popular dieting trends. Here, 
people restrict their diet avoiding carbohydrates and mainly rely on foods high in fat 
and moderate levels of protein [101]. Altering carbohydrate metabolism through either 
diet, endurance exercise or starvation results in increased production of ketone bodies 
[101-104]. When glucose levels are low, increased gluconeogenesis results in reduced 
oxaloacetate levels [2, 101, 102, 104]. As acetyl-CoA is dependent on oxaloacetate to 
enter the TCA-cycle, the excess acetyl-CoA is converted into acetoacetate or β-
hydroxybuturate, which along with acetone are named ketone bodies [2, 101]. Even 
though the brain is largely dependent on glucose, ketone bodies have been shown to be 
an important alternate fuel, especially when glucose is scarce [96]. The ketogenic diet 
is relatively safe in controlled environments, however, in uncontrolled diabetes, high 
blood levels of glucose and ketone bodies may result in reduced blood pH resulting in 
diabetic ketoacidosis, a condition which may be fatal if not addressed properly [101]. 
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1.2.5 Mitochondrial oxidative phosphorylation  
During aerobic conditions, the NADH and FADH2 produced in catabolic oxidation 
reactions acts as electron donors, which fuel the mitochondrial electron transport chain. 
The electron transport, and subsequent proton pumping through the complexes located 
in the mitochondrial inner membrane, is what drives the ATP production, a process 
named oxidative phosphorylation or OXPHOS (Figure 8) [1, 105-107].  
The OXPHOS system is comprised of five different multi-subunit complexes located 
in the inner mitochondrial membrane (IMM). The NADH ubiquinone oxidoreductase 
(Complex I) is a proton pump which oxidizes NADH and pumps protons across the 
membrane to the intermembrane space [106]. Succinate ubiquinone oxidoreductase 
(Complex II), also named succinate dehydrogenase, consists of four subunits SDHA, 
SDHB, SDHC and SDHD. SDHC and SDHD are anchored to the membrane, whereas 
SDHB and SDHA are the catalytic subunits which links the SDH to the mitochondrial 
matrix [108]. It is, as the only complex in the ETC, a part of the TCA cycle where it 
oxidizes succinate and FAD (SDHA bound) to fumarate and FADH2, however without 
any proton pumping involved [1, 107, 109]. Both Complex I and II transfer electrons, 
which reduces ubiquinone (Q) to ubiquinol (QH2). QH2 then delivers electrons to 
ubiqinol cytochrome c oxidoreductase (Complex III). Complex III transports electrons 
to cytochrome c while pumping protons to the intermembrane space. Cytochrome c 
shuttles electrons to cytochrome c oxidase (Complex IV) where O2 acts as the terminal 
electron acceptor to form H2O, all while protons are translocated to the intermebrane 
space [22, 107]. The proton pumping in Complex I, III and IV generates a proton 
gradient that creates the electrochemical membrane potential. The membrane potential 
represents a proton motive force which drives the ATP synthase (Complex V) [22]. 
Complex V acts like a membrane-bound rotor that generates ATP from ADP and 
phosphate (Pi) [107, 110]. The theoretical combined amount of ATP produced from 
the conversion of one glucose molecule to ATP in aerobic conditions is reported to be 
38 ATP. However the exact amount depends on many interacting processes and is 
estimated to range somewhere around 30 – 36 ATP [2, 46, 106]. 
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Figure 8: Mitochondrial oxidative phosphorylation. Electrons (e-) donated by NADH or FADH2 
enter the electron transport chain via Complex I and Complex II. O2 acts as an electron acceptor in 
Complex IV which results in the production of H2O. Q, QH2 and cytochrome c all participates in 
electron shuttling to the respective complexes. Complex I, III and IV driven proton pumping create the 
proton motive force which drives the ATP synthase and produces ATP from ADP and Pi. 
Abbreviations are listed in the beginning of the thesis. Figure based on [46, 105, 107]. 
Examples of proteins regulating mitochondrial OXPHOS function are uncoupling 
proteins (UCP), which influence the mitochondrial membrane potential as they 
facilitate proton re-entry to the inner membrane [111, 112]. UCPs are known as proton 
channels that induce energy release as heat due to mitochondrial uncoupling [112]. 
Upon compromised membrane potential induced by UCPs, mitochondrial damage or 
mutations, Complex V may act in reverse and aid in proton translocation by the use of 
ATP to sustain mitochondrial membrane potential [22, 113]. Inhibitory factor 1 (IF1) 
has been shown to be an important regulator of both forward and reverse ATP synthase 
activity [113]. Moreover, IF1 expression has been shown to promote coupling, and to 
protect against cell death in relation to hypoxia and glucose depriving states [113, 114]. 
Whereas IF1 knockdown reduce mitochondrial mass and alter cristae formation [113, 
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114]. Furthermore, increased mitochondrial uncoupling and reduced IF1 activity has 
been linked to reduced ROS production, as a reduced membrane potential results in a 
decrease in ROS formation [111, 112, 114]. 
1.2.6 Mitochondrial reactive oxygen species 
Although ROS are also produced in peroxisomes [99], the mitochondrial Complex I-
III are considered the main producers of ROS in cells [110, 115]. The formation of 
ROS is normally a highly regulated process and important in cellular signaling 
processes, but disturbances in this machinery may lead to various diseases as oxidative 
damage accumulate. When the antioxidant defense system is saturated, the excess ROS 
may induce mtDNA mutations, lipid peroxidation and mitochondrial oxidative damage 
[116]. Superoxide (O2-) is a ROS that is spontaneously produced when the 
mitochondria utilize O2 as the main electron acceptor in the ETC [110, 117]. 
Superoxide can be converted into hydrogen peroxide (H2O2) and hydroxyl radical (OH-
), which are considered the three main forms of ROS. Reverse electron transport (RET) 
in Complex I is also shown to be an important driver of ROS production, which is 
mediated by a highly reduced Q pool along with increased membrane potential [115, 
118, 119]. Succinate and FAO have been shown to be important drivers of RET [115, 
119, 120], for example isolated mitochondria have been found to produce ROS through 
RET when respiring on succinate and fatty acids [120].  
Important mediators combating ROS are antioxidants such as superoxide dismutases 
(SODs) which are found in the cytoplasm (SOD1) and mitochondria (SOD2). These 
are crucial enzymes as they turn superoxide to hydrogen peroxide. Other important 
regulators are glutathione peroxidase (GPX) and catalase which reduces hydrogen 
peroxide to water [110]. Disturbances in the equilibrium between ROS production and 
antioxidant defense may lead to apoptosis, through opening of mitochondrial pores and 
release of cytochrome c [110]. Furthermore, increasing antioxidant levels may reduce 
neuronal damage in Alzheimer’s and Parkinson’s disease as reducing ROS production 
has been known to have a neuroprotective effect [117]. As antioxidants have a 
protective function on mitochondrial function and cellular homeostasis, they were 
hypothesized to be protective against tumorigenesis. To study the effect of antioxidants 
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in cancer, the Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group 
performed a study where over 29 000 male smokers participated. The results were 
surprising, as smokers taking beta carotene (antioxidant) supplements had a higher risk 
of developing lung cancer [121]. A follow-up study published in 2003 confirmed this 
observation stating that beta carotene supplements increased both risk and mortality 
rate [122].  
1.3 Cancer  
Cancer is most commonly described as an increase in cell proliferation, accompanied 
increased invasion of surrounding tissue and metastasis from tumor origin to a 
secondary site [123, 124]. Thus, cancer is rather a generic description of a disease that 
differs greatly within and between specific tissues [123, 125, 126]. According to the 
global cancer observatory (GLOBCAN 2018), there were over 18 million cancer cases 
diagnosed and over 9.5 million cancer related deaths worldwide in 2018 [127-129]. 
Lung cancer was ranged as the cancer type with the highest number of incidences and 
deaths (Figure 9). If separated by sex, lung cancer incidence and death was ranked 
highest in men, whereas breast cancer was ranked highest in women.  
 
Figure 9: Top 10 cancer incidence and death rates in 2018. Top 10 cancer incidence and death rates 
in both sexes combined and separately (Numbers displayed per 106). NHL = Non-Hodgkin’s 
lymphoma. Numbers from [127]. 
 
Cancer incidence and deaths in 2018
(Per million,worldwide, ages 0 - 85+)
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1.3.1 Lung cancer classification and treatment 
At the time of diagnosis, lung cancer is most often classified into stages according to 
size (T), lymph node status (N) and metastatic status (M) (TNM status) [130]. Lung 
cancer is further divided into two main sub types based on histology: small cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC), where NSCLC attributes to 
over three quarters of all lung cancer cases [131]. The most common subtypes of 
NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcinomas. In 
NSCLC, surgical resection is the most effective treatment option; however, it is not 
feasible in over 70 % of the cases as many tumors have metastasized or advanced 
locally [131]. Therefore, treatment options vary and may include immunotherapy, 
radiation, surgery and chemotherapy [131-133]. Targeted therapy has also proven to 
be beneficial for NSCLC patients and is based on tumor biomarkers such as oncogenic 
mutations [132, 134, 135]. The most common include epidermal growth factor receptor 
tyrosine kinase inhibitors (EGFR TKI), anaplastic lymphoma kinase inhibitors or Kras 
protein inhibitors [132, 134, 136].  
Mutations in the EGFR has been found to exist in over 10 % of NSCLC cases reported 
in the U.S, with even higher percentages found in Asia [137]. These mutations sensitize 
the tumor to EGFR inhibitors. EGFR activation is known to occur by extracellular 
ligand binding which activate signaling pathways associated with phosphatidylinositol 
3-kinase (PI3K)/AKT and mTOR regulation, along with the STAT and MAPK/ERK 
pathways, leading to increased survival, proliferation, angiogenesis, invasion and 
metastasis [132, 138, 139]. There have been numerous EGFR TKI inhibitors 
developed, including first-generation inhibitors such as erlotinib and gefitinib that 
binds reversibly to the mutated EGFR. However, they may also cause off target effects 
as they may interact with wild type EGFR. Moreover, acquired resistance usually 
develops within a year of treatment [133]. To overcome this, second generation 
inhibitors (afatinib and dacotinib) were developed. These inhibitors bind irreversible 
to EGFR; however, side effects are evident as they also may target wild type EGFR. 
Recently, third generation EGFR inhibitors targeting the specific T790M mutation 
(rociletinib and osimertinib) to relieve wild type EGFR binding, have been developed 
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[133, 140]. Despite efforts in improvement of EGFR inhibitors, development of 
resistance still is a devastating fact for most patients [140].  
1.3.2 Breast cancer classification and treatment 
Other than TNM status, breast cancer sub-classification provides a useful strategic 
implementation for breast cancer treatment [141-145]. Recent advances has been made 
in classifying breast cancer the last decade, which started twenty years ago when Perou 
et al., were able to classify breast cancer subtypes into estrogen receptor positive (ER+) 
and negative (ER-) based on gene expression analysis [142]. A short time later they 
expanded the classification to include five intrinsic sub types [142, 145]. Sub-
classification include hormone receptor (HR) status such as ER and progesterone 
receptor (PR), and human epidermal growth factor receptor 2 (HER2) [146-148]. The 
underlying subtypes include HR+ luminal A, luminal B and normal-breast like which 
are ER+, and/or PR+, but are otherwise separated by differing gene signatures. The 
HR- sub types include HER2 enriched (HER2+) and triple negative breast cancer 
(TNBC). As TNBC have very heterogeneous gene profiles, the amount of subtypes is 
rapidly increasing, examples being basal like 1 and 2, claudin high and low, 
mesenchymal, mesenchymal stem like, immunomodulatory and luminal androgen 
receptor [143, 144, 148, 149]. The most common type is HR+, which attribute to ~70 
% of all cases, whereas 15 – 20 % are diagnosed with HER2+ and ~15 % with TNBC 
[150].  
Due to the heterogeneity within breast cancer, treatment options vary according to 
TNM status and sub classification. For example, stage I HR+ tumors benefit from 
targeted therapy, which results in good overall prognosis with a five-year overall 
survival of ~85% [143]. However, in TNBC, the treatment options reflect the diversity 
within the subclass as there is no clear treatment option. Although TNBC initially 
appear to be highly sensitive to chemotherapy, the limited therapeutic options and the 
aggressive nature of TNBC makes the overall prognosis poor [143, 149]. 
A common denominator in treatment of both NSCLC and breast cancer is development 
of drug resistance [136, 151, 152]. Acquired EGFR TKI resistance is for example 
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reported to develop within 9–13 months in NSCLC [153]. Thus, the major contributor 
to a high mortality rate in lung cancer and breast cancer is often not the primary tumor 
itself, but invasion, metastasis and drug resistance, which are all features characterizing 
cancer cell plasticity [154, 155].  
1.4 Cancer cell plasticity 
Cellular plasticity encompasses the ability of cells to adapt to changes in terms of stress, 
injury, altered nutrient supply or drug exposure. In adult tissue, plasticity is needed 
when the stem cells in the intestines regenerate tissue in order to absorb nutrients or in 
wound healing [154]. However, the term plasticity is also used to describe the 
genotypic and phenotypic heterogeneity within a tumor. The plastic nature of tumors 
may be driven by mutations, microenvironmental signals, therapeutic treatment or 
epigenetic changes [156]. What characterizes the plasticity of cancer cells is increased 
inflammation and expression of proliferation related growth factors and cytokines 
epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), 
transforming growth factor beta (TGFβ) and tumor necrosis factor alpha [155, 157].  
A well described example of cellular plasticity induced by some of these factors is 
epithelial to mesenchymal transition (EMT), a process where epithelial cells loose cell-
cell contacts and cell polarity, thus becoming more migratory (Figure 10). EMT is 
commonly defined by loss of the associated epithelial marker E-cadherin, and gain of 
mesenchymal markers like N-cadherin, Axl and vimentin, although several other 
factors are involved (markers of EMT is further discussed Chapter 3.2) [136, 158, 159]. 
EMT is crucial for embryonic development and wound healing. Research by Chen and 
Behringer showed that knock-out of the EMT related transcription factor TWIST in 
mice resulted in failure in the formation of the cranial neural tube resulting in 
embryonal death at day 11 [160, 161].  
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Figure 10: Epithelial to mesenchymal transition.  
Epithelial cells in light orange are held together by adherens junctions, tight junctions and desmosomes, 
and retain an apical-basal polarity. As the cells acquire more mesenchymal properties they lose cell-
cell contacts, polarity and become more migratory (yellow and green). Key characteristics of epithelial 
cells is expression of E-cadherin, the mentioned adhesion molecules, claudins and cytokeratins. As the 
cells undergo EMT, they increase expression of N-cadherin, vimentin, fibronectin, in addition MMPs 
and transcription factors SNAI1, SNAI2 and TWIST. It is of importance to note that the cartoon only 
shows a few of the related EMT-MET markers and that EMT is a reversible plastic process meaning 
cells can fluctuate between the different EMT-MET states. Abbreviations are listed in the beginning 
of the thesis. Illustration composed of smart medical art [162] and is adapted from [163]. 
 
The process of EMT is reversible, meaning that cells can undergo mesenchymal to 
epithelial transition (MET), and many have suggested that cells display a various 
degree of EMT within a tumor, with hybrid and multiple intermediate stages [157, 
158]. In recent years, it has become clear that EMT is a transient process, where the 
cells fluctuate between the different epithelial and mesenchymal states [163, 164]. The 
transient characteristics of EMT-MET has made the term epithelial to mesenchymal 
plasticity (EMP) increasingly popular. EMT has been shown to be induced by 
microenvironmental growth factors like TGFβ and EGF. Hypoxia mediated signaling 



























associated factors like vimentin, SNAIL and ZEB [165-167]. Moreover, EMT and 
hypoxia is also associated with mutations in the TCA-cycle linked enzymes SDH, 
fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) (Chapter 1.5.2) [168, 
169]. EMT is known to alter metabolism through increased glycolysis and glutamine 
metabolism, and to reduce fatty acid metabolism [166].  
1.4.1 Drug resistance 
Apart from being an important step in invasion and metastasis, EMT and cancer cell 
plasticity has been linked to development of drug resistance [136, 161, 170]. Drug 
resistance is often defined by intrinsic or acquired resistance, which involve cells 
already harboring or developing tolerance to chemotherapeutics during the course of 
treatment [132]. Intrinsic resistance includes innate factors such as already present 
mutations, altered drug transport or drug metabolism. Acquired drug resistance may 
include secondary mutations in the direct target of the drug (like the EGF receptor 
(EGFR)) or amplification of possible compensatory receptors like tyrosine-protein 
kinase MET (c-MET). Induction of the EMT machinery may also result in altered drug 
response [132]. As most tumor cells have a high mutational load, providing variance 
and possible survival benefits, drug resistance can be described as a way of evolution 
by natural selection. Only the “fittest” cell with the most favorable variation enabling 
intrinsic resistance or otherwise is able to acquire increased tolerance, will sustain 
prolonged drug treatment [5, 126].  
The major mechanisms of EGFR resistance include secondary mutations like the 
Thr790Met (T790M), c-MET amplification which activates the PI3K/AKT signaling 
pathways, and phenotypical changes like EMT [133, 171]. How EMT induces drug 
resistance is complex, but upregulation of associated EMT-linked markers including 
TWIST, is found to increase expression of ATP binding cassette (ABC) transporters, 
which are important for drug influx and efflux [172]. Furthermore, tumors that display 
high levels of mesenchymal markers appear to have a negative response to drugs 
targeting the EGF receptor (EGFR) in NSCLC [136]. 
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1.5 Cancer cell metabolism 
Twenty years ago, Hanahan and Weinberg described six “Hallmarks of Cancer” [173], 
which later were updated to ten in the publication “Hallmarks of Cancer: The Next 
Generation” [124]. One of the added hallmarks was deregulating cellular energetics, 
which highlighted the fact that cellular energy metabolism needs to be further 
investigated in respect to cancer initiation and development.  
1.5.1 Rewiring cellular energetics 
Metabolic reprogramming is a critical part of cancer development as increased 
biosynthesis and ATP production is a necessity to fuel tumor growth. In fact, the altered 
tumor energetics like increased glucose uptake has been advantageous in cancer 
diagnostics by the use of 18F-fluorodeoxyglucose (18F-FDG). 18F-FDG is a 
radioactively labeled glucose analogue that can be imaged using positron emission 
tomography [124, 174, 175]. Otto Warburg described the increased preference of 
aerobic glycolysis in cancer cells almost a hundred years ago, a characteristic which 
has been termed “the Warburg effect” [125, 176, 177]. In 1956 Warburg followed up 
the observation with a study where he concluded that the glucose preference was due 
to faulty mitochondria [178]. The Warburg effect, which is described to be a 
dysregulation of the ratio of glycolysis to oxidative phosphorylation, is to date the most 
recognized metabolic alteration observed in cancer. Normally, during aerobic 
conditions, the mitochondria are the main producers of ATP through OXPHOS (net: 
30 - 36 ATP). However, cancer cells are described to have a preference towards aerobic 
glycolysis (net: 2 ATP), meaning that the theoretical ATP yield from glucose is more 
than 15 times higher if oxidized completely to CO2 [106, 124].  
A range of different studies on the different glucose transporters and glycolytic 
enzymes has been performed to understand the altered glucose transport. As an 
example GLUT1 upregulation has been linked to oncogenic PI3K/AKT and Ras 
signaling [34, 179]. Furthermore, upregulation of GLUT1, GLUT3 or GLUT4 has been 
linked to reduced survival in numerous cancer types [33, 34, 38, 179]. Glycolytic 
enzymes, such as HK and PKM, are also found to be involved in regulation of 
apoptosis, aerobic glycolysis and to fuel tumor growth [180-184]. Why cancer cells for 
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the most part rely on aerobic glycolysis for ATP production is not fully understood, but 
it is believed that reducing mitochondrial OXPHOS results in protection against cell 
death and damage via mitochondrial induced ROS and apoptosis [124, 176, 185]. Other 
advantages of increased glucose uptake and lactate production includes rapid ATP 
generation, sustained glycolysis branched biosynthesis (e.g. pentose phosphate 
pathway (PPP)) and increased acidification of the microenvironment [176]. For 
instance, the PPP is important for nucleotide synthesis and generation of the ROS 
scavenger NADPH [186, 187]. Moreover, lactate has been shown to be involved in 
invasion and migration through increasing cancer cell motility, while reducing immune 
cell function [188, 189].  
1.5.1.1  Nutrient scavenging 
A central part of the metabolic plasticity of cancer cells is the ability to scavenge 
nutrients. Continuous nutrient supply is of essential importance in order to sustain 
proliferation, however, within a tumor nutrient levels are highly variable and 
sometimes limiting, [190]. For example, amino acid and glucose concentrations have 
been found to be low in pancreatic, colon and breast tumors compared to normal tissue 
[190, 191]. In addition, intratumoral location, such as distance to blood vessels in the 
growing tumor is essential for nutrient availability. Therefore, in order to gain 
sufficient nutrient supply, tumor cells exhibit increased nutrient scavenging through 
upregulated amino acid uptake, substrate recycling and macropinocytosis.  
Some tumor cells have been shown to recycle lactate which fuel the TCA cycle [174], 
while some have increased glutamine dependence or altered amino acid uptake [125, 
185, 192]. The theory behind lactate recycling is that hypoxic cells within the tumor 
convert pyruvate to lactate. The lactate is secreted before it is taken up and oxidized by 
the cells in the oxygenated part of the tumor [53, 124, 174]. Lactate recycling is only 
one example energy supply to fuel tumor growth when nutrients are limiting. 
Macropinocytosis is important in growing cells, and is an example of a non-specific 
scavenging pathway where extracellular nutrients and solutes are taken up through an 
endocytic process [193]. It is an evolutionary conserved form of endocytosis, which 
allows for catabolism of amino acids which may in turn be used for anaplerosis of the 
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TCA-cycle and fuel cellular energetics [194]. It is found to be important in cancer as 
well as neurodegenerative diseases, atherosclerosis and kidney disorders [193].  
Kim et al., has reported that adenosine monophosphate activated protein kinase 
(AMPK) activation is necessary for macropinocytosis in prostate cancer [195]. AMPK 
is known to be a master regulator of cellular energetics through its activation of β-
oxidation, mitochondrial biogenesis and glucose uptake [195-197]. Macropinocytosis 
may also be induced by cytokines and growth factors like EGF, and has been reported 
to be triggered by Ras mutation [193, 198]. Qian and colleagues (2014) proposed that 
extracellular uptake of ATP through macropinocytosis is necessary to maintain growth, 
increase survival and development of drug resistance in the NSCLC cell line A549 
[199]. Furthermore, in a study by Colin et al., 60% of genes associated with 
macropinocytosis was deregulated in glioblastoma, suggesting that macropinocytosis 
may be a promising target to diminish tumor cell nutrient supply and drug resistance 
[198]. As some cancer cells appear to some extent to be relatively dependent on 
macropinocytosis for nutrient scavenging, it has been suggested as a useful tool for 
drug delivery [198]. 
Nutrient scavenging can also occur through autophagy, where cytoplasmic organelles 
and molecules are degraded in lysosomes, which may provide amino acids, glucose 
and fatty acids for ATP production [200]. Autophagy may also be used to maintain 
cellular homeostasis, through the removal of dysfunctional mitochondria through 
mitophagy. As mitophagy is important for handling dysfunctional mitochondria it is 
believed to be important in tumorigenesis. Deletions in BCL2-interacting protein 3 
(BNIP3) or PARK2 has been linked to multiple cancer types, such as pancreas, ovarian, 
breast and liver cancer [30, 201]. BNIP3, which is also known for harboring tumor 
suppressive functions such as induction of apoptosis, is a regulator of hypoxia-induced 
mitophagy [30, 202]. Furthermore, Zhang et al., found increased PARK2 expression 
mediated by p53 both in vitro and in vivo [201]. p53 is one of the most described tumor 
suppressor genes and is, amongst other things, important in glucose metabolism. 
PARK2 has been found to be important for p53 mediated glucose regulation and 
antioxidant defense [201].  
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A major regulator of both autophagy and macropinocytosis is mammalian target of 
rapamycin (mTOR). mTOR, which is known to be suppressed by AMPK activation, 
acts as a nutrient sensor which increase cell growth when cellular amino acids levels 
are high [194, 203, 204]. Moreover, mTOR expression is induced by intracellular 
amino acid levels, and has been found to inhibit autophagy and macropinocytosis [194, 
205]. mTOR is also believed to be important in EMT induction, as inhibition of the 
PI3K/mTOR pathway has been found to prevent E-cadherin downregulation and 
induction of EMT [206]. mTOR is also involved in hypoxic response as HIF stabilizers. 
Moreover, mTOR is known to be regulated by hypoxia, although the mechanism is still 
relatively unclear [203, 204].  
1.5.1.2  Hypoxia 
A major contributor to metabolic reprogramming in tumor cells other than nutrient 
availability and scavenging is the amount of oxygen present. Healthy cells located more 
than 200 micrometers (oxygen diffusion limit) from the nearest blood vessel die unless 
new vasculature is formed [207]. As the oxygen levels within the tissue decrease 
(hypoxia), growth factors inducing blood vessel formation (angiogenesis) may 
increase. Hypoxic conditions have been found to drive tumorigenesis and effectuate 
drug resistance and metastasis [208]. Master regulators of the cellular response to 
hypoxia are hypoxia inducible factors (HIFs). HIFs is a heterodimer consisting of two 
subunits, α and β, with three known α and two known β subunits [85]. The α subunit is 
oxygen sensitive whereas the β is constitutively expressed [209]. HIFs are normally 
degraded when oxygen is present, a process which is enabled by α-ketoglutarate 
dependent prolyl hydroxylases (PHD) [85, 183, 210]. An E3-ubiquitin ligase 
recognizes the hydroxylated group of the α subunit, and targets it for proteasome 
degradation [85, 209]. HIFs are known to activate genes involved in survival, 
angiogenesis, growth, invasion, metastasis and EMT [165, 211]. They are also found 
to be important regulators of metabolic reprogramming through their regulation of 
major glycolytic enzymes like GLUTs and HK [165, 183, 211]. Further, PKM2 is 
reported to both regulate and be regulated by HIF, and to be upregulated in cancer [42, 
183]. Mitochondrial respiration is also shown to be disturbed by HIF activation through 
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upregulation of PDKs, as HIF directly targets PDK1, thus disrupting pyruvate 
oxidation [165, 211, 212].  
1.5.2 Mitochondrial tumor suppressor genes and oncometabolites 
Mitochondrial metabolites such as fumarate and succinate are found to act as signaling 
molecules driving oncogenesis upon accumulation, and are therefore considered to be 
oncometabolites [210]. Mutations in TCA-cycle associated enzymes like SDH, FH and 
IDH are known to prompt oncometabolite accumulation and drive tumorigenesis.  
Mutations in either of the genes encoding Complex II subunits SDHA–D, and SDH 
assembly factor 2 (SDHAF2) are known to be related to benign tumors such as 
paraganglioma and pheochromocytomas [108, 213-215]. Mutations associated with 
SDH are also connected to gastrointestinal tumors and paragangliomas in Carney-
Stratakis syndrome (mutations in SDHB, C and D), Leigh syndrome (SHDA) and 
neoplasms in Carney triad (diseased SDH, not mutational). Thus, highlighting the 
importance of a functional SDH and its role as a tumor suppressor gene [7, 108, 210, 
214].  
Mutations in other TCA-related enzymes such as IDH and FH has also been associated 
with a range of different tumors, as well as induction of EMT [85, 168, 169, 213, 216, 
217]. Wild type IDH normally convert isocitrate to α-ketoglutarate (as shown in Figure 
6). However, mutations in IDH induce a loss of function and is found to instead drive 
conversion of α-ketoglutarate to 2-hydroxyglutarate (2-HG), which also is considered 
an oncometabolite [166, 210, 218]. FH converts fumarate to malate and is considered 
a tumor suppressor gene as mutational inactivation is known to drive tumorigenesis 
[85, 168, 210, 219]. FH is also believed to be involved in DNA damage response and 
the antioxidant defense system [85, 219]. Moreover, mutations in SDH, IDH and FH 
are all known to induce “pseudohypoxia” which means activation of hypoxic responses 
during normoxic conditions [85, 220]. A pseudohypoxic response occur when 
mutations or a dysfunction in TCA-cycle related enzymes efficiently stifle 
mitochondrial electron donor supply, or otherwise initiate an hypoxic response through 
HIF activation [210, 220, 221]. Accumulation of TCA-cycle oncometabolites such as 
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fumarate, succinate and oxaloacetate, and depletion of α-ketoglutarate, has been linked 





















2. Aim of study 
The aim of the presented work was to characterize metabolic rewiring mechanisms 
controlling cancer cell plasticity, and thereby crucial features of tumor malignancy. 
The presented project focused especially on cellular energetics in epithelial to 
mesenchymal transition (EMT) and drug resistance, which represent well-documented 
examples of cancer cell plasticity. The purpose was to provide knowledge that may 
lead to identification of new therapeutic targets and enable development of new 
treatments. 
Specific aims:  
1) To explore regulatory and functional associations between succinate 
dehydrogenase (SDH) and EMT in breast cancer in order to uncover new 
mechanisms underlying malignant development. 
2) To characterize the role of pyruvate dehydrogenase kinase 4 (PDK4) in 
regulation of cellular energy fuel utilization.  
3) To identify metabolic signatures in non-small cell lung cancer (NSCLC) and 
investigate their possible impact on acquired resistance to epidermal growth 











3. Methods and methodological considerations 
As the choice of advanced methodologies and optimal cell models have been recurrent 
topics throughout this project (Paper I-III), I will here consider some methodological 
experimental aspects that has emerged during the course of the work included in this 
thesis.  
3.1 Cells and cell culture 
Upon investigating mitochondrial function and dynamics, there are numerous 
laboratory methods available, most of them being applied in vitro on cultured cells, 
harvested muscle fibers or isolated mitochondria. We chose to mostly rely on 
immortalized cell lines as they are easier to work with in terms of gene editing and 
stable doubling time [223-226]. The use of immortalized cells in cancer research 
remains a discussed topic in laboratories today. The advantages of using immortalized 
cells are unlimited replicative potential and a relatively homogenous population. 
However, the genetic and epigenetic drift during culture time, as well as the risk of 
contamination of other cells or microorganisms, remains challenging [224, 227]. 
To ensure experimental consistency and check for contaminations, we regularly sent 
our cell lines to ATCC for cell line authentication through short tandem repeat (STR) 
profiling and tested cells for Mycoplasma, Acholeplasma, Entomoplasma and 
Spiroplasma by using the MyCoAlert kit from Lonza. Mycoplasma is a relatively 
common infection in cell culture and is often ignored, as it is hard to detect in routine 
culturing conditions and believed not to influence experimental results. However, 
Mycoplasma has been shown to alter the metabolism of infected cells. A microarray 
expression analysis has shown that an mycoplasma infection affect genes involved in 
metabolic processes and stress response, as well as genes encoding cytokine and 
oncogenes to name a few [228]. Moreover, a study performed by [229] showed that a 
variety of different metabolic pathways and metabolites were changed in mycoplasma 
infected PNAC-1 cells compared to controls. Further, gentamicin, a common antibiotic 
used to treat mycoplasma, is also known to alter metabolism and cellular function 
[230]. 
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3.2 Relevancy of cell models  
The EGFR pathway is an important driver in a major subgroup of non-small cell lung 
cancer (NSCLC) (Chapter 1.4.1) and EGFR TKIs are widely used in clinics today 
[231]. Acquired resistance to EGFR TKIs in the patient is normally developed within 
the course of treatment and is one of the many contributors to the high mortality rate 
in NSCLC [127, 129]. To investigate possible therapeutic strategies to overcome 
acquired resistance, we chose to develop our own drug resistant clones in vitro in the 
NSCLC cell line HCC827 and HCC4006 (ATCC) that have a Thr790Met (T790M) 
mutation in the EGFR receptor making it constitutively active. This mutation makes 
them sensitive to first generation EGFR inhibitors, and resistant clones were 
established through continuous growth in 1 µM erlotinib as described in Paper III. The 
main difference between the two cell lines is that the HCC827 cells are harvested from 
the lung of a 39-year-old female whereas the HCC4006 is harvested from a metastatic 
site (pleural effusion) in a > 50-year-old male. To verify our findings in HCC827 and 
HCC4006, we used the H1975 cell line, which have an additional EGFR 
Leu858Arg/Thr790Met (L858R/T790M) mutation in the EGFR, and are resistant to 
erlotinib [140, 152]. However, they are sensitive to third-generation inhibitors like 
rociletinib (co-1686). A resistant H1975 clone were provided by Clovis Oncology and 
prepared as described in Walter et al., [140].  
Further, for Paper I we chose cell lines that have an epithelial phenotype (MCF10A 
and MCF7) to study possible alterations in metabolism during in vitro induced EMT. 
As EMT is a plastic process, consisting of several phenotypic shifts, there is no specific 
biomarker for EMT [157, 158, 164, 232]. Therefore, a combination of markers 
associated with either epithelial phenotype or mesenchymal phenotypes were 
investigated in order to define the process of EMT. Examples being the EMT related 
transcription factors TWIST, SNAI1 (SNAIL), SNAI2 (SLUG), ZEB1 and ZEB2, Axl, 
and/or cytoskeleton markers such as cell adhesion molecules E-Cadherin (CDH1), N-
cadherin (CDH2) or the intermediate filament marker vimentin (VIM) [164, 232-234]. 
Regulation of these markers is widely dependent on tissue and setting, which is why a 
combination of these markers is used to ensure consistency in experimental procedures 
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performed [164]. Two distinct EMT signatures, including one “global” signature as 
well as one less comprehensive signature was used to analyze the breast cancer cohorts 
in Paper I, and a wide range of different markers of EMT was used in qPCR and western 
blot throughout this thesis.  
3.3 Data normalization  
Data normalization is a necessity in order to acquire consistent and trustworthy 
quantitative data. Normalization serves to neutralize potential differences due to 
variation in sample mass or cell number between groups. In cell culture experiments, 
we chose to normalize to µg protein as described in Paper I–III. In quantitative PCR 
(qPCR) and western blot, reference markers that are stable between samples, are 
needed. Commonly used reference markers for both qPCR and western blot include 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), cytoskeleton markers such as 
actin and alpha tubulin, and the ribosomal RNA marker 18s for qPCR. However, the 
expression levels of these markers are dependent on tissues and setting. For example, 
18s RNA and GAPDH were found to be the most reliable in lamb lung tissue [235]. 
However, Glare et al., found that GAPDH along with β-actin are not suitable references 
when looking at lung tissue harvested from asthmatic patients [236]. We also found 
differences in GAPDH expression in normal vs NSCLC tumor samples (Paper III, 
Figure 1). This highlights the need to test the references best suited for each 
experimental and tissue setting. As a way of minimizing the discrepancy between 
different references in western blot analyses, we chose to display the total amount of 
protein loaded using image analysis (Paper I) in order to get an overview over the total 
protein loaded [237, 238].  
3.4 Investigating metabolic adaptations 
Measuring metabolic function was performed using two distinct methods, the Seahorse 
XFe96 Analyzer (Seahorse) and by measuring oxidation through carbon-14 (14C) 
labeled substrates, which is hereby referred to as substrate oxidation. These two 
methods may complement each other as the Seahorse methodology provides a general 
insight into mitochondrial respiration and glycolysis, whereas 14CO2 trapping 
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following substrate oxidation provides a more detailed description of cellular substrate 
preference (Further discussed in Chapter 5.3). 
3.4.1 Measuring mitochondrial oxygen consumption and glycolysis  
The Seahorse methodology was extensively used in this thesis as it can measure the 
oxygen consumption rate (OCR), and glycolysis indirectly through the extracellular 
acidification rate (ECAR) in real time (Figure 11A-B). As the Seahorse is limited to 
addition of up to four modulators, careful titration of the stocks and cell number used 
prior to each experiment is required (Figure 11C-D). 
 
Figure 11: Measuring oxygen consumption rate (OCR) and glycolysis (ECAR) by the Seahorse 
XFe Analyzer. A and B) is adapted from Paper I and III and [239], and explains what information is 
gained in a standard Seahorse mitostress and glycostress test run. C-D) highlights the need to titrate 
each individual compound with C) oligomycin titration in MCF10A cells and D) CCCP in MCF7 
cells. Please refer to Paper I-III for more detailed information regarding each specific experiment. 
Abbreviations are listed in the beginning of the thesis 
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Upon measuring basal OCR one gets information on the mitochondrial activity during 
basal culture conditions (Figure 11A). Through addition of the ATP synthase 
(Complex V) inhibitor oligomycin, one gets information about the integrity of the 
mitochondria as it gives indications of proton leak across the mitochondrial membrane 
and the amount of oxygen which was used to produce ATP (ATP-linked) [240, 241]. 
Upon oligomycin titration (Figure 11C), we found that in order to fully inhibit ATP 
synthase, a concentration over 1.5 µM was needed in MCF10A cells, and that 
concentrations as high as 10 µM gave similar results as 1.5 µM. Further, upon adding 
carbonyl cyanide m-chlorophenylhydrazone (CCCP), which acts as an uncoupler, one 
gets information on the respiratory capacity of the cell as well as the reserve capacity. 
CCCP is a protonophore which alters the ETC proton gradient, consequently resulting 
in collapsed mitochondrial membrane potential [240, 241]. The protons can thereby 
freely cross the mitochondrial membrane which results in a rapid consumption of 
oxygen, though, without ATP production. CCCP needs to be carefully titrated, as lower 
concentrations will not provide a true maximal respiratory rate and higher 
concentrations will result in a collapse of the mitochondrial membrane potential 
(Figure 11C) [240-242]. Addition of rotenone, a Complex I inhibitor, gives indication 
of Complex I independent respiration. Upon antimycin A stimulation, the 
mitochondrial Complex I, V and III are all inhibited, which provides information on 
non-mitochondrial respiration [240, 241]. 
When investigating the glycolytic activity by measuring (ECAR) some of the same 
metabolic modulators are used (Figure 11B). First, the ECAR is measured without 
glucose added in order to get insight into the endogenous levels of glycolysis. When 
adding glucose, it fuels the glycolysis and the ECAR rises. As oligomycin inhibits ATP 
synthase, it efficiently blocs mitochondrial ATP production, meaning that the 
metabolism is further shifted towards glycolysis, which is further fueled by CCCP 
stimulation [240]. This may also provide information on the glycolytic reserve. The 
addition of 2-dexy glucose (2-DG), is an important control as it acts as a glucose 
analogue that inhibits glycolysis, which gives information on non-glycolytic 
acidification [240, 243]. A factor to consider when measuring glycolysis (ECAR) is 
that mitochondrial activity may influence the acidification of the medium. When 
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glucose is broken down to lactate- through glycolysis, H+ protons are produced. The 
lactate and protons H+ are secreted, and the H+ is what dictates the ECAR. However, as 
the cells respire, the CO2 produced is converted into HCO3- and H+, meaning 
mitochondrial respiration also influence the ECAR [244].  
A limitation of the standard methods measuring the OCR and ECAR in real time is that 
one does not get direct insight into substrate preference nor the molecular mechanisms 
causing subsequent changes in the metabolic rate. However, one can look at function 
directly related to the mitochondrial compartments by using isolated mitochondria or 
permeabilized cells. In permeabilized cells the importance of keeping a balanced 
environment is more profound, therefore we used a buffered mannitol and sucrose 
based medium with added fatty acid free BSA (MAS medium) [245]. In Paper I, as we 
wanted to specifically investigate SDH, and as succinate is unable to cross the 
mitochondrial membrane, we permeabilized the cells using a plasma membrane 
permeabilizer (PMP). An advantage when it comes to using permeabilized cells as 
opposed to isolated mitochondria is the reduction in the number of cells needed. 
Moreover, many of the cellular compartments remains relatively intact and the 
mitochondria retain their network [245]. Other important additions used except PMP 
and succinate, was rotenone, oligomycin and ADP. Rotenone was added to inhibit 
Complex I dependent respiration. Further, ADP was added to assay the succinate 
driven OXPHOS, and oligomycin and antimycin A was added to control for 
mitochondrial integrity and non-mitochondrial respiration [238, 245]. A more detailed 
description of the concentration of compounds and assay medium used can be found in 
the respective papers. 
3.4.2 Substrate oxidation 
In order to measure the dependency and oxidation of each substrate, we used 14C 
labeled pyruvate, glucose, lactate or palmitic acid as described in Paper II and III. The 
principle behind the method is that the 14C labeled substrates is taken up by the cells 
and oxidized, releasing 14C labeled CO2. The CO2 released through cellular respiration 
is absorbed by a filter plate immersed with NaOH, creating HCO3. After trapping the 
CO2, the amount of radioactivity absorbed by the filter plate can be counted using a 
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scintillation counter, and provides information on the substrate oxidation activity 
(Figure 12A) [246]. The amount of µCi used was carefully optimized prior to each 
experiment in order to reduce the amount of exposure to ionizing radiation in 
accordance to health and safety regulation. Also, in regards to minimizing the amount 
of 14C, non-labeled (referred to as cold) substrate was added in combination with 
radioactive (referred to as hot) substrate, as described in Paper II and Paper III. A full 
description of the assay medium composition can be found in the respective articles. In 
most of the substrates used, the 14C label was uniformly distributed on all carbon atoms. 
However, in order to get a better insight into PDH function, we used pyruvate labeled 
only in the first carbon atom (Figure 12B-E). Labeling only the first carbon atom, 
enables the detection of the CO2 which is released from the PDH dependent step of 
turning pyruvate into acetyl CoA, and thereby gives an indication of the efficiency and 
functionality of the PDH enzyme. 
Figure 12: Substrate oxidation: trapping of radioactively labeled 14CO2. A) Adherent cells in 
blue grown in a monolayer, with 14C -labeled substrate. The filter plate is attached on top of the 
culture plate, with a silicone gasket seal. As the cells respire, the 14CO2 released from oxidation is 






























carbons released as CO2 molecules in A) glucose, B) lactic acid, C) palmitic acid and finally D) 
pyruvate oxidation [65]. Figure A) was adapted form [246] by using illustrations from smart medical 
art [162] and B-E is adapted from [65]. 
3.4.3 Metabolic modulators 
The following metabolic modulators were used in this thesis (Table 1). 
Table 1: Metabolic modulators. Cell number and concentrations of compound added was titrated and 
optimized prior to running all assays. Abbreviations are listed in the beginning of the thesis. 
Name Assay Effect Reference 
2-DG Seahorse, trapping Inhibits glycolysis competitively. Induce 
oxidative stress, autophagy and AMPK 
pathway 
[247] 
AICAR Seahorse, trapping 
and cell culture 
AMPK activator and triggers mitochondrial 
biogenesis 
[197] 
ADP Seahorse, Increases oxidative phosphorylation.  [245, 248] 
Antimycin A Seahorse  Inhibits Complex III [241, 249] 
Carnitine Trapping Aids in LCFA transport [248] 





Inhibits pyruvate dehydrogenase kinase [63, 251] 
Oligomycin Seahorse  Inhibits ATP synthase [241, 249] 
Malonate Seahorse Inhibits succinate competitively [249] 
PMP Seahorse Permeabilizes cells [245, 252] 
Rotenone Seahorse Inhibits Complex I [241, 249] 
Succinate Seahorse  Fuel for CII (succinate dehydrogenase) [248] 
 55 
TTA Seahorse, trapping 
and cell culture 
Induces mitochondrial fatty acid oxidation [65] 
WY 14,643, Seahorse, trapping 




















4. Summary of Papers 
4.1 Paper I 
Title: Epithelial to mesenchymal transition (EMT) is associated with attenuation of 
succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC 
Here we investigated the role of the mitochondrial Complex II succinate 
dehydrogenase (SDH) subunit C in EMT. In two breast cancer patient cohorts we found 
an inverse relationship between EMT associated markers and SHDC. The reduced 
expression of SDHC was more profound in basal-like molecular subtypes than non-
basal subtypes. Upon CRISPR heterozygous knockdown of the SDHC subunit in 
epithelial MCF7 cells (MCF7 SDHC +/- cells), we found EMT related markers and 
characteristics such as increased wound healing and reduced abilities to form 
spheroids. These properties were also evident when using the SDH enzymatic inhibitor 
malonate on the non-tumorigenic cell line MCF10A. Interestingly, when we 
overexpressed the EMT inducing transcription factors TWIST and SNAI2 
independently in MCF10A cells we found a reduction in both the SDHB and SDHC 
subunit. The MCF7 SDHC +/- cells showed reduced respiratory capacity, whereas both 
MCF10A malonate, MCF10A/TWIST and MCF10A/SNAI2 cell lines showed reduced 
mitochondrial basal respiration and respiratory capacity compared to parental controls.  
Upon measuring oxygen consumption rate in permeabilized cells, we found a common 
characteristic in both MCF10A/TWIST, MCF10A malonate treated and 
MCF7/SDHC+/-, namely reduced succinate dehydrogenase activity. When assaying 
mitochondrial mass and morphology in the MCF10A/TWIST overexpressing cells, we 
found a higher fraction of smaller and fragmented mitochondria in the TWIST 
overexpressing cell lines compared to the control. This was supported by a reduction 
in the fission related protein Drp1. Furthermore, we found that the TWIST 
overexpressing cells had a larger proportion of small mitochondria, lower expression 
of the mitochondrial fusion protein Opa1 and thinner tubular mitochondrial structures 
compared to the parental control. 
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In conclusion, we found a link between SDHC expression and EMT, through 
remodeling of mitochondrial dynamics. This was followed by reduced mitochondrial 
activity, suggesting that mitochondrial remodeling play an important role in cancer cell 
plasticity. The altered mitochondrial activity may provide tolerance to hypoxia and 
nutrient deprivation, however, it may also imply reduced tolerance to metabolic 
modulators targeting glucose metabolism. As the mitochondrial structure and volume 
is altered in EMT, and EMT is induced upon SDH knockdown, we propose further 
research into the use of mitochondrial specific drugs alongside conventional cancer 
therapy.  
4.2 Paper II 
Title: Upregulated PDK4 expression is a sensitive marker of increased fatty acid 
oxidation 
In this study, we set out to investigate the role of pyruvate dehydrogenase kinase 4 
(PDK4) in cellular regulation of fuel utilization. We specifically looked at the role of 
PDK4 in mitochondrial fatty acid oxidation (FAO), and whether PDK4 could be an 
associated marker of metabolic adaptation through a substrate switch from glucose to 
fatty acid oxidation. Measuring fatty acid oxidation in the laboratory is difficult, as it 
usually involves measuring radioactively labeled derivatives of FAO and not FAO 
directly, a process which often require fresh sample material like intact cells or tissue 
homogenates. 
We found the PDK4 expression, along with other associated markers such as Cpt, Acox 
and Me-1, to be upregulated in tissue harvested from rats treated with 
tetradecylthioacetic acid (TTA). Furthermore, after upregulating PPARα in MDA-MB-
231 cells and inducing PDK4 upregulation, we used 14C-labeled substrates and 
discovered an increase in palmitic acid oxidation; conversely, the glucose oxidation 
was significantly reduced.  
Treatment with AICAR, WY 14,643 and ranging concentrations of TTA in MDA-MB-
231 cells revealed an increase in CPT1A and PDK4, along with an increase in palmitic 
acid oxidation in the TTA treated cells. However, only WY 14,643 and the higher 
concentrations of TTA showed increased basal oxygen consumption rate compared to 
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controls. Furthermore, TTA was found to cause acute uncoupling effects when added 
to cultured cells. 
To conclude, PDK4 upregulation was found to be a marker of metabolic adaptations as 
it was consistently upregulated upon increased fatty acid oxidation. PDK4 expression 
analysis can be used to evaluate changes in fatty acid oxidation as a component of 
metabolic adaptation, and provide a useful implementation when investigating FAO in 
the laboratory.  
4.3 Paper III 
Title: Inhibition of pyruvate dehydrogenase kinase redirects NSCLC cell metabolism 
and counteracts development of resistance to epidermal growth factor receptor 
tyrosine kinase inhibitors. 
In 2018, over 2 million new lung cancer cases were diagnosed. A common feature of 
lung cancer is drug resistance, which represents one of the major contributors to lung 
cancer mortality. Here we aimed to identify metabolic targets in non-small cell lung 
cancer (NSCLC), and upon acquired epidermal growth factor tyrosine kinase inhibitor 
(EGFR TKI) resistance.  
We found increased PDK1 expression in two NSCLC cohorts, and increased 
expression of glycolytic and antioxidant related markers, which paralleled a decrease 
in fatty acid oxidation markers and mitochondrial biogenesis. We used three NSCLC 
cell lines harboring EGFR activating mutations. These included the EGFR TKI 
sensitive HCC827 and HCC4006 cell lines with a T790M mutation. In addition, we 
used the L858R/T790M mutated H1975 cell line, which are resistant to first generation 
EGFR TKIs such as erlotinib. Upon targeting pyruvate metabolism using 
dichloroacetate (DCA), we found glycolysis to be reduced in an acute manner, and that 
DCA alone or in combination with EGFR TKIs inhibited cell growth. Further, 
treatment of NSCLC with DCA increased pyruvate and lactate oxidation, in addition 
to reducing glucose oxidation. DCA treatment further increased markers of 
mitochondrial biogenesis and reduced lactate dehydrogenase expression (LDH). 
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In order to further investigate pyruvate metabolism and the effects of DCA treatment 
in resistant NSCLC clones, we developed subtypes resistant to erlotinib, and acquired 
a rociletinib H1975 resistant clone from Clovis Oncology. Upon acquired drug 
resistance, we found increased expression of EMT related markers, which was 
followed by altered expression of PDKs, mitochondrial superoxide dismutase, glucose 
transporters, mitochondrial pyruvate carrier and monocarboxylate transporters. The 
dysregulated glucose, pyruvate and lactate transporters indicated metabolic rewiring in 
EGFR TKI resistance. Although the metabolic phenotype varied between the resistant 
cell lines upon investigating mitochondrial oxygen consumption rate and glycolysis, 
they responded to DCA treatment by reducing glycolysis. The reduction in glycolysis 
was followed by a trending or decreased glucose oxidation, and increased lactate and 
pyruvate oxidation. Further, when investigating cell growth upon EGFR TKI and DCA 
alone or in combination, we found that DCA further mediated the effects of EGFR 
TKIs.  
Based on our findings in the two patient cohorts and resistant models, we propose that 
DCA treatment result in increased energetic stress which further sensitizes cells to the 
additional therapeutic effect of EGFR TKIs. DCA treatment may results in reduced 
acidification of the extracellular environment due to decreased lactate production in 
addition to increased lactate and pyruvate oxidation. We hypothesize that targeting 
cellular pyruvate metabolism by the use of DCA will increase therapeutic efficacy of 








5.  Discussion 
One of the leading causes of mortality in cancer is cell plasticity through invasion, 
metastasis and drug resistance [124, 185, 208]. The development of these 
characteristics, enables the cancer cells to evolve and change according to the 
microenvironment, and can be viewed as a way of evolution [6, 126]. The term 
evolution by natural selection is often associated with Charles Darwin [253]. 
Interestingly, in a similar manner as animals adapt to environmental changes, 
cancerous cells do the same within the body [5]. For cancer cells, such environmental 
changes include hypoxia, nutrient availability, pH and cancer therapy [6, 126, 165, 
208]. As an example, upon drug exposure, cancer cells harboring or acquiring 
mutations overcoming treatment are able to survive and sustain proliferation. Due to 
the uncontrolled growth rate in cancer cells compared to normal tissue, they are prone 
to a rapid turnover of genetic mutations. In my opinion, which is shared by others, 
cancer development may be described as rapid evolution [254]. The adaptive 
capabilities of cancer cells are underlined through tumor heterogeneity, as a tumor may 
contain a variety of cells harboring different epigenetic and genetic properties. 
Tumorigenic cells face trade-offs between proliferation, evading immune suppression, 
invasion and metastasis [126, 155, 255]. As an example, slow proliferating cells 
harboring metastatic properties often reside on the edges of tumors [6]. Within the 
growing tumor there are highly proliferating cells, however, as oxygen and nutrient 
levels become limiting, the core often contain glycolytic cells more resistant to hypoxia 
[6, 255]. An essential part of the “survival of the fittest cancer cell” is adaptation of 
metabolic pathways, which are important suppliers of precursors for biosynthesis and 
sustained survival.  
In the present study, we identified pathways and regulators crucial for metabolic 
rewiring in processes of cell plasticity. In Paper I we found EMT associated 
transcription factors to induce changes in mitochondrial structure and function, and that 
the process of EMT is associated with altered mitochondrial Complex II function. We 
further observed that low levels of Complex II subunit SDHC was associated with the 
development of EMT in breast cancer. In Paper II, we identified PDK4 as a sensitive 
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marker of FAO both in cells and rats. In the third paper we further investigated how 
metabolism is influenced by EMT and drug resistance, and how targeting specific 
metabolic pathways may aid in combating cancer therapy resistance. Pinpointing areas 
of metabolic flexibility in cancer, through discovering markers or regulators of 
metabolic changes and cancer cell plasticity, may assist in identify pathways inducing 
energy stress which can act as possible therapeutic targets. 
5.1 Is metabolic deregulation involved in cancer cell plasticity and 
drug resistance? 
EMT is an acknowledged example of cellular plasticity as it is associated with wound 
healing and embryonal development. It also remains an important feature of cancer cell 
plasticity through facilitating drug resistance, invasion and metastasis. [155, 158, 159, 
166]. Metabolic reprogramming has been linked to EMT, as it has been shown that 
dysregulation and dysfunction of key metabolic enzymes, including FH, SDH and IDH, 
can drive EMT and tumorigenesis [168, 169, 210, 213]. As mentioned in the 
introduction, dysfunction in either of these enzymes is associated with pseudohypoxia, 
meaning that the hypoxic response is initiated even in aerobic conditions, for example 
through HIF stabilization [85, 210, 220-222]. HIF1α is known to regulate cancer cell 
plasticity through activation of genes that are associated with angiogenesis, invasion 
and metastasis [157, 166, 208]. Research done by Zhang et al., has linked SDH to 
osimertinib (EGFR TKI) resistance and pseudohypoxia via miR-147b SDH targeting 
in NSCLC [256]. However, how these metabolic alterations are driving cellular 
plasticity is relatively unexplored. In Paper I, we identified the mitochondrial Complex 
II SDHC subunit to be negatively associated with EMT in a breast cancer cohort. 
Moreover, overexpression of EMT related transcription factors TWIST and SNAI2, 
resulted in reduced mitochondrial respiration and altered the intrinsic mitochondrial 
networks, which resulted in more fragmented mitochondria (Paper I, figure 6). 
Overexpression of TWIST in MCF10A cells also lead to reduced SDH driven 
respiration (Paper I, figure 5) in a similar manner as by treatment of the known SDH 
inhibitor malonate (Paper I, figure 4), indicating that deregulation of Complex II is an 
important step in EMT. We saw the same trend in a breast cancer cohort, i.e. that EMT 
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and SDH were found to have an inverse relationship. The inverse relation between 
EMT and SDHC was shown to be particularly strong in the basal-like breast cancer 
(BLBC) subgroup. In addition, we found that BLBC with low SDHC had a trend (P < 
0.1) towards reduced survival compared to high SDHC (Paper I, figure 2), indicating 
decreased SDHC as a possible prognostic marker. Although, BLBC is considered 
highly aggressive, it appears that it can be divided into two sub-groups. One with poor 
five-year survival rate, and the other with increased long-term survival [257, 258]. 
Even if the differences between these subtypes remains elusive, it is tempting to 
speculate that metabolic markers and markers of EMT can be important prognostic 
factors to consider. 
Research on the link between EMT and drug resistance has been increasing during the 
last 20 years. Li and colleagues showed in vitro that Adriamycin treatment induced 
EMT in MCF7 cells [259]. The cells that displayed characteristics of EMT, developed 
multidrug resistance and increased invasion. Furthermore, knock out of TWIST 
resulted in a reduction of invasion and resistance upon Adriamycin treatment in vitro, 
and increased efficacy of the drug in vivo [259]. The link between metabolic 
dysregulation, EMT and drug resistance remain unclear, though it has been speculated 
that suppressing mitochondrial function is a way to avoid apoptosis and decrease ROS 
production [260, 261]. Furthermore, as increased lactate secretion is known to 
contribute to ECM degradation, the switch to aerobic glycolysis may further aid in 
invasion [181, 262]. As we found that mitochondrial dysfunction and altered metabolic 
pathways are important in EMT, and that EMT is linked to drug resistance and poor 
prognosis [136, 161, 170], we chose to investigate how metabolism may be targeted to 
increase drug sensitivity in NSCLC in Paper III. 
In order to fully explore the metabolic changes upon drug resistance, we developed in 
vitro models of acquired erlotinib resistance in two different NSCLC cell lines and 
obtained a cell line resistant to rociletinib from Clovis Oncology. We observed, in 
concordance with other findings, that EMT was induced upon drug resistance (Paper 
III, figure 4) [136, 161, 170]. Moreover, we found that the induction of EMT in our 
cell models were related to reduced respiration rate and/or reduced respiratory capacity 
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in the EGFR TKI resistant clones, resembling the results found upon EMT induction 
in Paper I. Interestingly, one of the three NSCLC cell lines had a different metabolic 
phenotype compared to the others. The HCC4006/BERL, except from reduced 
respiratory capacity, displayed higher OCR rates, and higher pyruvate and lactate 
oxidation compared to control. The main difference between the cells according to 
ATCC is that HCC4006 is harvested from a metastatic site, which may be a factor 
influencing their metabolic signature.  
Changes in metabolism of fatty acids is linked to a wide range of metabolically linked 
diseases such as diabetes, cancer and ME/CFS to name a few [65, 263, 264]. In Paper 
II we found that increased PDK4 expression is associated with increased FAO, which 
is in accordance with other studies [70, 71, 265, 266]. According to Bowker et al., 
PDK1 and PDK2 are important for short-term PDH regulation, whereas PDK4 is more 
involved during starvation [67]. Throughout Paper II we investigated gene regulation 
upon increased FAO. Either though overexpression of relevant FAO regulators, by 
adding pharmacological inducers of FAO to cell culture medium in vitro or through a 
TTA supplemented diet in rats in vivo. Overexpression in cell culture experiments 
included PPARα, as PPARs are known regulators of PDK4 expression and FAO. PPAR 
expression is induced as a consequence of starving and can be activated by LCFA 
which acts as agonistic ligands [77]. As expected, upon PPARα overexpression, we 
found increased FAO at the expense of glucose oxidation (Paper II, figure 2), along 
with increased expression of PDK4, CPT1A, ACOX in cell culture. Pdk4, along with 
other markers of FAO such as Cpt1a, Cpt1b, Cpt2 and Acox, were upregulated in the 
liver of TTA treated rats.  
Although the role of FAO in cancer remains elusive, changes in CPTs and other FAO 
associated markers have been reported [264]. Upon looking at FAO related genes in 
NSCLC such as CPT1A, ACOX, PDK4 and PPARG (Paper III, figure 1) we found a 
decreased expression in two distinct NSCLC cohorts. In Paper III, (Figure 1 and figure 
4), we found PDK1 upregulation in the patient cohorts compared to healthy tissue, and 
PDK2 upregulation upon acquired drug resistance in NSCLC. PDK3 and/or PDK2 
upregulation has previously been associated with poor survival in AML and lung 
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cancer patients [267, 268] and PDK2 to confer drug resistance in vitro in lung, head 
and neck cancer [82, 268].  
An emerging theory suggests that reduced rates of mitochondrial respiration and/or 
increased antioxidant activity in tumorigenesis is a way to reduce ROS production, and 
increase cancer cell survival [260, 269, 270]. Recent research has shown that many 
tumors have reduced levels of the antioxidant SOD2, and that a reduction in ROS 
production drive tumorigenesis and drug resistance [7, 260, 269, 270]. In Paper III we 
found upregulation of a range of different genes associated with antioxidant defense in 
NSCLC, in addition to SOD1 and SOD2 upregulation in EGFR TKI resistant NSCLC 
cells compared to parental cells (Paper III, figure 1). In Paper I, upon investigating 
SDHC levels in breast cancer cohorts, we found decreased levels of SDHC to be 
associated with increased expression of genes involved in ROS defense mechanisms 
(Paper I, figure 7).  
5.2 Targeting cancer metabolism 
As tumorigenesis involves dysregulation and deregulation of a network of pathways 
associated with metabolism, targeting cellular energetics represents a promising 
therapeutic option. There are numerous drugs that may target cancer metabolism 




Figure 13: Drugs targeting metabolism. Displaying a selection of drugs and how they target 
metabolism. In short, DCA targets PDKs thus increasing PDH activity and pyruvate and lactate 
oxidation. EGFR TKIs are found to induce ROS production and to reduce mitochondrial respiration. 
Tamoxifen inhibits Complex I, induce ROS and AMPK activation. Metformin inhibits Complex I, 
glucose uptake and gluconeogenesis. In addition, metformin induces AMPK and PGC1α. 
Abbreviations are listed in the beginning of the thesis. Figure based on [185]. 
 
DCA is known to rewire metabolism through PDK inhibition, thus increasing the 
activity of the PDH complex [271]. Increased PDH activation fuels mitochondrial 
respiration through increased acetyl-CoA production. As mentioned in the 
introduction, DCA inhibits PDK expression and increase oxidation of pyruvate and 
lactate, and reduce plasma lactate and glucose concentrations [63, 80]. As expected, 

































sensitive and resistant NSCLC cells upon DCA treatment. Furthermore, DCA 
treatment reduced LDHA mRNA in the three EGFR TKI sensitive NSCLC cell lines.  
The altered lactate flux upon DCA treatment could be one of the main reasons to why 
DCA show promising clinical results, as lactate is known to increase invasion and 
metastasis, and to disturb immune cell mobility, T-cell and NK cell function [188, 189, 
272-274]. Further, increased LDH expression is linked to decreased progression free 
survival and overall survival [275]. We found evidence of altered lactate metabolism 
in our NSCLC cohorts compared to normal tissue through LDHA upregulation. 
However, as we only investigated LDH levels through RNA sequencing cohorts, we 
cannot conclude. Though, the increased mRNA LDHA/LDHB ratio may indicate 
increased lactate production in NSCLC. LDH is important for the reversible conversion 
of pyruvate to lactate, where a LDHA dominated tetramer will aid in lactate formation 
[49]. Therefore, targeting LDHA has become a promising therapeutic option. Inhibiting 
LDHA along with PD-1 has for instance been shown to improve PD-1 efficacy through 
increased inflammation, NK cell and CD8+ T-cell activity [274]. Moreover, targeting 
LDHA in T790M, K-RAS and/or EGFR L858R mutated tumors resulted in reduced 
tumorigenesis in lung cancer and reduced growth of pre-existing tumors [276].  
Clinical trials elucidating the effect of DCA and conventional cancer therapy are 
already in progress [271, 277, 278]. DCA is suggested to be more potent in synergy 
with already established treatment such as cisplatin, tamoxifen and radiotherapy [278]. 
In order to improve DCA efficacy and reduce side effects, advances has been made 
into DCA design and engineering [279, 280]. As DCA has an anionic charge, it has 
low permeability due to difficulty crossing the plasma membrane via diffusion. 
Furthermore, solute carriers such as SLC5A8, which is able to mediate DCA transport, 
is often downregulated in cancer [279, 280]. Trapella and colleagues, reported that they 
were able to design a multiple DCA loaded compound (compound 10), which sustained 
the same effects as DCA with over a 30 fold lower concentration [279]. Moreover, 
Pathak et al., has shown that by using a DCA analogue targeted to mitochondria (mito-
DCA), they reduced the toxicity in normal tissue, whereas they retained the efficacy in 
cancer cells [280].  
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In Paper III, we show that the combination of EGFR TKIs and DCA show promising 
results to counteract acquired resistance in NSCLC. EGFR inhibitors are common 
drugs used to treat NSCLC and other EGF dependent cancers. Gefitinib has been 
known to induce ROS along with reduced mitochondrial respiration in resistant clones 
[261]. Furthermore, De Rosa et al., observed reduced lactate production and glucose 
uptake, increased OXPHOS in NSCLC cells treated with EGFR inhibitors. Based on 
their findings, they conclude that a combination of agents targeting oncogenic drivers 
(such as EGFR mutation), along with glucose metabolism, may increase therapeutic 
efficacy [175]. A drug, which has already been tried out in NSCLC and breast cancer, 
is metformin. Metabolic rewiring upon metformin treatment includes AMPK activation 
which is followed by PGC1α activation and mTOR inhibition [281, 282], and 
restoration of mitochondrial networks [281]. As to how metformin induces these 
master regulators is unknown, although many have proposed it is linked to ETC 
Complex I targeting [282]. It is commonly used to target diabetes through its reduction 
of blood glucose levels and gluconeogenesis, and induction of insulin sensitivity [283, 
284]. As it is commonly used in diabetic treatment, possible side effects are known, 
and it is well-tolerated in most patients. Diabetes type 2 has been linked to cancer 
development, which is likely to be caused by decreased insulin sensitivity and high 
glucose blood levels [283, 284].  
Fifteen years ago, Evans et al., hypothesized that metformin is a promising cancer 
preventing drug [285], which fueled further research on the topic. Several studies have 
now shown that diabetic patients treated with metformin have reduced cancer incidence 
rate and better overall survival compared to diabetic patients receiving different 
treatment [283, 284, 286, 287]. Moreover, metformin has also been shown to be 
preventative towards NSCLC development in patients with diabetes in the U.S military 
[287]. Research done on NSCLC and breast cancer has shown that metformin use 
increase survival, [185, 284, 286, 287]. Further, metformin is known to act 
synergistically with doxorubicin, 2-deoxy glucose and DCA [243, 283, 288, 289]. 
Though, the exact mechanism to how remains relatively unclear. The promising results 
on metformin use has led to numerous clinical trials which are currently in progress 
[282]. 
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PPARs as targets in anti-cancer therapeutics has proven to be a double-edged sword. 
For example, PPARγ ligands has been shown to induce apoptosis and reduce lung 
cancer growth [290], whereas prolonged treatment with PPARα ligands such as WY-
14,643 has shown increased hepatocellular neoplasia in rodents [291]. The PPARδ 
agonist GW501516 is known to be involved in tumor growth of both breast and lung 
cancer [292]. Further, PPARδ activation was shown to increase mTOR expression 
[292]. The important role of mTOR as a nutrient sensor has made the use of mTOR 
inhibitors in cancer research another promising therapeutic option [206, 293]. 
However, the effects of mTOR inhibitors also appear challenging, due to the many 
roles of mTOR signaling [194, 294]. For example, mTOR has a dual role as both a 
nutrient sensor modulating cell growth, and as an inhibitor of macropinocytosis and 
autophagy [194]. Although, mTOR targeting has been hypothesized to be an important 
target in combating EMT induction [206], inhibiting mTOR may increase cellular 
energetic plasticity as the cancer cells are increasingly able to absorb extracellular 
proteins to be used for catabolic and anabolic processes [194]. The inconsistent efficacy 
of targeting master metabolic regulators such as PPARs and mTOR may explained by 
their numerous roles in cellular energetics. For instance, along with their role in 
metabolism, they are also known to be involved in inflammation, angiogenesis, insulin 
resistance, adipocyte differentiation, apoptosis, EMT, hypoxia and proliferation [76, 
194, 203, 290, 292]. 
A promising therapeutic option in cancer treatment is targeting solute carriers such as 
GLUTs and MCTs [295]. Since these are essential for cellular substrate transport, they 
are important for contextual substrate uptake in the cell. Also, as the level of these 
carriers often are increased in cancer, they serve as promising drug delivery options 
[296]. In Paper I, we found saw upregulation of GLUT1 and/or GLUT2 in NSCLC 
cohorts and upon development of EGFR TKI resistance in our cell models, in 
accordance with other findings [34, 38, 53]. GLUT1 is also associated with hypoxic 
response, as its expression has been shown to be increased by HIF in glioblastoma 
[209]. GLUTs are essential for glucose transport and their upregulation is found to be 
associated with poor overall survival [38, 39].  
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MCTs are essential for import and export of both pyruvate and lactate, and we found 
MCT1 and/or MCT2 to be upregulated in both the NSCLC patient cohorts as well as 
upon development of drug resistance in vitro. MCTs are often found to be upregulated 
in tumors compared to healthy tissue, and is associated with a poor patient outcome in 
numerous cancer types, including breast and lung cancer [295]. MCT is known to 
support invasion and migration, highlighting the possible therapeutic implications of 
MCT inhibitors [57, 295]. MCT inhibitors in synergy with chemotherapy has already 
proven to be beneficial, and there are currently clinical trials in progress evaluating the 
effects of MCT1 inhibitors [51, 52, 295, 297]. Confirming altered pyruvate metabolism 
and transport, the MPC1/2 ratio was reduced. MPCs are multisubunit complexes 
consisting of MPC1, MPC2 and MPC3 (yeast) [58, 59]. MPC1 downregulation is 
known to induce EMT and resistance to ionizing radiation [298]. Further, MPC 
suppression is believed to be a mediator of aerobic glycolysis (the Warburg effect) [59, 
298, 299]. 
5.3 Current prospects in metabolic phenotyping  
Tracking metabolic changes in cultured cells was relevant for all three papers in this 
thesis, which included both state-of-the art technology such as the Seahorse technology 
and well established methods such as substrate oxidation. During standard cell culture 
conditions, where cells have an abundance of substrates available, the energy 
metabolism often remain unchallenged and metabolic weaknesses remain 
undiscovered. Examples of such effects are shown both in Paper I and II, where 
modulation of metabolism through SDHC knockdown, AICAR (AMPK stimulator), 
and PPAR overexpression or activation by WY-14,643 resulted in modest effects on 
cellular metabolism (Paper I, figure 3 and Paper II, figure 5). This might be reflected 
by an unchanged mitochondrial respiration and glycolytic balance, as metabolic 
rewiring enables acetyl-CoA production via alternate metabolic pathways. In order to 
gain more insight into these metabolic adaptations, reducing glucose concentrations or 
replacing glucose with galactose, which promotes OXPHOS, may provide a useful 
strategy [299].  
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Implementing substrate oxidation in parallel to measuring OCR is another strategy to 
measure altered substrate preference in cultured cells and tissue homogenate. As seen 
in Paper III, the NSCLC EGFR TKI resistant subtypes had differing metabolic 
phenotypes when measuring mitochondrial respiration (OCR) and glycolysis (ECAR). 
These phenotypes were reflected by the detected substrate oxidation of pyruvate, 
lactate and glucose (Paper III, figure 5). The use of radioactively labeled substrates is 
not only useful in vitro. 18F-FDG is commonly used in cancer diagnostics as a measure 
to gain insight into cancer therapy response as it gives high contrast resolution of 
tumors compared to healthy tissue [174, 300]. However, 18F-FDG use is not as 
effective in cancer types with inflamed tissue, a high FDG uptake in surrounding tissue 
or in cancer types with low FDG uptake and low metabolic rates [300, 301]. Witney et 
al., has provided insight into 13C labeled pyruvate as a means of detecting therapeutic 
response [300], and suggests that measuring 13C labeled lactate and pyruvate flux by 
using magnetic resonance imaging (MRI) is a promising alternative to using 18F-FDG. 
Along with limiting patient exposure to ionizing radiation, the use of 13C pyruvate can 
be implemented in tumor tissue with limited FDG imaging quality such as the brain 
and prostate [300, 301]. 
Further advances into implementing cellular energetics in tumor imaging has been 
made by Momcilovic and colleagues. They have recently developed a membrane 
potential sensitive radiotraceable probe (4-[18F] fluorobenzyl-triphenylphosphonium), 
which can be imaged by the use of positron emission tomography [302]. By the use of 
this radiotracer, they show that it is feasible to phenotype solid tumors based on 
metabolic activity, including glycolytic- and mitochondrial activity. They could further 
predict the effect of inhibitors of Complex I in the electron transport chain, as cancer 
cells with high mitochondrial activity showed an increased sensitivity towards these 
inhibitors [302]. Thus, by including this method, there might be a robust clinical 
experimental approach that enables the inclusion of mitochondrial activity. 
The metabolism of cancer cells includes dysregulation of a wide network of pathways 
supporting energy homeostasis. With increased metabolic requirements, comes the 
need to increase ATP production and biomolecule synthesis through alternate 
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pathways. In the present thesis I aimed to gain a deeper insight into the role of 
metabolic rewiring in cancer cell plasticity and progression. We found examples of 
metabolic reprogramming through deregulation of mitochondrial function and 
pyruvate metabolism in the processes of EMT and drug resistance. Redirection and 
targeting of cell metabolism represents a promising therapeutic strategies as cancer 
cells are highly dependent on metabolic adaptations to maintain the vast energy 

















6. Concluding remarks 
The main aim of this thesis was to investigate metabolic rewiring in cancer cell 
plasticity and drug resistance, and how altered cellular energetics may represent a 
therapeutic target. Three different approaches were used to address aspects of 
metabolic rewiring in this context, and the following conclusions were obtained: 
In breast cancer, EMT has shown to be associated with attenuated SDH activity and 
altered mitochondrial dynamics through regulation of mitochondrial fission and fusion. 
Further, we found that upon SDH inhibition or SDHC knockdown, the cells increased 
their invasive properties through induction of EMT. Likewise, overexpression of the 
EMT-linked transcription factor TWIST resulted in changed mitochondrial 
morphofunction through reduced SDH activity, increased mitochondrial fragmentation 
and reduced mitochondrial size, resulting in reduced mitochondrial respiration.  
PDK4 expression was found to be a marker of metabolic rewiring involving increased 
FAO in vitro and in vivo. In cultured cells, pharmacological and genetic strategies to 
activate the PPARα transcription factor caused increased FAO and reduced glucose 
oxidation. Thus, increased PDK4 expression signals a shift from glucose to fatty acids 
as energy fuels, and can therefore be a useful marker for altered substrate utilization 
for energy metabolism.  
In NSCLC patients, increased expression of genes involved in glucose metabolism and 
ROS defense was found in tumor tissue compared to normal tissue. These effects were 
correlated with increased PDK1 expression. Moreover, altered glucose, pyruvate and 
lactate transport was indicated by differential expression of solute carriers upon 
development of drug resistance. Data from cultured NSCLC cells indicated that the 
PDK inhibitor DCA may counteract features of EGFR TKI resistance, potentially by 
mediating an influential shift in energy metabolism towards pyruvate oxidation. The 
data support further evaluation of targeting PDKs to obtain beneficial effects against 
EGFR TKI resistant cancer. 
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To summarize, our data points to specific molecular mechanisms of metabolic rewiring 
associated with key malignant phenotypes involving cancer cell plasticity. The finding 
warrants further exploration of targeted strategies to modulate metabolism to 



















7. Future perspectives 
As metabolic rewiring in cancer cell plasticity is a vast and uncharted field, many 
questions remain unanswered. Therefore, there are numerous studies which would have 
been interesting to further elucidate in this thesis, some which are highlighted below. 
One of the major questions I would have preferred to further address, is whether 
induction of EMT or acquired drug resistance regulate ROS production. ROS 
production, in addition to being important in cell signaling, is reported to be 
deregulated in tumorigenesis and drug resistance [261, 269]. However, measuring ROS 
is difficult to do as they have a short half-life, are spontaneously produced as cells 
respire and are regulated by the antioxidant defense system [115, 117].  
In Paper I, it would be of interesting to further investigate the role of SDHA-D 
knockdown on cellular energetics, especially since SDHD was positively associated 
with EMT. As both SDHC and SDHD are mitochondrial anchor proteins, it would be 
interesting to further elucidate the differences between the subunits in regard to both 
cellular plasticity, ROS production through reverse electron flow and mitochondrial 
OXPHOS.  
In Paper II and III, it would be of interest to quantify mitochondrial mass and 
morphology as performed in Paper I, figure 6. This includes investigating 
mitochondrial networks and volume in PDK4 overexpressing cells, and in NSCLC 
sensitive and resistant cells before and after DCA treatment. Gaining such insight into 
mitochondrial structure and network would provide useful information on 
mitochondrial morphofunction.  
Moreover, would be interesting to verify the DCA effect other EGFR mutated cancers, 
or in different cancer treatments associated with a high rate of drug resistance. In 
addition, it would be useful to implement the already redesigned DCA (compound 10 
or mito-DCA), in order reduce concentration and increase DCA cellular uptake [279, 
280]. As immune cells are influenced by the acidity of the tumor microenvironment, it 
would also be interesting to investigate how DCA, or other relevant drugs modulating 
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lactate oxidation, influences inflammation, T-cell infiltration and NK cell activity upon 
cancer treatment.  
Metformin, which is thoroughly described in Chapter 5.2, is a highly promising drug 
when it comes to synergy with already approved therapeutic options [283, 286, 288]. 
It would therefore be of interest to see whether metformin could aid in combating drug 
resistance, and how it alters substrate oxidation. Further, as there seem to be a link 
between type 2 diabetes and cancer, and that certain antioxidant supplements have been 
shown to increase mortality in lung cancer [122, 284], it would be of interest to further 
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Abstract
Background: Epithelial to mesenchymal transition (EMT) is a well-characterized process of cell plasticity that may
involve metabolic rewiring. In cancer, EMT is associated with malignant progression, tumor heterogeneity, and
therapy resistance. In this study, we investigated the role of succinate dehydrogenase (SDH) as a potential key
regulator of EMT.
Methods: Associations between SDH subunits and EMT were explored in gene expression data from breast cancer
patient cohorts, followed by in-depth studies of SDH suppression as a potential mediator of EMT in cultured cells.
Results: We found an overall inverse association between EMT and the SDH subunit C (SDHC) when analyzing
gene expression in breast tumors. This was particularly evident in carcinomas of basal-like molecular subtype
compared to non-basal-like tumors, and a low SDHC expression level tended to have a prognostic impact in those
patients. Studies in cultured cells revealed that EMT was induced by SDH inhibition through SDHC CRISPR/Cas9
knockdown or by the enzymatic inhibitor malonate. Conversely, overexpression of EMT-promoting transcription
factors TWIST and SNAI2 caused decreased levels of SDHB and C and reduced rates of SDH-linked mitochondrial
respiration. Cells overexpressing TWIST had reduced mitochondrial mass, and the organelles were thinner and more
fragmented compared to controls.
Conclusions: Our findings suggest that downregulation of SDHC promotes EMT and that this is accompanied by
structural remodeling of the mitochondrial organelles. This may confer survival benefits upon exposure to hostile
microenvironment including oxidative stress and hypoxia during cancer progression.
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Introduction
Epithelial to mesenchymal transition (EMT) provides a
useful mechanistic framework for studying the regula-
tion and dynamics of cell fate transitions (i.e., cell plasti-
city) central to developmental and cancer cell biology
[1–3]. Events involving downregulation or dysfunction
of mitochondrial enzymes have been linked to EMT, but
the potential role of mitochondrial remodeling as part of
the EMT program has not yet been evaluated through
systematic studies of mitochondrial physiology [4].
EMT is a reversible transdifferentiation program
whereby epithelial cells convert into migratory mesenchy-
mal cells with enhanced cell survival attributes [1, 2].
EMT is recognized by a loss of epithelial markers such as
cytokeratins and E-cadherin, followed by a concomitant
increase in mesenchymal markers such as N-cadherin and
vimentin [5]. In cancer development, this is associated
with therapy resistance and poor clinical outcome [6]. The
cellular processes of EMT are orchestrated by several key
transcription factors (e.g., TWIST, SNAI1, SNAI2, ZEB1/
2) that act in concert with epigenetic mechanisms and
post-translational protein modifications to coordinate the
cellular alterations [1]. Application of gene expression sig-
natures combining multiple EMT-linked genes has proven
useful to evaluate EMT as a contributing factor in tumor
development in human cancers [7].
Cellular metabolism provides the energy and building
blocks required for cell function and growth and is regu-
lated in close relation to changes in the physiological
state of the cell and in the microenvironment [8]. To
this end, mitochondrial reprogramming has been shown
to be of significance in oncogenic events [9, 10]. Several
oncometabolites recognized as drivers of tumor develop-
ment and progression have been identified, including fu-
marate, D-2-hydroxyglutarate (D-2HG), and succinate
[11]. Such metabolites have been found to have causative
influence in cancers with genetic deficiencies in associ-
ated enzymes, including fumarate hydratase (FH) [12],
isocitrate dehydrogenase 1 (IDH1) [8], and succinate
dehydrogenase (SDH) [13]. Mutations (germline) in
SDH subunits have been linked to familial paraganglioma
syndromes, pheochromocytomas (PGL/PCC), renal cell
carcinomas (RCC), and gastrointestinal stromal tumors
(GISTs) [14], both as predisposing and prognostic factors
[13]. Thus, in PGL/PCC, GIST, and RCC, SDH is classi-
fied as a tumor suppressor [13, 15–18].
The SDH complex, also referred to as respiratory com-
plex II in the mitochondrial electron transport chain, is
composed of four subunits (SDHA, SDHB, SDHC, and
SDHD). It has a central role in energy metabolism, as it
directly links the tricarboxylic acid cycle (TCA-cycle) to
the respiratory machinery [19]. SDHA and SDHB are
hydrophilic subunits and form the catalytic unit of the
complex, whereas SDHC and SDHD represent the
hydrophobic membrane-bound part of the complex.
SDH genes can act as classic tumor suppressor genes, as
the mutated alleles often are inherited in a heterozygous
manner, and the respective wild-type allele is lost in tu-
mors [9]. Mutations in or downregulation of the SDHB
subunit have previously been associated with
TGFβ-induced EMT in cancer cells [20–22]. In a previ-
ous study investigating breast cancer, the protein expres-
sion level of SDHA and B was lost in 3% of the samples
[23]. Such effects may indicate that metabolic rewiring
could be a facilitating feature for cell plasticity, as it also
has been linked to cell state transitions such as differen-
tiation, senescence, and oncogenic transformation [4,
24–27]. In summary, there are several observations sup-
porting that genetic defects in mitochondrial enzymes
may affect features of EMT [4, 13, 28, 29]. However, the
potential role of metabolic rewiring as a more general
driving force of cellular plasticity in human tumors re-
mains poorly explored.
In this study, we present gene expression analysis of
human breast cancer samples, correlating the level of
SDH subunits to the levels of EMT-related genes. We
show that reduced expression of SDHC was particularly
associated with EMT in the breast cancer cohorts of this
study, especially the ductal- and basal-like subgroups. In
subsequent cell studies, we found a bilateral causative
relationship between SDH attenuation and EMT induc-
tion, which involved significant changes in mitochon-
drial morphofunctional properties.
Methods
Gene expression analysis of human breast cancer samples
We investigated the association between EMT and SDH
genes in a breast cancer patient cohort obtained from
the Haukeland University Hospital (n = 204) [30], as
well as an Affymetrix breast cancer meta-cohort (n =
3992) [7]. In this study, we used two distinct signatures,
one generic comprising 315 genes related to EMT in
various tissues (EMT315 signature) [7], and the other
consisting of 8 genes of particular relevance for EMT in
breast cancer (EMT8 signature). The EMT8 signature
was designed based on a previously described 5-gene
signature (CDH1, CTNNB1, CTNNA2, CDH2, CDH3)
[31], which we extended with KRT19, an established
marker for breast cancer cells, and SNAI2 and TWIST
due to their role as determinants of EMT in breast can-
cer metastasis and invasion. The correlation between
the two different EMT signature scores was strong in
our study cohorts (for the meta-cohort Rho = 0.674, p <
0.0001 and for the n = 204 cohort Rho = 0.6651, p <
0.0001). Further details about the gene expression analysis
(GEA) are provided in Additional file 1: Supplemental
methods.
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Cell models
The breast epithelial cell line MCF10A and the breast can-
cer cell line MCF7 (both from ATCC, Manassas, VA) were
cultured according to conventional procedures (further
described in Additional file 1: Supplemental methods).
Overexpression of EMT-linked transcription factors
Stable modified MCF10A subclones overexpressing TWIST
or SNAI2 were established by retroviral transduction, as de-
scribed previously [32], and termed MCF10A/TWIST and
MCF10/SNAI2, respectively. The plasmid constructs used
are previously described [33]. The cells were exposed to the
virus for 2 × 8 h, interrupted by 8-h incubation in standard
medium. In addition, a control subclone was prepared by
insertion of the empty vector, which contained the
gene for GFP (MCF10A/GFP). Transduction positive
cells were sorted by FACS using the GFP marker.
CRISPR/Cas9 in vitro gene editing of SDHC and SDHD
MCF7 cells with heterozygous knockdown of SDHC
(MCF7 SDHC+/−) was obtained by introducing a frameshift
deletion within the coding region (exon 3) of the gene.
Twenty nucleotides gRNA targeting SDHC were designed
(ATAGTAATGTGGGGAGACAG) using the Benchling
online tool (www.benchling.com). The oligo-nucleotide
sequences were synthesized with the suitable overhangs
for plasmid insertion (CACCGATAGTAATGTGGGG
AGACAG and AAACCTGTCTCCCCACATTACTATC),
before insertion into the pX458SpCas9 plasmid (Addgene,
Waltertown, MA, USA), which had been modified to
increase the fidelity of Cas9, (according to [34], kindly
provided by Ole M. Seternes). The primers were
phosphorylated and annealed using T4 PNK (NEB),
followed by digestion/ligation into the plasmid, utiliz-
ing Golden Gate reaction using BbsI enzyme (NEB)
and T7 ligase (NEB). The gRNA inserts were further
sequenced to confirm the correct insertion using the
U6 primer (GATACAAGGCTGTTAGAGAGATAATT).
The cells were transfected with the gRNA containing con-
struct using Lipofectamine LTX (Invitrogen, Carlsbad,
CA, USA) for 5 days. Subsequently, cells were sorted into
a 96-well plate (one cell per well) based on GFP expres-
sion from the vector, using Sony SH800S cell sorter. Upon
colony formation in the wells, DNA was purified from
each clonal colony and the targeted region was amplified
by PCR and sequenced using forward primer CTCG
GCCTCCCAAAGAGCTGAGATTA and reverse primer
CTCATCTACATAGCAGTATTTTGGTTGAGTAA. The
PCR products revealing deletion(s) were further inserted
into (vector) by TOPO TA cloning and subject to
re-sequencing, in order to confirm that mutation was
introduced.
mRNA expression analysis by quantitative polymerase
chain reaction
Total RNA was isolated from cell pellets using the
RNeasy MINI KIT (74104, Qiagen, Venlo, Netherlands).
cDNA was synthesized using the High-Capacity cDNA
Reverse Transcription Kit (4368813, Thermo Fisher
Scientific, Waltham, MA) and Biorad MJ Mini Thermal
Cycler (Hercules, CA, USA). The quantitative polymerase
chain reaction (qPCR) was performed using the Light
Cycler 480 system (Roche, Basel, Germany) and the Light
Cycler 480 Probes Master reaction mix
(Cat# 04887301001, Roche). The gene-specific probes
used are listed in Additional file 2: Table S3. The ΔΔct
method was used for calculating fold change in gene ex-
pression relative to the control sample.
Mitochondrial DNA quantification
Total DNA was purified from cell pellets using the DNeasy
blood and tissue kit from Qiagen (69504, DNeasy Blood
and tissue kit, Qiagen). Taqman probe/primer mixtures for
mitochondrial NADH dehydrogenase 1 (mitochondrial
DNA (mtDNA) gene; Hs02596873_s1 MTND1) and
eukaryotic 18 s rRNA (nuclear gene; 4333760F, Applied
Biosystems, CA, USA) were used. Following quantification
by qPCR, the amount of mtDNA relative to nuclear DNA
was calculated as the ratio between the levels of MTND1
and 18 s RNA using the ΔΔct method [32].
Western blot analysis
Cells were scraped and lysed in RIPA lysis buffer
(sc24948, Santa Cruz Biotechnology, Dallas, TX). Protein
concentration of the lysed samples were measured by
the Pierce® BCA Protein Assay Kit (Thermo Fisher Sci-
entific). Electrophoresis was done using premade Biorad
stain-free gels (Biorad Mini-PROTEAN 3 Cell), and the
protein was transferred to polyvinylidene fluoride PVDF
membranes (GE Healthcare, Little Chalfont, U.K) by
BioradTurbo Transfer System. Before stained with respect-
ive antibodies (Additional file 2: Table S3), total protein was
assessed by imaging on ChemiDocTM XRS+ with Image
Lab Software (Biorad).
Spheroid and scratch-wound assays
For measurement of spheroid formation capacity,
Geltrex LDEV-free (Thermo Fisher Scientific) was used
as a gel matrix. In a 12-well plate, 350 μl/well of Geltrex
was casted and solidified at 37 °C for 30 min. Twenty-
five thousand cells were suspended in 500 μl of assay
medium (2% of geltrex in medium) and added to the
solidified matrix. Cells were incubated at 37 °C and cell
growth and colonies were observed for 3–7 days. For ana-
lysis of spheroid stability and growth, centrifugation-assisted
spheroid formation was performed by transferring the cells
(5000 cells/well) to a 96-well u-bottom ultralow attachment
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plate (Corning, Thermo Fisher Scientific), followed by cen-
trifugation for 15min at 300 rcf (room temperature). The
Incucyte ZOOM 2016B (EssenBioscience Ltd., UK) was
used for time-lapse imaging of the spheroids and for
scratch-wound assay. For MCF7 spheroids, the area was
calculated from the average radius retrieved from measuring
two perpendicular diameters (Image Pro Software ver-
sion 7.0, Media Cybernetics, Inc., Washington, USA).
Ten spheroids were measured in each group. For the
scratch-wound assay, cells were plated at 45 k cells/
well (IncuCyte ImageLock Plates cat #4397) for an
optimal 80–90% confluency and incubated over-night.
Just prior to the time-lapse imaging sequence, scratch
wound was made to the monolayer using the wound
maker (IncuCyte Cell Migration Kit, cat# 4493). The
cultures were imaged using the Incucyte ZOOM
2016B or by phase contrast microscopy of monolayers
fixed in methanol with crystal violet. The percent
wound closing after 24 h relative to start was mea-
sured using the IncuCyte scratch-wound cell migra-
tion software module (Cat# 9600-0012), or by phase
contrast microscopy with ocular micrometer, measur-
ing the gap distance at a fixed location.
Mitochondrial respiration
Oxygen consumption rate (OCR) was measured using
the Seahorse XFe96 Analyzer (Agilent, Santa Clara, CA),
according to the manufacturer’s protocols and previous
descriptions [32, 35]. All materials were from Sigma-Al-
drich (St. Louis, MO) unless otherwise stated. For ana-
lysis of SDH-linked activity, the cells were permeabilized
to facilitate cellular uptake of succinate and ADP, by
adding the Seahorse XF plasma membrane permeabili-
zer (PMP) (Agilent), as indicated. The concentration of
PMP and metabolic modulators (uncoupler, inhibitors)
were optimized for each cell type. The data were nor-
malized to cell number using Hoechst 33342 (Thermo
Fisher Scientific) or protein content (Pierce® BCA Pro-
tein Assay Kit, Thermo Fisher Scientific). Further de-
tails are provided in Additional file 1: Supplemental
methods.
Flow cytometric G0–G1 separation by Pyronin Y and
Hoechst 33258 staining
Cell pellets (1 mill cells) were treated with 50 μg/ml
Hoechst 33342 (Thermo Fisher Scientific) for 1 h in 37 °C.
After washing, the cells were stained with 1 μg/ml Pyronin
Y (Sigma-Aldrich) for 30min in 37 °C. Cells were washed
and filtered before flow cytometric analysis. Pyronin Y was
detected at ca 570 nM and Hoechst was detected at 405 nm
at the Fortessa LSR (BD Biosciences, San Jose, CA). Ana-
lysis was performed in FlowJo software.
Immunocytochemistry
Cells were plated on cover slips in 24-well culture plates
(10,000 cells/well) and left until they reached 70% con-
fluency. The cells were then fixed in 3.7% PFA,
permeabilized with TBS-T, and stained with primary
antibodies for E-cadherin (cat # 14472, Cell Signaling,
Leiden, Netherlands) and vimentin (AB92547, Abcam,
UK), and diluted 1:100 in TBS-T with 0.5% BSA. Alexa
594 anti-mouse and Alexa-647 anti-rabbit were used as
secondary antibodies. The cells were thereafter stained
with 1:40 Phalloidin AF555 (a34055, Thermo Fisher Scien-
tific) according to the manufacturer’s instruction, before
mounting with Prolong Dimond with Dapi (Thermo
Fisher Scientific). Images were acquired on a Leica TC2
SP8 STED 3X with HC PL APO CS2 lasers using the
100 × 1.4 NA oil objective.
Confocal microscopy and three-dimensional image
analysis of mitochondria
Mitochondria were stained using immunocytochemistry
(ICC) (as described above) with primary antibodies against
TOM20 (FL145 Santa Cruz Biotech, Dallas, Texas; 1:100);
and ATPB (AB5452 Abcam, Cambridge, UK; 1:500). Im-
aging was performed by confocal microscopy (Leica TCS
S5 microscope, Leica microsystems, Wetzlar, Germany).
Image processing, three-dimensional (3D)-modeling and
quantitative analysis of mitochondrial structures were per-
formed using the Image-Pro Plus software (version 7.0)
(Media Cybernetics), as described previously [32, 36]. Fur-
ther details are provided in Additional file 1: Supplemental
methods.
Results
Association between EMT and reduced SDHC expression
in human breast cancer
We investigated the association between EMT and the
different SDH subunits in human breast tumors, based
on gene expression in a patient cohort obtained from
the Haukeland University Hospital (n = 204) [30] and an
Affymetrix breast cancer meta-cohort (n = 3992) [7].
Using both a breast cancer-directed 8-gene signature
(EMT8) and a generic 315-gene signature (EMT315),
EMT was found to be particularly associated with reduced
SDHC expression in the n = 204 cohort, with a Rho value
of − 0.422 (p < 0.0001) using the EMT8 signature (Fig. 1a)
and Rho value of − 0.55 (p < 0.0001) using the EMT315
signature (Fig. 1b). SDHA and SDHB expression were not
associated with EMT, whereas SDHD demonstrated a
positive relationship upon using the EMT315 signature
(Rho = 0.303, p < 0.0001) (Fig. 1b). We also investigated if
the expression of the SDH subunits was specifically asso-
ciated with the central EMT-linked transcription factors
TWIST and SNAI2. The analysis indicated that SDHC
was inversely correlated to both TWIST1 (Rho = − 0.337,
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p < 0.0001) (Fig. 1c) and SNAI2 (Rho = 0.27, p < 0.0001),
whereas SDHD showed a positive correlation to SNAI2
(Rho = 0.328, p < 0.0001) (Additional file 2: Figure S1A).
Neither SDHA, SDHB, nor SDHD showed associations
to TWIST1. To verify these results, we applied the
EMT315 signature on the Affymetrix breast cancer patient
meta-cohort (n = 3992). In concordance with our previous
observations in the n = 204 cohort, there was an inverse as-
sociation between EMT and SDHC (Rho = − 0.283, p <
0.0001) (Fig. 1d). In support, we found a similar inverse
correlation between EMT315 and SDHC gene expression
in a breast invasive carcinoma cohort (Rho = − 0.337, p <
0.0001) as well as in breast cancer cell lines (Rho = − 0.517,
p < 0.0001) in TCGA RNA-seq data (Additional file 2: Table
S1). Correlation analysis between the individual SDH sub-
units in the n = 204 cohort generally returned statistically
significant associations between subunit pairs, although
with relatively low Rho-value (Additional file 2: Figure S1B).
This suggests some level of co-regulation of the expression
of the individual subunits, as would be expected since the
resulting proteins belong to the same enzyme complex. In
summary, these data linked EMT to SDHC suppression in
breast cancer and suggested that TWIST and SNAI2, two
of the master promoters of EMT, could be involved.
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Fig. 1 Association between SDH and EMT in gene expression data from breast cancer patient cohorts. Gene expression (mRNA) correlation
analysis (Spearman) between SDH subunits and EMT signature in datasets from breast cancer patients. a Breast cancer patient cohort (n = 204),
using the EMT8 signature (8 genes). b Breast cancer patient cohort (n = 204), using the EMT315 signature (315 genes). c Breast cancer patient
cohort (n = 204), correlation with TWIST1 expression. d Affymetrix breast cancer patient meta cohort (n = 3992), relative to the EMT315 signature.
The gene expression data are displayed with relative arbitrary units
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Low SDHC expression is associated with a poor prognosis
in basal-like tumors
Next, we investigated the relationship between EMT and
SDHC when the cohort was divided into molecular sub-
groups. When we looked at the relative levels of SDHC
mRNA, we found no difference between the n = 204
cohort tumors classified as either ER+ and ER−, or
as ductal and lobular carcinoma (Fig. 2a). Note-
worthy, we found significantly lower SDHC expres-
sion in basal-like compared to non-basal tumors,
and this coincided with significantly higher EMT8
score (Fig. 2b). A higher EMT8 score was seen in
ER− tumors compared to ER+, but there was no difference
between the histological ductal and lobular types. This is in
agreement with the known phenotypic differences between
basal-like and other breast tumor subtypes. The higher
EMT status in ER− vs ER+ tumors and basal-like vs
non-basal-like tumors were further supported in the Affy-
metrix meta-cohort, using either of the EMT signatures
(Fig. 2d); however, the overall SDHC expression did not dif-
fer between the subgroups of this cohort (Fig. 2c). Histo-
logical subclassification (i.e., ductal vs lobular carcinoma)
was not available for the Affymetrix meta-cohort. Correl-
ation analysis was performed to evaluate the relationship
between SDHC expression and EMT status within each
breast cancer subgroup. The SDHC mRNA level was in-
versely associated with the EMT8 score in each subgroup
of the n = 204 cohort (with Rho between − 0.431 and −
0.373), except for lobular breast cancer (Fig. 2e). In support,
we found an inverse association between SDHC expression
and EMT315 score in the subgroups of the Affymetrix
meta-cohort, somehow stronger in basal-like tumors
(Rho = − 0.361, p < 0.0001) compared to the non-basal-like
tumors (with Rho between − 0.292 and − 0.256) (Fig. 2f).
Interestingly, low SDHC expression tended to be associ-
ated with poorer survival in patients with basal-like tu-
mors, compared to patients with a high level of SDHC
(chi-square = 2.821, p = 0.093) (Fig. 2g). This trend was
not seen in patients with non-basal like tumors.
SDH attenuation by SDHC knockdown induces EMT in
breast cancer cells (MCF7)
The initial gene expression analysis in human breast
tumors and cell lines convincingly suggested that
EMT is associated with reduced SDHC expression. To
explore the impact of reduced SDHC expression on
EMT-related features, we knocked down this gene in
MCF7 breast cancer cells, using the CRISPR/Cas9
system. Successful heterozygous CRISPR/Cas9 editing
of SDHC (MCF7 SDHC+/−) was confirmed by sequencing
(Additional file 2: Figure S2), and the resulting reduction
in SDHC mRNA and protein was verified (Fig. 3a and b).
Immunostaining and fluorescence microscopy indicated
reduced protein levels of E-cadherin in MCF7 SDHC+/−
compared to MCF7 SDHC+/+cells, and F-actin staining
with phalloidin revealed a concordant transition from
epithelial to mesenchymal-like cell morphology (Fig. 3c).
The knockdown of SDHC was also accompanied by
marker expression consistent with induction of EMT,
i.e, E-cadherin (CDH1) was downregulated and vimentin
(VIM), SNAI2, TWIST, and AXL [33] were upregulated
(Fig. 3d). The level of N-cadherin (CDH2) mRNA was un-
detectable in both MCF7 SDHC+/+ and MCF7 SDHC+/−
cells. Consistent alterations in morphological phenotype
were also visualized by contrast enhancement microscopy
during the course of these experiments. The MCF7
SDHC+/− cells demonstrated reduced capacity to form
spheroids in plates with low surface adherence when com-
pared to MCF7 SDHC+/+ cells (Fig. 3e). Further, following
centrifugation-aided spheroid formation, the MCF7
SDHC+/− spheroids decreased in size, whereas the MCF7
SDHC+/+ spheroids grew significantly (Fig. 3f and g). This
reduced growth and stability of the multicellular spheroids
are consistent with a mesenchymal phenotype, as is the
loss of cell-cell adherence observed near the periphery of
the MCF7 SDHC+/− spheroids.
In order to study effects of SDHC knockdown on mito-
chondrial respiration, we measured the oxygen consump-
tion rate (OCR) under normal cell culture conditions
(DMEM medium) with glucose, pyruvate, and glutamine
as the major fuels and then under conditions specifically
composed to access changes in SDH function. In the pres-
ence of glucose, pyruvate, and glutamine as the major oxi-
dative substrates, the MCF7 SDHC+/− cells demonstrated
normal basal respiratory rate; however, they had signifi-
cantly reduced uncoupled respiratory capacity after
addition of oligomycin and CCCP (Fig. 3h). To investigate
succinate-dependent mitochondrial respiration, OCR was
measured in permeabilized cells, in the presence of the
complex I inhibitor, rotenone, and with succinate as the
only oxidation fuel (Fig. 3i). After adding succinate, the
OCR increased immediately and continued to rise in the
MCF7 SDHC+/+ cultures. In contrast, succinate caused
only a transient OCR induction in the MCF7 SDHC+/−
cultures. Furthermore, while OCR increased after addition
of ADP in MCF7 SDHC+/+ cultures, there was no effect of
ADP for MCF7 SDHC+/−. The increased OCR after
addition of ADP, and the subsequent inhibition by the
ATP synthase inhibitor oligomycin, confirms that this
SDH-linked respiration was coupled to ATP production
through oxidative phosphorylation (OXHOS) in the
MCF7 SDHC+/+ cells. The absence of such ADP-linked ef-
fects in the MCF7 SDHC+/− cells indicates that these cells
were unable to utilize succinate to fuel ATP production.
In summary, the MCF7 SDHC+/− cells were incapable of
maintaining succinate-driven mitochondrial respiration
and OXPHOS under these conditions, consistent with an
attenuation of SDH activity.
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Further, properties of migration were investigated
in a scratch wound experiment, where we also in-
cluded MCF7 SDHD+/− cells (sequencing data in
Additional file 2: Figure S2B), as SDHD demon-
strated a different relationship with EMT compared
to SDHC in the previous tumor gene expression ana-
lysis. Similar to the control MCF7 SDHC/D+/+ cells (par-
ental), and in contrast to the mesenchymal-like MCF7
SDHC+/− cells, the MCF7 SDHD+/− cells had an epithelial
morphology (Fig. 3j). The scratch-wound study clearly
showed that MCF7 SDHC+/− cells had significantly higher
wound healing capacity compared to MCF7 SDHC/D+/+
and MCF7 SDHD+/− cells, as evident by a significantly
smaller gap distance 24 h after the wound was made
(Fig. 3k and l).
SDH enzyme inhibition triggers EMT
The results so far suggested that EMT is associated with
downregulation of SDH and that defective function of
this enzyme may be a causative factor for EMT in
tumors. To investigate if this link between EMT and
SDH has a general relevance also in non-tumorigenic
cells, we studied the effects of the competitive succinate
dehydrogenase enzymatic inhibitor malonate in the hu-
man mammary epithelial cell line MCF10A. Treatment
with malonate for 3 days significantly reduced basal
respiration and uncoupled respiratory capacity (Fig. 4a
and b). Further, malonate treatment was confirmed to
inhibit SDH by reducing SDH-linked respiration mea-
sured in permeabilized cells in the presence of succinate
and ADP (Fig. 4c and d). In both of these experiments,
the normal response to the addition of oligomycin, and
subsequently ADP or uncoupler, confirmed that the in-
tegrity of the OXPHOS system remained intact upon
malonate treatment. Importantly, the malonate treat-
ment caused increased expression of vimentin and
N-cadherin and reduced expression of E-cadherin, both
on the level of mRNA (Fig. 4e) and on protein (Fig. 4f ).
This typical marker profile of EMT was consistent with
the consequent change in cellular morphology (Fig. 4g).
These data support that inhibition of SDH enzyme ac-
tivity may constitute an inherent trigger of the EMT
program.
Overexpression of EMT-linked transcription factors leads
to attenuation of SDH
Gene expression analysis suggested that there is a
regulatory relationship between EMT-related genes
and SDH subunits, especially regarding SDHC, in the
breast cancer cohorts of this study. To determine if
EMT-linked transcription factors could be involved in
SDH downregulation, we overexpressed TWIST and
SNAI2 in MCF10A cells (MCF10A/TWIST and MCF10A/
SNAI2, respectively). Both the modified cell types presented
a switch from epithelial to mesenchymal phenotype, as seen
by confocal imaging showing characteristic changes in cell
morphology, remodeling of the cytoskeleton, increased level
of vimentin, and a reduced level of E-cadherin (Fig. 5a). In-
duction of EMT was further verified by increased expres-
sion levels of vimentin, N-cadherin, Axl, PRXX1, and
downregulated E-cadherin, as well as reduced cell prolifera-
tion (Additional file 2: Figure S3). In a centrifugation-aided
spheroid formation experiment, the parental MCF10A cells
formed dense spheroid structures, whereas the MCF10A/
TWIST and MCF10A/SNAI2 cells formed less compact
structures with loosened cell-cell contact, as expected upon
EMT (Fig. 5b). Moreover, a congruent reduction in total
RNA level was measured in MCF10A/TWISTcells (Fig. 5c),
reflecting a higher content of cells in the state of quiescence
due to EMT. Following the verification of EMT in the
modified cells, we investigated the effects on SDH. Reduced
protein expression of both SDHB and SDHC was detected
in the MCF10A/TWIST cells (Fig. 5d). Analysis of oxygen
consumption demonstrated that the rates of mitochondrial
respiration were lower in MCF10A/TWIST and MCF10A/
SNAI2 cells, compared to controls (Fig. 5e–g). The lower
rates of leak respiration in the overexpressing cells contra-
dict the possibility that the integrity of mitochondrial inner
membrane could be compromised, as this would lead to in-
creased leak respiration due to uncoupling effects. Rather,
the lower leak respiration may be explained by a general de-
crease in mitochondrial respiration. Similar to the previous
studies, we then measured SDH-linked respiration in
permeabilized cells, in the presence of rotenone, succinate,
and ADP (Fig. 5h and i). We found that the activity of SDH
was significantly reduced in the MCF10A/TWIST cells,
compared to control. Also in these cells, mitochondrial in-
tegrity remained intact despite the loss of SDH activity,
(See figure on previous page.)Fig. 2 SDHC gene expression in subgroups of breast cancer. The two cohorts included in the study was
subdivided based on molecular characteristics such as estrogen receptor positive and negative (ER+ and ER−) and basal- and non-
basal phenotype. Claudin-low and triple negative subgroups were included in the basal category. In addition, the breast cancer
patient cohort (n = 204) was subgrouped based on histology, i.e., into ducal and lobular characteristics. a mRNA expression of SDHC
and b EMT8 signature were assessed for the distinct subgroups in the n = 204 cohort. c mRNA expression of SDHC and d EMT8 and
EMT315 signatures were determined for the subgroups in the n = 3992 Affymetrix meta cohort. e Spearman correlation analysis for
SDHC expression relative to EMT8 signature for subgroups of the breast cancer cohort (n = 204) and f the Affymetrix meta cohort. g
Kaplan-Meier survival plots for basal- (n = 42) and non-basal-like (n = 161) breast carcinoma of the breast cancer cohort. The gene
expression data are displayed with relative arbitrary units
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Fig. 3 (See legend on next page.)
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(See figure on previous page.)
Fig. 3 Induction of EMT in MCF7 upon SDHC knockdown. Parental MCF7 cells (MCF7 SDHC+/+) were modified by CRISPR/Cas9 editing to knock
down the expression of SDHC (MCF7 SDHC+/−). a SDHA-D mRNA was analyzed by qPCR. b SDHC protein expression was analyzed by western
blotting. c Confocal microscopy was performed to evaluate E-cad (immuno-stained, green) expression level and cell morphology (F-actin stained
by phalloidin, red). dmRNA expression of the EMT markers E-cad (CDH1), vimentin (VIM), TWIST1, SNAI2, and Axl. e Spheroid formation (anchorage-
independent) was evaluated after seeding the cells in wells with low surface adherence. f Spheroid growth and stability was assessed after centrifugation-
aided spheroid formation. The spheroid size was measured after 48 h in culture. g The diagram shows statistical data from the experiment described in (f).
h Mitochondrial respiratory rates were measured in MCF7 SDHC+/+ and MCF7 SDHC+/− cultures, with glucose, pyruvate, and glutamine provided as the
major fuels. Oxygen consumption rate (OCR) was monitored upon sequential additions of oligomycin (O, 3 μM), CCCP (C, 0.75 μM), rotenone (R, 1 μM), and
antimycin A (A, 1 μM) as indicated, to assess specific properties of mitochondrial respiration. i For measurement of SDH-dependent mitochondrial
respiration, the cells were permeabilized (with PMP) and rotenone was added prior to analysis in restricted assay medium (MAS). Succinate (SUCC, 10mM),
ADP (4mM), oligomycin (OLIGO, 3 μM), and antimycin A (AMA, 1 μM) were added sequentially as indicated. j Fluorescence microscopy was performed to
compare cell morphology (F-actin stained by phalloidin, white) in MCF7 SDHD/C+/+, MCF7 SDHC+/−, and MCF7 SDHD
+/− cultures. k Scratch-wound assay
comparing MCF7 SDHD/C+/+, MCF7 SDHC+/−, and MCF7 SDHD
+/− cells. The images were taken 24 h after the scratch was made. l In the experiment
described in (k), we measured scratch size as gap distance (d) at a fixed position, after 24 h, and calculated the results relative to the initial scratch size. Each
dot represents separate wells. Data are shown as mean ± SD for (a), (d), (g), and (l) and mean ± SEM for (h) and (i). Student’s t test was used for statistical
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Fig. 4 SDH enzyme inhibition causes induction of EMT. We investigated if SDH enzyme inhibition causes induction of EMT by treating MCF10A
cells with the SDH inhibitor malonate (25 mM) for 3 days. a Conventional analysis of mitochondrial respiratory function by measuring oxygen
consumption rate (OCR) in DMEM medium in malonate treated MCF10A cells. b The diagram shows statistical data from the experiment
described in (a). c SDH-linked respiration was assessed with succinate (Succ) as the only provided substrate, following the addition of cell
permeabilizing agent (PMP) and ADP. Oligomycin (Oligo) and antimycin A (AMA) was added to control mitochondrial integrity and background
activity, respectively. d The diagram shows statistical data from the experiment described in (c). e mRNA and f protein expression of
epithelial (E-cadherin (CDH1)) and mesenchymal (N-cadherin, (CDH2); vimentin, (VIM)) markers. g Phase contrast microscopy. Student’s t
test was used for statistical analysis. Data are shown as mean ± SEM for (a)–(d) and mean ± SD for (e). *p < 0.01
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supported by the normal response to oligomycin in
the presence of ADP. In summary, these data suggest
that initiation of the EMT program leads to attenu-
ation of SDH.
TWIST overexpression leads to reduced mitochondrial
biomass and changed organelle morphology
Based on the findings suggesting that EMT involves a
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Fig. 5 Induction of EMT in MCF10A cells overexpressing TWIST or SNAI2. The EMT-linked transcription factors TWIST and SNAI2 were
overexpressed in epithelial MCF10A cells. EMT was manifested by acquisition of mesenchymal traits. a Fluorescence microscopy for
detection of vimentin and E-cadherin, and cell morphology (using phalloidin to stain F-actin), in the parental cells (MCF10A/Par), and cells
overexpressing TWIST (MCF10A/TWIST) and SNAI2 (MCF10A/SNAI2). b Images (phase-contrast microscopy) showing spheroid formation
capacity. c Total cellular RNA versus DNA content (Hoechst 33258) in MCF10A/TWIST, compared to MCF10A/Par (flow cytometry). d
Protein expression of subunit SDHB and SDHC in MCF10A/Par and MCF10A/TWIST cells. e Mitochondrial respiration after overexpression of
EMT-linked transcription factors. Oxygen consumption rate (OCR) was measured after sequential additions of oligomycin (Oligo), CCCP,
rotenone (Rot), and antimycin A (AMA), in DMEM medium. f Extracted data from the experiment in (e), showing rates of basal and leak
(with oligomycin) respiration and respiratory capacity (uncoupled, with CCCP), in the MCF10A/TWIST and MCF10A/SNAI2 cells relative to
parental cells (CTR). g Leak respiration (with oligomycin) as the percentage of respiratory capacity (uncoupled, with CCCP), from the
experiment in (e). h SDH activity measured in restricted medium (MAS) after the supply of rotenone (Rot), succinate (Succ), ADP, and
permabilizing agent (PMP). Oligomycin (Oligo) and antimycin A (AMA) were then added to control mitochondrial integrity and
background activity. i The diagram shows statistical data from the experiment described in (h). Data are shown as mean ± SD (column
plots) or mean ± SEM (OCR traces). Student’s t test was used for statistical analysis. *p < 0.01
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through SDH downregulation, we investigated mito-
chondrial morphology in MCF10A/TWIST compared to
parental MCF10A cells using confocal microscopy and
quantitative 3D-image analysis. The mitochondria in
MCF10A cells were tubular and formed a compact and
continuous reticulum throughout the cytoplasm (Fig. 6a).
Mitochondria in MCF10A/TWIST cells were also tubu-
lar, but the structures were thinner and there was a frac-
tion of relatively small peripheral organelles dissociated
from the major mitochondrial assembly. Quantitative
analysis revealed that the number of organelles was sig-
nificantly higher in MCF10A/TWIST cells, compared to
parental cells (Fig. 6b). However, the total mitochondrial
volume was smaller (Fig. 6c), though the total mitochon-
drial tubule length was unchanged (Fig. 6d). Frequency
distribution analysis of single mitochondria showed
increased proportion of smaller organelles in the
MCF10A/TWIST cells (Fig. 6e). Consequently, small-
and medium-size mitochondria were found to constitute
a larger fraction of the total mitochondrial volume, com-
pared to epithelial MCF10A cells (Fig. 6f ). Increased
surface-to-volume ratio in MCF10A/TWIST mitochon-
dria further supported a change towards thinner tubular
structures compared to the parental phenotype (Fig. 6g).
Taken together, these imaging data show that EMT in































































































































































































































































































































































Fig. 6 Mitochondrial mass and morphology. Mitochondrial mass and morphology were compared in MCF10A (parental, epithelial) and MFC10A/
TWIST (mesenchymal) cells. a–g Confocal microscopy and quantitative image analysis of immune-stained mitochondria (TOM20 + ATPB). a Based
on confocal z-stacks, 3D-models of mitochondrial volume and filament structure were generated, as indicated from left to right in the two image
panels. b Mean number of mitochondria per cell (Nm). c Mean mitochondrial total volume per cell (Vm,cell). d Mean mitochondrial total tubule
length per cell (Lm,cell). e Size (volume) frequency distribution comparing mitochondria in MCF10A (parental) versus MCF10A/TWIST cells. f Volume
fraction analysis of mitochondrial subclasses (size). g Surface area (S.A.) to volume (Vm) regression analysis of individual mitochondria in MCF10A
(parental) and MCF10A/TWIST cells. The analysis comprised (parental/TWIST) 937/3643 mitochondria with total volume 9020/9554 μm3, in 30/61
cells (n). h–n Effects of TWIST overexpression on mtDNA and gene expression of mitochondrial proteins. h Amount of mtDNA in MCF10A/TWIST
relative to parental MCF10A. i Protein expression (WB) of TOM20. j Protein expression of PGC1α, including MCF10A/SNAI2 cells. k mRNA
expression of CPT1 and CYCS. l Protein expression (WB) of Drp1 (DMN1L) and Opa1. m mRNA expression of DMNL1 (Drp1), OPA1, MFN1, and
MFN2. n mRNA expression of PINK1 and PARK2. Student’s t test was used for statistical analysis. Data are shown as mean ± SD. *p < 0.01
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mitochondrial volume and a morphological change from
a compact mitochondrial reticulum to a more dispersed
and fragmented network of thinner tubules. Congruent
with reduced mitochondrial biomass, the MCF10A/
TWIST cells had reduced amounts of mitochondrial
DNA (mtDNA), TOM20 protein, the transcriptional co-
activator and key regulator of mitochondrial biogenesis
PGC1α, and mRNA levels of the mitochondrial proteins
carnitine palmitoyl transferase 1 (CPT1A) and cyto-
chrome c (CYCS) (Fig. 6h–k). Further supporting the
observed changes in mitochondrial dynamics, the mito-
chondrial fission-related Drp1 protein was found to be
upregulated, whereas the mitochondrial fusion protein
OPA1 was downregulated (Fig. 6l). Additional mRNA
expression analyses confirmed the upregulation of DMN1L
(DRP1) and indicated a trend for the downregulation of
OPA1 and MFN2 but not for MFN1, in the MCF10A/
TWIST cells compared to MCF10A/Par (Fig. 6m). Further,
we observed significantly higher PINK1 and PARK2 expres-
sion in MCF10A/TWIST cells (Fig. 6n). These data sup-
ports that EMT involves loss of mitochondrial biomass and
more fragmented organelle structure, consistent with re-
duced respiratory rates.
Potential links between SDH regulation and EMT activation
Finally, to investigate if the four SDH subunits may have
specific impacts on tumor metabolism, mitochondrial
dynamics and antioxidant systems related to EMT, we
performed correlation analysis including panels of marker
genes on the Affymetrix breast cancer cohort. A heat map
of the correlation coefficients (Spearman Rho) comparing
associations between specific genes of interest relative to
the SDH subunits and EMT markers is shown in Fig. 7
(the dataset is provided in Additional file 1: Table
S2). To clarify, since we aimed to identify potential
links between attenuated SDH and EMT activation,
we were looking for genes demonstrating an opposite
relationship towards SDH compared to EMT (i.e., Rho
value with opposite signs). In general, SDHA, SDHB, and
SDHC, demonstrated similar patterns of association with
this panel of genes, in contrast to SDHD that showed
some divergence compared to the other SDH subunits.
This association analysis did not suggest that expression
of the EMT315 signature, TWIST1, and SNAI2 was con-
sistently linked to HIF-1 target genes associated with gly-
colysis, apart from GLUT3 (Fig. 7a). The expression of
SDHA, SDAB, and SDHC tended to be positively associ-
ated with the metabolic HIF-1 target genes. Moreover,
western blot analysis of HIF-1α revealed no signs of in-
creased protein stabilization in MCF10A overexpressing
TWIST, or MCF7 SDHC/D+/+ and MCF7 SDHD+/− cells
(Additional file 2: Figure S4). Hence, although our findings
do not directly support that SDH suppression promotes a
HIF-1-regulated shift towards increased glycolysis in these
tumors, it still remains a possibility. HIF1-regulated genes
involved in EMT and invasion demonstrated a clear ten-
dency of inverse regulation relative to SDHA, SDHB, and
SDHC, while positively linked to EMT markers. Moreover,
the increasing expression of the SDH subunits was associ-
ated with increasing expression of markers of mitochon-
drial biomass (Fig. 7b). These markers generally showed
weak inverse relationships with EMT-linked gene expres-
sion. SDH subunit expression was also associated with
genes involved in both mitochondrial fission and fusion,
probably reflecting a parallel regulation of genes encoding
mitochondrial proteins. Further, a tendency of positive
association with autophagy genes such as BECN1 and
BNIP3 suggests that SDH downregulation is related to
modulation of autophagy, and an inverse association with
PARK2 may suggest that mitochondrial quality control is
activated under such conditions. Downregulation of SDH
subunits tended to be associated with downregulation of
antioxidant systems (i.e., positive associations), apart from
GPX2 and GPX5 showing inverse relationships with all
SDH subunits (Fig. 7c). The effects of such changes may
be complex, and these data do not reveal if potential
changes in tumor redox state due to reduced SDH subunit
expression may be associated with EMT. Although some
antioxidant enzymes appeared to linked to EMT, such as
GPX7 and GPX8, we did not find clear reciprocal relation-
ships with reduced expression of SDHC or the other SDH
subunits. Finally, analysis of three anticipated target genes
did not indicate that AMPK was coherently activated in
the context of SDH suppression but rather showed that
these genes were individually regulated, with CPT2 show-
ing a clear positive relationship with expression of SDHA,
SDHB, and SDHC (Fig. 7d).
Discussion
This study support that attenuation of SDH represents
an inherent element and driver mechanism of the EMT
program and especially points to SDHC as a contribut-
ing factor in the context of breast cancer. Through com-
prehensive cellular analyses, we characterized regulatory
and functional aspects of the relationship between EMT
and SDH, and further found the EMT program to in-
volve distinct changes in mitochondrial function and
morphology.
Based on previous reports suggesting that mitochon-
drial dysfunction and SDHB mutations promote EMT
[4, 37], we hypothesized that altered enzyme function of
SDH may be a determining factor and possibly an integral
part of EMT in human tumors, which could be linked to
an overarching shift in mitochondrial function and dy-
namics. Thorough analyses in breast cancer patient co-
horts revealed a relatively consistent inverse association
between EMT and reduced expression of the SDHC sub-
unit. Upon molecular and histological classification of the




Fig. 7 (See legend on next page.)
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breast cancer cohorts, we found that the relationship
between SDHC and EMT was stronger in the basal-like
subgroup compared to the non-basal-like subgroup.
Interestingly, when looking at overall survival, low
SDHC level was associated with a worse outcome in
basal-like breast carcinoma. This finding can imply that
suppressed activity of SDH-linked mitochondrial pathways
is associated with a worse prognosis in basal-like breast
carcinomas. As mitochondrial function is challenging to
assess in frozen and paraffin-embedded samples, there is an
urgent need for indicative markers reflecting mitochondrial
abnormalities. Our results suggest that SDHC expression
could serve as a potential prognostic marker to enable fur-
ther discrimination in the basal-like breast carcinoma sub-
group. Furthermore, upon histological classification of the
n = 204 breast cancer cohort, we found the inverse associ-
ation between SDHC and EMT to be more pronounced in
the ductal subgroup, compared to the lobular, but we did
not see an impact on the overall survival.
The relationship between SDHC and EMT was sup-
ported in subsequent studies revealing that EMT is in-
duced by CRISPR/Cas9-mediated knockdown of SDHC,
or SDH enzyme inhibition with malonate in respective
cell models. Under these conditions, EMT clearly in-
volved inhibition of SDH enzyme activity, as the ability
to utilize succinate as respiratory fuel was significantly
reduced. These findings extend the potential impact of
SDH attenuation on malignant mechanisms beyond the
role as tumor suppressor, as they suggest that transcrip-
tional suppression, not only genetic SDH defects, may
promote EMT.
Overexpression of EMT-linked transcription factors
(TWIST and SNAI2) caused SDH suppression, reduced
mitochondrial respiration, decreased amount of mitochon-
drial biomass (mtDNA and organelle volume), downregu-
lated mitochondrial biogenesis (including PGC1α), and
altered organelle structure. Noteworthy, context-dependent
changes of mitochondrial functional state are also often ac-
companied by accordant effects on organelle structure and
amount (i.e., mitochondrial dynamics) [38]. Our findings
provide mechanistic insights for previous reports elucidat-
ing context-dependent links between SDH inhibition, mito-
chondrial dysfunction, and EMT [4, 13, 22, 39]. The results
are also in agreement with findings suggesting that SNAI1
modulates cell metabolism by decreasing respiratory
activity via reduced SDH activity [40]. The EMT-linked
mechanisms involving reduced SDH activity may share
similarities with the action of other mitochondrial
tumor suppressors, such as fumarate dehydrogenase,
fumarate hydratase, and isocitrate dehydrogenase, as
well as OXPHOS defects that contribute to tumor de-
velopment [18, 41, 42]. According to our findings, it
can be speculated that an increased population of
smaller mitochondrial organelles may facilitate cellular
plasticity accompanying EMT and that this is associated
with processes of mitochondrial quality control, as sug-
gested by increased expression of PINK1 and PARK2. This
aspect is emphasized by findings in stem cells where mito-
chondrial quality is supported through asymmetric organ-
elle sorting during cell division [43] and the role of
mitochondrial dynamics during embryogenesis [44].
Interestingly, we found a clear relationship between
the cells’ ability to form spheroids, wound healing capacity,
and EMT state, related to downregulation of SDHC. This
observation constitutes a convincing example of how meta-
bolic rewiring may represent an integral part of cellular
plasticity. It may also incorporate established paradigms of
tumor metabolism where suppressed mitochondrial en-
ergetics supports biomolecule synthesis or antioxidant
defense [45]. Moreover, decreased proliferation and re-
duced dependency on mitochondrial respiration may
constitute a protective adaptation mediating tolerance
for a harsh microenvironment, including hypoxia, nu-
trient deprivation, and therapeutic pressures [46]. This
may, however, also open for targeted therapeutic strat-
egies. For instance, RCC tumors with SDHB mutations
has been shown to be highly dependent on an increased
influx of glucose, and glucose interfering drugs have
already been proposed as possible therapeutic strategies
[47]. Also, it has been shown that mutations in SDH
establishes a hypermethylated phenotype in PGL/PCC,
possible through the accumulation of succinate [48].
Interestingly, KRT19, one of the genes showing the
strongest evidence for epigenetic silencing in hyper-
methylated PGL/PCCs, is closely associated with EMT.
This may explain the particularly invasive phenotype of
SDHB-related tumors.
Gene expression analysis on the Affymetrix breast can-
cer cohort confirmed that downregulation of SDHA,
SDHB, SDHC, and/or SDHD is associated with increased
expression of EMT and invasion/migration markers and
pointed to specific genes that may link to accompanying
effects on energy metabolism, mitochondrial quality
control, and antioxidant systems to the induction of
EMT (Fig. 7). Although HIF-1 and AMPK may be in-
volved in these processes, it appears likely that some of
(See figure on previous page.)
Fig. 7 Gene expression analysis of potential links between SDH suppression and EMT activation. Gene expression (mRNA) analysis correlating
(Spearman) SDH subunits, EMT signature, TWIST1, and SNAI2 to panels of genes focusing on specific processes, based on data from the
Affymetrix breast cancer patient meta cohort (n = 3992). The heat map panels reflect the directions and strength (Rho value) of the associations.
The panels of genes included a HIF-1 targets, b factors involved in mitochondrial dynamic, c antioxidant enzymes, and d AMPK targets
Røsland et al. Cancer & Metabolism             (2019) 7:6 Page 15 of 18
their anticipated target genes may also be regulated by
other mechanisms. Moreover, interactions of SDH and
other components of the respiratory chain may affect
EMT through effects on reactive oxygen species (ROS)
generation and scavenging. Such mechanisms likely de-
pend on cellular origin and phenotype, and probably the
state of EMT. Our investigations primarily focused on
long-term effects associated with EMT. Whether ROS
play a role in the induction of EMT, or transition be-
tween different states of EMT, would be an interesting
aspect for further studies, provided the metabolic links
revealed in the presented work.
As EMT is recognized as a driver mechanism of me-
tastasis, therapy resistance, and immune evasion, our
findings provide mechanistic support for further investi-
gations of mitochondrial features as potential thera-
peutic targets. To this end, mitochondria-targeted drugs
such as resveratrol and metformin have been reported to
inhibit EMT [49], and metformin has a preventive effect
on cancer incidence [50]. The presented findings point-
ing to SDH suppression as an integral part of the EMT
process may therefore open for new strategies to prevent
and treat malignancies.
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Figure S1: (A) Correlation analysis (Spearman) between the 
expression of the four SDH subunits relative to SNAI2 in the n=204 breast cancer 
cohort. (B) Correlation analysis (Spearman) between the individual SDH subunits 


































Figure S2: (A) Sequence alignment of the SDHC gene in CRIPSR/
Cas9- modified  MCF7 cells and the SDHC wild-type gene, revealing an 11bp 
frameshift deletion. (B)Sequence alignment of the SDHD gene in CRIPSR/Cas9-
modified MCF7 cells and the SDHD wild-type gene, revealing an 29bp frameshift 

























































































































































































































































































Figure S3: Characterization of the EMT process in MCF10A cells 
upon overexpression of TWIST and SNAI2 (Slug). (A) Cell proliferation was 
measured by the use of the xCelligence RTCA DP instrument (ACEA Bioscience, 
San Diego, CA), which measures cellular impedance (expressed as “Cell index”). 
The cells (MCF10A, MCF10A/GFP, MCF10A/TWIST, MCF10A/SNAI2) were 
seeded at a density of 10 000 cells/well. (B) mRNA and (C) protein expression of 
TWIST and SNAI2, and epithelial (E-cadherin (CDH1)) and mesenchymal (N-
cadherin (CDH2), Vimentin (VIM), Twist, SNAI2, Axl and PRXX1) markers. The 
numbers at the end of the sample name in the western blots refer to passage 






Figure S4: Western blot analysis of HIF1α in MCF7 SDHC/D+/+, 








































Table S1: Spearman correlation analysis was applied to assess 
associations between SDH subunit gene expression and EMT315 score on (A) 
Encyclopedia breast cancer cell line collection (56 cell lines) and for (B)TCGA RNA-seq 
extracted from GDAC version 2018_01_28 from breast cancer carcinoma cohort (7).
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Table S2: Gene expression (mRNA) correlation analysis (Spearman) between SDH 











































































Table S3: (A) Probes used in experiments presented. (B) Antibodies used 






Gene expression analysis (GEA) of human breast cancer samples 
Breast cancer samples were from a HUS-cohort of 204 patients diagnosed with locally 
advanced disease and randomized to neoadjuvant epirubicin or paclitaxel monotherapy in a 
prospective study aiming at identifying predictive factors (termed the n=204 cohort). These 
patients have been described in detail previously [1]. The breast cancer meta-cohort (n=3992) 
[2] was previously curated from 26 Affymetrix U133A or U133 Plus2 gene expression cohorts 
publicly available on GEO. Briefly, the 26 cohorts were RMA-normalized, and subsequently 
standardized using ComBat [3]. An EMT signature score (here called EMT8 score) was 
calculated as previously reported, including the EMT related genes CDH1, CTNNA2, CTNNB1, 
CDH2 and CDH3 [4, 5] in addition to TWIST, SNAI2 and KRT19 expression. The sum of the 
downregulated genes (CDH1, CTNNB1, CTNNA2 and KRT19) were subtracted from the sum 
of the upregulated genes (CDH2, CDH3, SNAI2 and TWIST). A second score (here called 
EMT315 score) is based on the two-sample Kolmogorov-Smirnov test, and estimates the 
difference in cumulative distribution between consensus epithelial and mesenchymal genes 
(315 genes in total) derived from 6 carcinoma types [2]. For both EMT signature scores the 
expression values were mean normalized and scaled to the same standard deviation (SD). 
Analysis was performed using the statistical software SPSS (Statistical Package of Social 
Science) version 22.0. Spearman correlation coefficient analyses were applied to assess 
correlation between SDHs gene expression and EMT315 score. The breast cancer subtypes 
were classified based on the molecular subgroups published by Perou CM, et al in 2000 [6].  
When relevant, the tumors were analyzed as estrogen receptor negative vs positive (ER-/+), or 
as basal like vs non-basal like.  Additional histological subclassification into ductal and luminal 
carcinoma was available for the n=204 cohort. 
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Cell culture 
The breast epithelial cells MCF10A (ATCC, Manassas, VA) were grown in DMEM/F12 
(Dulbecco’s Modified Eagle’s Medium/Nutrient F-12 Ham, Sigma) containing 50 µg/mL 
penicillin/streptomycin (P-0781, Sigma), 5 % horse serum (B15021, PAA/GE Healthcare, 
Little Chalfont, UK), 20 ng/ml EGF (E9644, Sigma), 10 µg/ml insulin (I1882, Sigma), 0.5 
µg/ml hydrocortisone (H0888, Sigma) and 100 ng/ml cholera toxin (C8052, Sigma). The MCF7 
breast cancer cell line (ATCC) was cultured in EMEM (BL12-125F, ATCC) which was 
supplemented with 10 % heat-inactivated fetal bovine serum (FBS, SH30079.03, GE 
Healthcare Hyclone), 1 % L-glutamine (G7513, Sigma) and 50 µg/mL penicillin/streptomycin. 
All cells were routinely incubated in 5 % CO2 at 37ºC. Cells subjected to gene editing by 
CRISPR/Cas9 were STR-profiled before and after editing. The GlobalFiler™ PCR 
Amplification Kit and GeneScan 600 LIZ dye size standard  (Life technologies), was used 
according to the manufacturer’s instructions. Results were assessed by the GeneMapper®ID-X 
software (v.1.4) and observed alleles were compared to the theoretical alleles available at 
(www.atcc.org). The experiments were performed with cultures passaged less than 10 times 
from thawing. 
Mitochondrial respiration analysis 
Oxygen consumption rate (OCR) was measured using the Seahorse XFe96 Analyzer (Agilent, 
Santa Clara, CA), according to the manufacturers protocols and previous description [7, 8]. All 
materials were from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. Cell number and 
concentrations of compounds were optimized for each cell type. The cells were transferred to 
the analysis plate the day before measurement, and incubated overnight. For analysis of SDH-
linked activity, the cells were permeabilized to facilitate cellular uptake of succinate and ADP, 
by adding the Seahorse XF plasma membrane permeabilizer (PMP) (Agilent; MCF10A, 1.5 
nM; MCF7, 1 nM) immediately before or under the analysis, as indicated. The cell plate was 
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transferred to the instrument after replacing the culture medium with the mitochondrial assay 
solution (MAS), containing mannitol (229 mM), sucrose (70 mM), KH2PO4 (10 mM), MgCl2 
(5 mM), HEPES (2 mM), EGTA (1 mM) and 0.2 % fatty acid free BSA. Succinate (10 mM), 
ADP (4 mM), oligomycin (3 µM), antimycin A (10 µM) and rotenone (10 µM) were added as 
indicated in the figures. For studies of mitochondrial respiration in intact cells, OCR was 
recorded after successive administrations of oligomycin (3 µM), CCCP (MCF10A, 1.5 µM; 
MCF7, 0.75µM), rotenone (1 µM) and antimycin A (1 µM). These studies were performed in 
cell culture medium (D5030) supplemented with glucose (10 mM), pyruvate (2 mM) and 
glutamine (4 mM) as the major substrates; or in MAS medium without BSA, supplemented 
with pyruvate (2 mM), glutamine (4 mM) or succinate (10 mM). All data were normalized to 
cell number using Hoechst 33342 (Thermo Fisher Scientific), or protein content, measured 
using the Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA). 
Confocal microscopy and quantitative image analysis of mitochondria  
Cells were plated at a density of 50000 cells/well on coverslips placed in 24-well cell culture 
plates. Following over night incubation, the cells were fixed in 4 % PFA for 15 min and 
permeabilized with 0.5 % Triton X-100 for 4 min. After washing and blocking in TBS-
T/5%BSA the cells were incubated with a mixture of primary antibodies (1:100 TOM20,  
FL145 Santa Cruz Biotech, Dallas, Texas;  1:500 ATPB, AB5452 Abcam, Cambridge, UK) in 
the blocking solution for 1 h at room temperature, and then over night at 4 oC. After washing 
and blocking, the cells were incubated with secondary antibodies (Alexa 546 anti-rabbit and 
Alexa 647 anti-mouse, (Molecular Probes, Eugene, OR) for 1 h at room temperature. The 
coverslips were mounted in Prolong Diamond antifade with DAPI (Thermo Fisher Scientific, 
Waltham, MA).  
Confocal z-stacks were acquired on a confocal Leica TCS S5 microscope (Leica 
microsystems, Wetzlar, Germany), using a Lambda 63x 1.4 NA oil objective. Image pixel size 
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was 0.0944 µm (x and y) and bit depth 12, z-spacing 0.34 µm. Image processing and 
quantitative analysis were performed using the Image-Pro Plus software (version 7.0) (Media 
Cybernetics, Inc., Washington, USA), as described previously [9]. The acquired 12 bit z-stacks 
were background corrected (fixed level within each experiment) and processed by 3D blind 
deconvolution. Single cells were manually segmented to enable analysis of individual cells. 
The single cell z-stacks were loaded into the 3D module of the software and analyzed. The 
surface level was fixed for the experiments in this study. Structures larger than 0.05 µm3 were 
accounted as mitochondrial objects. Mitochondrial network analysis was performed as 
previously described [7, 9]. 
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A B S T R A C T
Fatty acid oxidation is a central fueling pathway for mitochondrial ATP production. Regulation occurs through
multiple nutrient- and energy-sensitive molecular mechanisms. We explored if upregulated mRNA expression of
the mitochondrial enzyme pyruvate dehydrogenase kinase 4 (PDK4) may be used as a surrogate marker of
increased mitochondrial fatty acid oxidation, by indicating an overall shift from glucose to fatty acids as the
preferred oxidation fuel. The association between fatty acid oxidation and PDK4 expression was studied in
different contexts of metabolic adaption. In rats treated with the modified fatty acid tetradecylthioacetic acid
(TTA), Pdk4 was upregulated simultaneously with fatty acid oxidation genes in liver and heart, whereas muscle
and white adipose tissue remained unaffected. In MDA-MB-231 cells, fatty acid oxidation increased nearly three-
fold upon peroxisome proliferator-activated receptor α (PPARα, PPARA) overexpression, and four-fold upon
TTA-treatment. PDK4 expression was highly increased under these conditions. Further, overexpression of PDK4
caused increased fatty acid oxidation in these cells. Pharmacological activators of PPARα and AMPK had minor
effects, while the mTOR inhibitor rapamycin potentiated the effect of TTA. There were minor changes in mi-
tochondrial respiration, glycolytic function, and mitochondrial biogenesis under conditions of increased fatty
acid oxidation. TTA was found to act as a mild uncoupler, which is likely to contribute to the metabolic effects.
Repeated experiments with HeLa cells supported these findings. In summary, PDK4 upregulation implies an
overarching metabolic shift towards increased utilization of fatty acids as energy fuel, and thus constitutes a
sensitive marker of enhanced fatty acid oxidation.
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Mitochondrial fatty acid oxidation is a crucial and highly regulated
fueling pathway for aerobic ATP production in mammalian organisms.
Abnormalities of mitochondrial fatty acid oxidation affects diverse
cellular and systemic functions, and have been linked to conditions
such as diabetes, metabolic syndrome, cancer, cancer cachexia, neu-
rodegeneration and ME/CFS (Naviaux et al., 2016; Germain et al.,
2017; Rohlenova et al., 2018; Adeva-Andany et al., 2018; Fukawa et al.,
2016). Functional analysis of mitochondrial fatty acid oxidation in
conventional biopsies are difficult, partly since it requires viable cells or
non-frozen tissue samples. Identification of sensitive and effective sur-
rogate markers of mitochondrial fatty acid oxidation may thus provide
new opportunities to assess (patho)physiological effects on metabolism.
Fatty acid catabolism is co-regulated with other pathways of cell me-
tabolism to support homeostasis when the energy supply or demand
change. There is a well-established concept of reciprocal regulation
between fatty acid and glucose oxidation for energy purposes. Different
types of metabolic adaptations may occur to accommodate (patho)
physiological changes (Sugden and Holness, 1994; Trexler et al., 2014;
Jose et al., 2013). The pyruvate dehydrogenase (PDH) complex and the
carnitine palmitoyltransferase (CPT) system are important in this con-
text. PDH converts pyruvate from glycolysis to acetyl-CoA and CO2
through oxidative decarboxylation, whereas the CPT system transports
fatty acids into mitochondria, a rate-limiting process for acetyl-CoA
production by mitochondrial fatty acid oxidation. PDH and the CPT
system are both regulated in response to changing energy conditions,
partly through contextual nutrient-gene and nutrient-protein interac-
tions that leads to metabolic adaptations. Increased rates of fatty acid
oxidation, e.g. due to starvation or insulin-deficient diabetes, is asso-
ciated with suppression of PDH activity (reviewed in (Holness and
Sugden, 2003)). This is important for conserving 3‑carbon precursors
for glucose synthesis when glucose is scarce. Such long-term adaptive
effect on PDH activity status can partly be explained by altered ex-
pression of PDH kinases (PDKs), which phosphorylate and inhibit the
PDH complex (Holness and Sugden, 2003). There are four PDK iso-
enzymes, PDK1–4, all expressed in a tissue-specific manner (reviewed
in (Jeong et al., 2012)). As suggested by Holness and Sugden, the PDKs
may be considered to act as tissue homeostats supporting adequate
context-dependent regulation of energy fueling pathways (Holness and
Sugden, 2003). In particular, changed PDK4 expression appears to play
an important role in lipid-related metabolic adaptations in various tis-
sues (reviewed in (Holness and Sugden, 2003; Sugden, 2003; Roche and
Hiromasa, 2007)). Increased level of PDK4, e.g. due to starvation (Wu
et al., 2000), favors inactivation of PDH in oxidative tissues, and
thereby implements an influential metabolic shift from glucose to fatty
acid oxidation. Furthermore, under such conditions, reduced produc-
tion of malonyl-CoA, an important inhibitor of mitochondrial fatty acid
uptake and oxidation (the CPT system), will support increased rates of
fatty acid oxidation.
Fatty acid oxidation is also controlled by nutrient- and energy-sen-
sitive factors, such as AMP-dependent protein kinase (AMPK), the fa-
mily of peroxisome proliferator-activated receptor transcription factors
(PPARs) and the mammalian target of rapamycin (mTOR) (recently
reviewed in (Desvergne et al., 2006; Lin and Hardie, 2018; Saxton and
Sabatini, 2017)). The PPAR family consists of three main isoforms
(PPARα, PPARδ, PPARγ), among which PPARα is a central regulator of
context-dependent changes in fatty acid oxidation (Desvergne et al.,
2006). AMPK is activated by a low cellular energy state, which com-
monly leads to increased mitochondrial biogenesis and stimulated
oxidation rates (Hodneland Nilsson et al., 2015; Tronstad et al., 2014).
AMPK also inactivates acetyl-CoA carboxylase (ACC), which is an en-
zyme producing malonyl-CoA (Winder et al., 1997; O'Neill et al., 2014).
Pharmacological activation of AMPK with 5-aminoimidazole-4-car-
boxamide ribonucleotide (AICAR) causes increased fatty acid oxidation
in rat muscle (Merrill et al., 1997). In contrast to PPARα and AMPK, the
activity of mTOR primarily supports biosynthesis rather than catabo-
lism. Hence, in an energy-limited context, e.g. glucose deprivation,
increased rates of mitochondrial fatty acid oxidation may be supported
by multiple regulatory events, including PPARα and/or AMPK activa-
tion, and mTOR inhibition. The contextual effects depend on both the
type of trigger as well as cell-specific properties regarding the con-
tributing signaling factors and their downstream mediators, such as
PDKs. These mechanisms regulate both the activity balance between
glucose and fatty acid oxidation, and the ability to switch between these
fueling pathways, a trait often referred to as metabolic flexibility
(Galgani et al., 2008).
PDK4 is normally highly expressed in tissues with high energy de-
mand, including heart, skeletal muscle, liver, kidney, pancreatic islet
and lactating mammary gland (Holness and Sugden, 2003; Wu et al.,
2000). In these tissues, PDK4 expression is typically induced when the
blood free fatty acid level increases, such as during starvation; and this
is mediated partly through PPARα, but also by other mechanisms
(Jeong et al., 2012; Sugden et al., 2001). PPARα-agonists, such as WY-
14,643, have been found to significantly induce PDK4 expression in rat
muscle (Wu et al., 1999), and PDK4 upregulation through PPARα may
be involved in cancer cachexia (Pin et al., 2019). Further, PDK4 was
reported to be highly upregulated upon cardiac-restricted over-
expression of PPARα in mice, and this was associated with increased
myocardial fatty acid oxidation rates (Finck et al., 2002). Upregulation
of PDK4 was also found in adipocytes after treatment with the PPARγ-
selective activator rosiglitazone, but not liver and muscle (Cadoudal
et al., 2008). In muscle cells, PPARδ was found to mediate contextual
upregulation of PDK4 (Badin et al., 2012; Feng et al., 2014). Although
AMPK and mTOR are known to respond to low energy conditions, there
are few reports on how these factors may affect the relationship be-
tween PDK4 and fatty acid oxidation e.g. upon starvation. Combined
activation of AMPK and PPARδ caused increased Pdk4 expression in
mouse muscle, and this was associated with increased fat oxidation
during prolonged exercise (Manio et al., 2016). The hypolipidemic
modified fatty acid tetradecylthioacetic acid (TTA) is known to act
through multiple mechanisms to induce mitochondrial fatty acid oxi-
dation in cells and animals, both dependent and independent of PPARs
(Berge et al., 2005; Rost et al., 2009; Grav et al., 2003; Wensaas et al.,
2009). Potential effects of TTA on PDK4 expression have not yet been
reported.
Based on current knowledge, increased PDK4 expression appears to
imply a coordinated metabolic shift from glucose to fatty acids as major
energy fuel. The present study was undertaken to solidify the re-
lationship between PDK4 expression and fatty acid oxidation, by pur-
suing in vivo findings through extensive investigations of context-de-
pendent metabolic functions in living cells.
2. Materials and methods
2.1. Rat model
The rat study was part of a larger study previously reported
(Vigerust et al., 2012). The protocol was approved by the Norwegian
State Board of Biological Experiments with Living Animals. Ten weeks
old male Wistar rats (200–250 g) were obtained from Taconic Europe.
After one week of acclimatization, the control group was fed on high fat
diet (23% lard +2% soybean oil), and treatment group was given the
same diet supplemented with TTA (0.375%) for 50 weeks. The diets
were isocaloric (energetic value 4900 Kcal). Animals were anaes-
thetized and sacrificed under non-fasting condition. Blood was drawn
by cardiac puncture. All tissues were stored in liquid nitrogen before
analysis. Further information is provided in (Vigerust et al., 2012).
2.2. Cell culture
All cell cultures were incubated at 37 °C (5% CO2 in air).
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Compounds and materials were from Sigma-Aldrich (St. Louis, MO,
US), and catalogue numbers refers to products from this company,
unless otherwise stated. MDA-MB-231 and HeLa cells were cultured in
DMEM (4.5 g/l glucose, #D5671) supplemented with 10% heat-in-
activated fetal bovine serum (FBS, #SH30079.03, GE Healthcare
Hyclone), 50 μg/ml penicillin/streptomycin (#P-0781) and 2mM L-
glutamine.
2.3. Overexpression of PPARA and PDK4
For the overexpression of PPARA, a double-stranded DNA fragment
(g-Block) encoding human PPARA and containing BamHI and SalI re-
striction enzymes cutting sites was synthesized by Integrated DNA
Technologies (IDT, Coralville, IA, US). The g-block fragment was then
subcloned into the pBABE-puro (Addgene, plasmid 1764) retroviral
vector with a puromycin resistance gene. An empty pBABE-puro vector
was used as a control. HEK293T packaging cells were transfected with
the retroviral vector and packaging vectors by Lipofectamine-2000
transfection (#11668–019, Thermo Fisher Scientific, Waltham, MA,
US), following the manufacturer's instructions. At 5 h post-transfection,
the medium was replaced with 10ml fresh DMEM supplemented with
10% FBS. Virus were harvested after 24 h post-transfection. For retro-
viral infection, MDA-MB-231 cells were seeded in a 10-cm dish and
infected with virus in the presence of polybrene (8 μg/ml). Cells were
selected by puromycin (2 μg/ml) 48 h post infection.
For the overexpression of PDK4, A MMLV retrovirus gene expression
vector containing PDK4 cDNA (NM_002612) and Bsd, the blasticidine
resistance gene (Kimura et al., 1994) was acquired from VectorBuilder
(VectorBuilder Inc. 150 Pine Forest Drive, Suite 803, Shenandoah, TX
77384). HEK293 derived Phoenix-AMPHO (ATCC® CRL-3213™)
packaging cells were transfected with the retroviral vector by Lipo-
fectamine-2000 transfection, following the manufacturer's instructions.
Stably transfected virus producing packaging cells were selected in
DMEM medium containing 10 μg/ml blasticidin (#ant-bl-05, In-
vivoGen, 5, rue Jean Rodier F-31400 Toulouse, France), as described by
others (Pear et al., 1993). For retroviral infection, MDA-MB-231 cells
were seeded in 6-well plates and infected with virus in the presence of
protamine sulfate (5 μg/ml). Cells were selected by blasticidin (10 μg/
ml) 72 h post infection.
2.4. Cell culture treatment conditions
To investigate long-term effects (6 days) of metabolic modulators,
250,000 cells were plated in T75 flasks and incubated overnight to
allow proper attachment. Final concentrations of 5-aminoimidazole-4-
carboxamide 1-β-D-ribofuranoside (AICAR, 0.5 mM, Toronto Research
Chemicals Inc., North York, ON, Canada), rapamycin (50 nM), tetra-
decylthioacetic acid (TTA, 30 μM and 60 μM, Synthetica AS, Oslo,
Norway), 4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY
14,643, 10 μM) and vehicle (DMSO, 60 μM) were added to respective
flasks. On day 3, the medium was replaced, and treatment continued.
On day 5, the cells were re-plated at optimized cell densities for sub-
sequent analyses the next day (day 6).
2.5. Extracellular flux analysis to study cell metabolism
Extracellular flux analysis was performed with the Seahorse XFe96
Analyzer (Agilent, Santa Clara, CA, US). This simultaneously measures
the oxygen consumption rate (OCR) and extracellular acidification rate
(ECAR) in the medium directly above adherent cells. The experiments
were performed according to standard protocols, and cell number and
compound concentrations were optimized for each cell type. Cells were
seeded in 96-well assay plates (Hela; 20,000, MDA-MB-231; 30,000
cells/80 μl/well) and let adhere overnight (5% CO2 in air, 37 °C). The
next day, growth medium was replaced with assay medium (un-buf-
fered, phenol red-free DMEM, #D5030) supplemented for
mitochondrial respiration assay with 10mM glucose, 2 mM sodium
pyruvate, 4 mM L-glutamine, pH 7.4, and for glycolysis assay with 4mM
glutamine, pH 7.4. After 1 h incubation in the Prep Station (37 °C, CO2-
free, Agilent) the plate was placed in the Seahorse XFe96 Analyzer.
Chemical modulators were injected sequentially to obtain metabolic
flux profiles. For the mitochondrial respiration assay the final con-
centration of the modulators were 3 μM oligomycin, 1 μM CCCP, 1 μM
rotenone and 1 μM antimycin A. For the glycolysis assay, final con-
centrations of 10mM glucose, 3 μM oligomycin and 100mM 2-deox-
yglucose were added.
To study acute effects of palmitic acid (PA) and its modified ana-
logue TTA, the cells (untreated) were seeded according to standard
protocol (described above). The fatty acids (dissolved in DMSO) were
added at specified concentrations (final concentrations: 30, 60, 100 and
200 μM) to the mitochondrial respiration assay medium immediately
before inserting the plate into the Seahorse XFe96 Analyzer.
When relevant, data were normalized to protein content, measured
using the Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific,
Waltham, MA, US).
2.6. Substrate oxidation assay by 14CO2-trapping
Substrate oxidation was assessed by providing the radiolabeled
(14C) substrate of interest to the cells, accompanied by trapping of the
released 14CO2; a technique previously described in (Wensaas et al.,
2007). Cells were seeded in 96-well CellBind® microplates (MDA-MB-
231; 45,000, HeLa; 40,000 cells/well) in DMEM and incubated over-
night to allow proper attachment. The radiolabeled substrate of in-
terest, either [1-14C]pyruvic acid (0.25 μCi/ml), D-[14C(U)]glucose
(2 μCi/ml for MDA-MB-231, 4 μCi/ml for HeLa) or [1-14C]palmitic acid
(1 μCi/ml), all from PerkinElmer (Waltham, MA, US), was given in
DPBS (with MgCl2 and CaCl2, #D8662) supplemented with 10mM
HEPES and 10 μM BSA. L-carnitine (1mM) and glucose (0.5 mM) were
included in the assay medium for palmitic acid oxidation. Respective
amounts of non-radiolabeled substrate were added to obtain final
concentrations of sodium pyruvate (0.2 mM or 2mM), glucose (5mM)
and BSA-conjugated palmitic acid (100 μM), as indicated in the figures.
For uncoupled substrate oxidation, the optimized concentration of
CCCP (1 μM for pyruvate and glucose oxidation, 3 μM for palmitic acid
oxidation) was added to the medium. The optimal CCCP concentration
was higher for palmitic acid oxidation compared to the others due to
the increased amount of BSA, which binds hydrophobic molecules.
Etomoxir (40 μM) was added to selected wells during palmitic acid
oxidation, to monitor the contribution of non-mitochondrial CO2 pro-
duction, which usually was 10–20% of basal activity (data not shown).
The 14CO2 trapping was performed as described (Wensaas et al., 2007).
In brief, an inverted UniFilter®-96w GF/B microplate (PerkinElmer),
activated for CO2 capture with 1M NaOH, was sealed to the top of the
96-well CellBind® cell culture microplate, and incubated for the in-
dicated period of time at 37 °C. Subsequently, scintillation liquid (30 μl,
Ultima Gold XR or MicroScint PS PerkinElmer) was added to the filters
and the filterplate sealed with a TopSealA (PerkinElmer). Radioactivity
was measured using a microplate scintillation counter (TopCount NXT,
Packard, Meriden, CT, US or the MicroBeta2 Microplate Counter, Per-
kinElmer). Protein measurement was performed for data normalization.
The cells were washed twice with PBS, lysed (0.1M NaOH), and mea-
sured using Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific).
2.7. Gene expression by qPCR assays
Gene expression analysis in animal tissues was done as previously
reported (Vigerust et al., 2012; Lindquist et al., 2017; Dyrstad et al.,
2018). RNA was isolated from frozen tissues stored at −80 °C. In cell
culture experiments, the cells were washed with PBS, pelleted and
stored at −80 °C. Cellular RNA was extracted using the RNeasy mini kit
including DNase digestion (RNase-Free DNase) (QIAGEN, Venlo,
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Netherlands). Total RNA (50 ng/μl) was estimated by the use of a Na-
nodrop ND-1000 Spectrophotometer (NanoDrop Technologies, Boston,
MA, US) and reversely transcribed using the Applied Biosystem's High
Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific)
according to manufacturer instructions. All probes were obtained from
Applied Biosystems unless otherwise stated. Probes used were: Acyl-
CoA oxidase 1, (ACOX Human: Hs01074241, Acox Rat: Rn01460628),
Cytochrome c oxidase subunit IV (COX4I1 Human: Hs00971639),
Carnitine palmitoyltransferase 1A (Cpt1a Rat: Rn00580702, CPT1A
Human: Hs00912671), Carnitine palmitoyltransferase 1B (Cpt1b Rat:
Rn00682395), Carnitine palmitoyltransferase 2 (Cpt2 Rat:
Rn00563995), Pyruvate dehydrogenase kinase 4 (Pdk4 Rat:
Rn00585577_m1, PDK4 Human: Hs01037712), Peroxisome proliferator
activated receptor α (PPARA Human: Hs00947536), Malic enzyme-1
(Me-1 Rat: Rn00561502_m1, ME-1 Human: Hs00159110), Mitochon-
drial transcription factor A (Tfam Rat: Rn00580051_m1, TFAM Human:
Hs01082775) and Nuclear respiratory factor (Nrf Rat:
Rn01455960_m1). The reaction mixtures were loaded into a Light-
Cycler® 480 Multiwell Plate 384 (Roche, Basel, Germany) by the Mos-
quito HV® low volume pipetting instrument (TTP Labtech Ltd., UK)
(Dyrstad et al., 2018). The qPCR was run in a LightCycler 480 system
(Roche, Basel, Germany) with the “Dual Color Hydrolysis probe – UPL
Probe 384-11” instrument template-program. The expression level of
each gene was calculated as fold change based on the delta delta Ct
method (Livak and Schmittgen, 2001) and was normalized against 18S
rRNA (Rat: RT-CKFT-18S from Eurogentec, Seraing, Belgium, Human:
Eukaryotic 18S rRNA Endogenous Control, 4310893E).
2.8. Protein expression by western blotting
The cell pellets were lysed in RIPA lysis buffer (#sc24948, Santa
Cruz Biotechnology, Dallas, TX) following the manufactures instruc-
tions. Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific) was
used to measure protein concentration in the lysates. The protein lysate
mixed together with XT Sample Buffer (#1610791, Bio-Rad) were he-
ated at 95 °C for 5min, before 10–12mg protein was loaded per well.
The electrophoresis was done using Mini-PROTEAN® TGX™ Protein
Gels, 4–20% gradient, running buffer (#1610772, Bio-Rad) and Bio-
Rad Mini Protean 3 cell system (90 V for 15min, 110 V for 1 h). The
BioradTurbo Transfer System (2.5A, 25 V, 7min) was used to transfer
(transfer buffer, #1610734, Bio-Rad) the proteins onto the activated
(30 s in metanol) polyvinylidene fluoride (PVDF) membrane (Trans-
Blot® Turbo™Mini-size LF PVDF). The membranes were blocked, for 1 h
in room temperature, in Odyssey Blocking Buffer (TBS) (LI-COR
Biosciences) before labeled with anti-PDK4 antibody (#ab11033,
mouse monoclonal [1C2BG5], Abcam) diluted 1:500 in blocking buffer
overnight at 4 °C. Anti-GAPDH antibody (#60004–1, mouse mono-
clonal, Proteintech) at a dilution of 1:1000 was used as loading control.
After washing in TBS-T buffer the membranes were incubated for 2 h in
IRDye® 800CW Goat anti-Mouse IgG secondary antibody (1:20000)
(#P/N 926–32,210, LI-COR Bioscience). The protein bands were vi-
sualized using the 800 nm IRlong channel in the Amersham Typhoon
Gel and Blot Imaging Systems (GE healthcare). Amersham™ Imager 600
software was used to view and analyze the blot images together with
ImageJ software.
2.9. Live-cell reporter strategy to monitor mitochondrial biogenesis
Mitochondrial biogenesis was measured using a GFP-based live-cell
reporter strategy previously described in (Hodneland Nilsson et al.,
2015). Briefly, a reporter construct (NRF1mitoGFP) with mitoGFP
under the control of a promoter with NRF-1 responsive element was
inserted into HeLa (HeLaNRF1/c4) and MDA-MB-231 (MDA-MB-231/
NRF1) cells. Following the treatment, the cellular expression of mi-
toGFP (fluorescence intensity) was measured as a readout of mi-
tochondrial biogenesis. The cells were treated as indicated for 6 days,
before they were trypsinized, washed with PBS and kept on ice until
analyzed by flow cytometry (AccuriTM C6, BD Accuri Cytometers Inc.,
Ann Arbor, MI, US). The data were analyzed by FlowJo software.
2.10. Plasma lactate and glucose measurements
Biosen C-Line GP+ (EKF Diagnostics, Cardiff, UK) was used to
measure glucose and lactate concentrations in rat plasma, according to
manufacturer's instructions.
2.11. Statistical analysis
All data were analyzed using Graphpad Prism 8 software (Graph-
Pad Software; San Diego, CA, US). Results are shown as mean ± SD.
ANOVA and student's t-test were used to evaluate statistical differences
between the interventions and control. Pearson's correlation coeffi-
cients were used when comparing two independent variables. P < .05
was considered statistically significant.
3. Results
3.1. Pdk4 expression is a sensitive indicator of mitochondrial fatty acid
oxidation in rat tissues
Increased hepatic fatty acid oxidation is established as an important
mechanism behind the hypolipidemic effects of the modified fatty acid
TTA in rats (Berge et al., 2005). In multiple studies, upregulated fatty
acid oxidation has been demonstrated, both based on gene expression
and enzymatic activity, most extensively in liver, but also in heart
(Berge et al., 2005; Vigerust et al., 2012; Oie et al., 2013; Turell, 1989).
In the present study, we used TTA-treatment as a model to evaluate the
relationship between Pdk4 mRNA expression and fatty acid oxidation in
vivo. Gene expression was measured in tissue samples from a previous
experiment in rats, where rats were treated with TTA for 50 weeks
(Vigerust et al., 2012). Pdk4 expression was compared with the ex-
pression of genes related to fatty acid oxidation in liver, heart, skeletal
muscle and white adipose tissue (Fig. 1A, and Supplementary Fig. S1).
In the liver of TTA-treated rats, the level of Pdk4 mRNA increased 18-
fold (18.0 ± 2.6), compared to control rats. This was associated with
increased hepatic expression of Cpt1a (liver isoform, 2.4 ± 0.8), Cpt2
(5.1 ± 1.2), and the classical PPARα target gene Acox (10.1 ± 2.8),
supporting previous findings (Vigerust et al., 2012). Interestingly, TTA-
treatment caused a potent increase in the expression of the muscle
isoform Cpt1b in liver (487.1 ± 195.4), which has not previously been
reported. The hepatic expression of Tfam was increased (2.4 ± 1.1)
suggesting that elements of mitochondrial biogenesis may be involved,
although Nrf1 was not affected. We also analyzed the expression of
cytosolic malic enzyme Me-1 due to its interactions in pyruvate meta-
bolism, as well as fatty acid oxidation by mediating TCA anaplerotism
(Gibala et al., 2000; Carley et al., 2015). TTA-treated rats presented
significantly increased expression of Me-1 in liver (58.0 ± 21.9). In
heart, a moderate induction of Pdk4 (2.5 ± 0.7) was accompanied by
relatively small, but statistically significant, increases in Cpt1b
(1.2 ± 0.1), Acox (1.7 ± 0.3) andMe-1 (1.5 ± 0.3) mRNA levels, and
a small reduction in Tfam (0.8 ± 0.04), whereas the other transcripts
remained unchanged. None of these genes were significantly affected in
skeletal muscle or white adipose tissue in TTA-treated rats compared to
controls. Plasma glucose and lactate levels were measured to evaluate
how this long-term adaptation of oxidative metabolism affected sys-
temic glucose homeostasis (Fig. 1B-C). While no effect was found for
plasma lactate, the plasma glucose levels tended to be slightly lower in
TTA-treated rats compared to controls, although this effect did not
reach statistical significance. In summary, TTA-treated rats presented
regulatory effects on fatty acid oxidation genes in agreement with a
significant induction in liver and a moderate induction in heart, sup-
porting previous measurements (Berge et al., 2005; Oie et al., 2013).
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Importantly, upregulation of fatty acid oxidation was accompanied by
increased Pdk4 expression, generally to a higher magnitude compared
to other genes commonly used as indicators of mitochondrial fatty acid
oxidation.
3.2. Fatty acid oxidation and PDK4 expression are strongly induced by
PPARA-overexpression
As a proof of principle cell model where upregulation of fatty acid
oxidation is expected, we investigated PDK4 mRNA expression in MDA-
MB-231 cells modified to overexpress PPARA (MDA-MB-231/PPARA,
Fig. 2). Based on our previous experience with various cell models, the
MDA-MB-231 line was chosen as the primary model due to its active
oxidative metabolism, and the observation that these cells present a
significant increase in fatty acid oxidation under relevant conditions.
Several of the experiments were also repeated with HeLa cells, which
we commonly find to display similar metabolic effects as MDA-MB-231,
albeit often less pronounced.
The mRNA level of PPARA was 82.3 ± 14.4-fold higher in the
MDA-MB-231/PPARA cells, compared to the parental cells.
Noteworthy, this caused a 24.9 ± 1.8-fold increase in PDK4 mRNA
level, and upregulation of genes involved in fatty acid catabolism such
as ACOX (51.0 ± 12.5), CPT1A (2.3 ± 0.1), COX4I1 (1.9 ± 0.05)
and ME-1 (2.0 ± 0.03) (Fig. 2A). The expression of the mitochondrial
transcription factor TFAM was slightly reduced (0.7 ± 0.04) in the
MDA-MB-231/PPARA cells, suggesting that the increased expression of
these mitochondrial enzymes was not linked to increased mitochondrial
biogenesis.
To investigate if PPARA overexpression caused a metabolic fuel
change, we measured glucose and fatty acid oxidation by trapping
14CO2 produced under incubation with the respective radiolabeled
substrates. Fatty acid oxidation was increased nearly three-fold in the
MDA-MB-231/PPARA cells compared to the parental cells (Fig. 2B). In
the same cells, glucose oxidation was reduced by 20%, when glucose
was provided as the major substrate (Fig. 2C). These data support the
notion that PDK4 expression and fatty acid oxidation are co-regulated
by PPARα, leading to an overall metabolic shift towards increased
oxidation of fatty acid instead of glucose.
3.3. PDK4 overexpression leads to increased fatty acid oxidation
The increase in PDK4 expression may occur as a parallel effect be-
sides the stimulated fatty acid oxidation, or it may be a causative factor
of the metabolic shift. To address this question, we investigated the
effects of PDK4 overexpression in MDA-MB-231 cells (i.e. MDA-MB-
231/PDK4 cells). The levels of PDK4 mRNA and protein were low in the
parental cells, and the increased amounts in the modified cells con-
firmed successful overexpression (Fig. 3A-B). Although the PDK4 anti-
body gave weak band intensity, the immunoblot showed increased level
in PDK4-overexpressing cells (Fig. 3B). We then investigated if this
leads to reduced pyruvate oxidation, which would be the expected
consequence of PDK4-mediated inhibition of the PDH complex. Fol-
lowing incubation in high glucose environment (25mM), pyruvate
oxidation was 32% reduced in the MDA-MB-231/PDK4 cells (borderline
statistical significance), compared to the parental cells (Fig. 3C). This
activity was stimulated in both cell types when grown in low glucose
compared to high glucose medium, but pyruvate oxidation remained
lower in the MDA-MB-231/PDK4 compared to the parental cells. No-
teworthy, fatty acid oxidation was 74% increased in PDK4 over-
expressing cells compared to parental cells when grown in 25mM
glucose, but the difference disappeared following growth in 1mM
glucose, primarily due to a significant increase in the parental cells
(Fig. 3D). These data strongly support that there is a tight causative
relationship between PDK4 and fatty acid oxidation. Apparently, PDK4
overexpression lead to a shift towards fasting-type energy metabolism
even in a high glucose environment. Hence, the differences between
parental and PDK4 overexpressing cells were smaller following growth
in a low glucose environment, since this significantly enhanced fatty
acid oxidation in the parental cells but not to the same extent in PDK4-
overexpressing cells.
Fig. 1. Pdk4 expression and metabolic adaptation in TTA-treated rats.
Rats were administered control (CTR) or TTA-supplemented diet for 50weeks (Vigerust et al., 2012). (A) Gene expression in liver, heart, skeletal muscle and white
adipose tissue (WAT) was measured using real time quantitative PCR. The heat map indicates mean expression level relative to control (ddCT method, detailed data
in Supplementary Fig. S1). (B) Glucose and (C) lactate concentrations in plasma from the CTR and TTA fed rats. Each dot represent one animal and group mean ± SD
(n=8–10) is indicated. Statistical analysis was performed by t-test. *p < .05, p-values are shown in (B) and (C). TTA, tetradecylthioacetic acid.
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3.4. Increased PDK4 expression reflects upregulated fatty acid oxidation
under conditions of metabolic adaptation
In order to investigate the relationship between fatty acid oxidation
and PDK4 expression in different contexts of metabolic adaptation, we
studied the effects of long-term (6 days) treatment with TTA and se-
lective activators of AMPK (AICAR) and PPARα (WY 14,643) in MDA-
MB-231 cells. The mRNA level of CPT1A, which often is used as an
indicator of mitochondrial fatty acid oxidation, was lower after treat-
ments with AICAR and WY 14,643, compared to control, but increased
approximately two-fold in cultures treated with 30 μM or 60 μM TTA
(Fig. 4A). The effect of TTA on PDK4 expression was of significantly
higher magnitude (7.3 ± 0.3 at 30 μM TTA, 12.2 ± 1.2 at 60 μM TTA)
compared to CPT1A. AICAR treatment caused reduced PDK4 expres-
sion, whereas WY 14,643 had no effect. None of the agents were found
to induce the mRNA expression of the classical PPARα-target ACOX in
these cells. Only AICAR induced the expression of TFAM (2.7 ± 0.1),
suggesting that this treatment, in contrast to the others, causes activa-
tion of mitochondrial biogenesis. Replication of this experiment with
Hela cells supported that TTA, but not AICAR and WY 14,643, caused
moderate upregulation of CPT1A simultaneous with a strong induction
of PDK4 (Supplementary Fig. S2). HeLa cells tended to have a mild
upregulation of TFAM and ACOX expression for all the treatments ex-
cept for 60 μM TTA.
The highest concentration of TTA (60 μM) caused a 4-fold increase
in basal fatty acid oxidation in MDA-MB-231 cells, and the effect was
slightly less with the lower concentration (30 μM) (Fig. 4B). In our
experience, functional changes of this magnitude in cell metabolism are
rarely observed in living cell cultures. AICAR and WY 14,643 did not
affect fatty acid oxidation in these cells. Additional measurements in
presence of the mitochondrial uncoupler carbonyl cyanide 3-chlor-
ophenylhydrazone (CCCP) showed that the maximal fatty acid oxida-
tion capacity was approximately two-fold increased in the TTA-treated
cells (for both TTA concentrations). Enhanced fatty acid oxidation in
TTA-treated cells was not found to be accompanied by a reciprocal
reduction in basal glucose oxidation, yet there was a moderate decrease
in AICAR-treated cells (Fig. 4C). We then measured pyruvate oxidation
in order to obtain a more direct assessment of mitochondrial oxidation,
disconnected from the potential rate-limiting influence of glycolysis.
Basal pyruvate oxidation tended to be reduced after treatment with
60 μM TTA, with as significant 30% reduction under uncoupling con-
ditions (Fig. 4D). Similar effects were seen in HeLa cells after treatment
with AICAR, WY 14,643 or TTA (Supplementary Fig. S2). In summary,
metabolic adaptation involving induced fatty acid oxidation was ac-
companied by strongly increased PDK4 mRNA expression in these cell
models. This effect was observed after treatment with TTA known to
regulate multiple energy-sensitive mechanisms, but not with selective
activators of AMPK (AICAR) or PPARα (WY 14,643), under these
Fig. 2. Effect of PPARA overexpression on PDK4 expression and fuel oxidation.
The effects of increased PPARA expression were investigated in MDA-MB-231 cells. The figure compares the unmodified (231 Parental) and PPARA overexpressing
(231 PPARA) cells. (A) Expression of PPARA, PDK4, CPT1A, ACOX, TFAM, COX4I1 and ME-1, measured using real time quantitative PCR. The diagrams show mRNA
expression relative to the CTR group (ddCT method), as mean ± SD of triplicate measurements. (B) Fatty acid oxidation; 14CO2-production during 4 h incubation
with [1-14C]palmitic acid (1 μCi/ml, 100 μM), in presence of L-carnitine (1mM) and glucose (0.5mM). (C) Glucose oxidation; 14CO2-production during 4 h incubation
with D-[14C(U)]glucose (2 μCi/ml, 5 mM). The oxidation data are normalized to cell protein content (mg), and are displayed as mean ± SD of 4–8 replicates. The
pathway illustrations show the carbon flux fueled by the 14C-labeled substrates. The filled and open circles represent radiolabeled (filled, 14C) and non-labeled (open)
carbons, released as CO2 under the respective conditions. The shown experiments are representative for three separate experiments. Statistical analysis was per-
formed by t-test. *p < .05, **p < .01, ***p < .001, ****p < .0001.
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experimental conditions.
A previously established genetic reporter strategy was utilized to
further evaluate the potential role of mitochondrial biogenesis under
these conditions (Hodneland Nilsson et al., 2015). The reporter con-
struct consists of a gene for mitochondrial GFP under the control of a
responsive element of NRF1, which is a central nuclear transcription
factor controlling expression of mitochondrial proteins. Single cell
analysis was performed by flow cytometry in HeLa and MDA-MB-231
cells containing the reporter construct, following treatments with
AICAR, WY 14,643 or TTA (Fig. 4E). Only AICAR was found to have a
significant effect on mitochondrial biogenesis in HeLa cells, and this
agreed with the findings in MDA-MB-231 cells (borderline statistical
significance). This effect of AICAR was also previously observed in HeLa
cells (Hodneland Nilsson et al., 2015). Both the genetic reporter results
and the TFAM expression data indicated that the fuel shift from glucose
to fatty acids occurs without simultaneous induction of mitochondrial
biogenesis in these cell types. Western blot analysis supported that
PDK4 protein abundance was increased following treatment with TTA,
but not WY 14,643, in HeLa cells (Fig. 4F).
3.5. Effects of metabolic adaptation on mitochondrial respiration and
glycolysis
To investigate if increased fatty acid oxidation was associated with
changes in mitochondrial respiration, we measured oxygen consump-
tion rate (OCR) in MDA-MB-231 cells after long-term (6 days) treatment
with AICAR, WY 14,643 or TTA, and upon overexpression of PPARA
(Fig. 5). Following measurement of the basal respiratory rate, we as-
sessed descriptors of mitochondrial function through sequential addi-
tions of pharmacological modulators. Leak respiration rate was ob-
tained after addition of oligomycin (ATP synthase inhibitor), and
subsequently CCCP was administered to measure uncoupled respiratory
capacity. Rotenone (respiratory complex I inhibitor) was then added,
followed by antimycin A (respiratory complex III inhibitor) to assess
non-mitochondrial activity (residual oxygen consumption, background
activity). Interestingly, the basal respiratory rates were similar among
the different conditions of metabolic adaptation (AICAR, WY 14,643,
TTA and PPARA overexpression), and compared to respective controls
(untreated and DMSO (vehicle)), with a minor increase in cultures
treated with WY 14,643 and 60 μM TTA. Leak respiration was increased
2–3-fold in the TTA treated cultures compared to control (DMSO),
Fig. 3. Effect of PDK4 overexpression in pyruvate and fatty acid oxidation.
The effects of PDK4 overexpression were investigated in MDA-MB-231 cells. The figure compares the unmodified (231 Parental) and PDK4 overexpressing (231
PDK4) cells. (A) Confirming overexpression of PDK4 using real time quantitative PCR. The mRNA expression level is displayed relative to the 231 Parental cells (ddCT
method) as mean ± SD of triplicate measurements, and is representative for two separate experiments. (B) Increased PDK4 protein expression was confirmed by
Western blot analysis. (C-D) Pyruvate and fatty acid (palmitic acid) oxidation was measured following overnight pre-incubation in medium with 1mM or 25mM
glucose. (C) Pyruvate oxidation; 14CO2-production during 4 h incubation with [1-14C]pyruvic acid (0.25 μCi/ml, 0.2 mM), in presence of glucose (0.5 mM). (D) Fatty
acid oxidation; with [1-14C]palmitic acid (1 μCi/ml, 100 μM), in presence of L-carnitine (1mM) and glucose (0.5mM). The oxidation data are normalized to cell
protein content (mg) and are displayed as mean ± SD of 4–8 replicates, from one representative of three separate experiments. The pathway illustrations show
carbon flux fueled by the 14C-labeled substrates. The filled and open circles represent radiolabeled (filled, 14C) and non-labeled (open) carbons released as CO2 under
the respective conditions. Statistical analysis was performed by t-test. *p < .05, **p < .01, ***p < .001, ****p < .0001.
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Fig. 4. PDK4 expression and fatty acid oxidation in contexts of metabolic adaptation.
MDA-MB-231 were treated for 6 days with AICAR (0.5mM), WY 14,643 (10 μM) or TTA (30 μM or 60 μM). Control cultures were untreated (UNTR, for AICAR) or
DMSO-treated (DMSO, for WY 14,643 and TTA). (A) Real time quantitative PCR analysis of TFAM, ACOX, CPT1A and PDK4. The diagrams show mRNA expression
relative to the control group (ddCT method), as mean ± SD of triplicate measurements. (B-D) Substrate oxidation was assessed by measuring 14CO2-production
during 4 h incubation with the respective radiolabeled substrate, in the absence and presence of an uncoupler (CCCP). (B) Fatty acid oxidation; with [1-14C]palmitic
acid (1 μCi/ml, 100 μM), in presence of L-carnitine (1mM) and glucose (0.5 mM). (C) Glucose oxidation; with D-[14C(U)]glucose (2 μCi/ml, 5 mM). (D) Pyruvate
oxidation; with [1-14C]pyruvic acid (0.25 μCi/ml, 2 mM). CCCP concentrations were 1 μM for glucose and pyruvate oxidation, and 3 μM for palmitic acid oxidation
(higher due to the increased BSA concentration). The oxidation data are normalized to cell protein content (mg) and shown as mean ± SD of 4–8 replicates. The
pathway illustrations show the carbon flux fueled by the 14C-labeled substrates. The filled and open circles represent radiolabeled (filled, 14C) and non-labeled (open)
carbons, released as CO2 under the respective conditions. (E) Measurement of mitochondrial biogenesis using a GFP-based reporter construct in HeLa and MDA-MB-
231 cells. The reporter cells were treated before mitoGFP was detected by flow cytometry (10,000 cells per sample). (F) Western blot analysis of PDK4 in HeLa cells
treated for 6 days with TTA (30 μM or 60 μM) or WY 14,643 (10 μM). All diagrams display representative data as, mean ± SD, for three separate experiments.
Statistical analysis was performed by t-test. *p < .05, **p < .01, ***p < .001, ****p < .0001.
Fig. 5. Analysis of mitochondrial respiration and glycolysis.
Oxygen consumption rate (OCR) and extracellular acidification rates (ECAR) were measured in MDA-MB-231 cells after 6 days treatment with AICAR (0.5mM), WY
14,643 (10 μM) and TTA (30 μM or 60 μM), and in cells overexpressing PPARA. Control cultures were untreated (UNTR, for AICAR and PPARA) or DMSO-treated
(DMSO, for WY 14,643 and TTA) cells. (A) Representative traces of OCR (pmol O2/min/μg protein). Following measurement of basal respiration (BASAL), specific
modulators were added as indicated: 3 μM oligomycin to obtain leak respiration (LEAK), 1 μM CCCP to access uncoupled respiration (UNC), 1 μM rotenone to
measure rotenone-resistant respiration (ROT) and 1 μM antimycin A to measure residual oxygen consumption (ROX). (B) Data extracted from the analyses in A, after
subtraction of non-mitochondrial activity (ROX). (C) Analysis of functional integrity of mitochondria. Rates of interest calculated as % of basal OCR. (D)
Representative traces of ECAR (mpH/min/μg protein). The specific modulators were added following measurement of endogenous activity (ENDOG), as indicated:
10mM glucose (GLC) to obtain basal glycolysis (BASAL), 3 μM oligomycin to assess glycolytic capacity (CAP) and 100mM 2-deoxyglucose (2DG) to measure non-
glycolytic activity (non-Glyc). (E) Data extracted from the analyses in D. (F) Analysis of glycolytic function. Rates of interest calculated as % of basal ECAR. Data are
displayed as mean ± SD of 6–8 replicates, from one representative of three separate experiments Statistical analysis was performed by ANOVA. *p < .05,
**p < .01, ***p < .001, ****p < .0001.
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apparently in a concentration-dependent manner. The uncoupled re-
spiratory capacity was not significantly affected by AICAR, TTA or
PPARA-overexpression, however, WY 14,643 caused approximately
20% increase compared to the control (DMSO) (Fig. 5B). Calculating
these data as percentage of the basal respiratory rate (Fig. 5C) revealed
that TTA significantly increased the fraction of oxygen consumption
associated with leak respiration, and therefore caused a congruent de-
crease in ATP-linked respiration. The effects of the treatments on the
relative respiratory capacity (uncoupled) were generally negligible,
while TTA significantly reduced the reserve capacity. The findings were
reproduced in HeLa cells (Supplementary Fig. S3). In summary, the
highly increased fatty acid oxidation rate observed after treatment with
TTA and upon overexpression of PPARA was not associated with major
changes in basal mitochondrial respiration. However, TTA led to effects
consistent with mild uncoupling, which may represent an additional
mechanism contributing to metabolic adaptations.
Analysis of glycolytic function was performed by monitoring ex-
tracellular acidification rate (ECAR) following sequential additions of
glucose to obtain basal respiratory rate, oligomycin to measure glyco-
lytic capacity, and 2-deoxyglucose to determine non-glycolytic activity
(Fig. 5D). There was a general reduction in normalized ECAR after
treatment with AICAR and WY 14,643 in MDA-MB-231 cells (Fig. 5E),
but upon additions of glucose and upon addition of oligomycin, the
relative rates were similar to control (Fig. 5F), suggesting that glyco-
lysis was modulated as normal under these conditions. No change in
glycolytic activity was found in PPARA-overexpressing cells, compared
to control cells. TTA-treated cells were also similar to control, but had a
relatively high non-glycolytic acidifying component, displayed both
before addition of glucose and after addition of 2-deoxyglucose. The
TTA-treated cells tended to have slightly reduced reserve glycolytic
capacity, and this was statistically significant in the cultures treated
with 60 μM TTA (Fig. 5F). Similar findings were obtained in HeLa cell
cultures, where TTA also caused a statistically significant increase in
normalized basal glycolysis (Supplementary Fig. S3). In summary, the
effects of metabolic modulators on glycolysis did not demonstrate a
strong correlation with the changes in fatty acid oxidation under these
conditions.
3.6. Mild uncoupling may contribute to increased fatty acid oxidation upon
TTA-treatment
Based on the obtained data suggesting an uncoupling effect of TTA
on mitochondrial respiration, we designed an experiment to investigate
if TTA may mediate such effects through an acute mechanism. TTA was
compared with palmitic acid, a normal saturated fatty acid, when
added at different concentrations to MDA-MB-231 cells immediately
before OCR analysis (Fig. 6A-B). Acute uncoupling activity could then
be detected as an increase in leak respiration after addition of oligo-
mycin. The data clearly demonstrated that TTA, but not palmitic acid,
caused a concentration-dependent increase in leak respiration (Fig. 6C).
Both TTA and palmitic acid caused a minor concentration-dependent
decrease in uncoupled respiration after addition of CCCP (Fig. 6D). The
uncoupling property of TTA was found to be relatively mild, as the
highest concentration of 200 μM, which exceeds the normally tolerable
concentration for cell survival, caused approximately 30% uncoupling
compared to full uncoupling mediated by 1 μM CCCP (Fig. 6E). These
findings were also reproduced in HeLa cells (Supplementary Fig. S4).
Our data suggest mild uncoupling as a new mechanism of TTA, which
induces an additional energy stress likely to influence and accentuate
effects on nutrient-sensitive fueling pathways to support energy
homeostasis. Such a mechanism may explain the effects related to the
changed energy state previously observed in rat liver (Grav et al.,
2003).
3.7. PDK4 expression reports synergistic effects of TTA and rapamycin on
fatty acid oxidation
Rapamycin, an inhibitor of mTOR, has previously been found to
increase fatty acid oxidation (Sipula et al., 2006). Further, studies in rat
hepatocytes have linked the effects of TTA to regulation of mTOR
(Hagland et al., 2013). To investigate if mTOR inhibition influences
TTA-mediated metabolic adaptation, we treated MDA-MB-231 with
TTA and rapamycin, separately and in combination. Rapamycin alone
did not affect mRNA expression of CPT1A and PDK4. In combination
with TTA, however, the levels of both these mRNAs were significantly
higher than in cells treated with TTA alone (Fig. 7A-B). Exactly the
same pattern was seen on rates of fatty acid oxidation, both under basal
and uncoupled conditions (CCCP) (Fig. 7C). Further, we performed
correlation analysis of PDK4 and CPT1A expression relative to fatty acid
oxidation, with data from different conditions of metabolic adaptation
(Fig. 7D). Expression of PDK4 and CPT1A was found to correlate
strongly with each other, and with fatty acid oxidation activity. These
data support a tight regulatory and functional relationship between
PDK4 expression and fatty acid oxidation in different metabolic con-
texts. An advantage of using PDK4, above CPT1A, as an indicator of
fatty acid oxidation would be the significantly higher magnitude of
induction, and therefore a larger dynamic range and higher sensitivity.
4. Discussion
This study shows that upregulated PDK4 mRNA expression is
strongly associated with increased activity of mitochondrial fatty acid
oxidation in metabolically adapted cells and rat tissues. Overall, we
found good correlation between the relative magnitude of PDK4 upre-
gulation and the accompanying increase in fatty acid oxidation. Based
on these findings, we suggest that PDK4 mRNA expression may be used
as a sensitive surrogate marker for changes in mitochondrial fatty acid
oxidation when investigating (pato)physiological adaptations of energy
metabolism.
The activity of mitochondrial fatty acid oxidation is influenced by
many factors, including diet, physical activity, toxic exposure, epige-
netics and mutations. An unhealthy impact on fatty acid oxidation
could lead to suboptimal energy balance, energy deficiency, excessive
lipid storage and metabolic stresses, which ultimately contribute to
pathogenesis both at an organ and systemic level (Adeva-Andany et al.,
2018). On the other hand, metabolic adaptations may have positive
impact, for instance in response to endurance training which increases
the capacity of mitochondrial fatty acid oxidation to accommodate the
elevated demands of energy (ATP) (Booth et al., 2015). In the labora-
tory, mitochondrial fatty acid oxidation may be assessed by measuring
the products formed when radiolabeled fatty acid substrates are pro-
vided to intact cells or fresh preparations (extracts, homogenates) of
cell cultures or tissues (e.g. (Wensaas et al., 2007)). However, such
methods are often inaccessible, or incompatible with regards to the
available sample material. Measurement of surrogate markers, such as
mRNA expression of relevant genes, may therefore represent an at-
tractive strategy to study regulatory effects on fatty acid oxidation. As
far as we know, there is no consensus to which gene targets that are
optimal for serving as expression reporters of a metabolic shift invol-
ving increase in fatty acid oxidation. As for enzymes of the fatty acid
oxidation machinery, the changes in mRNA expression are often found
subtle and with complex cell-type specific regulation. Therefore, we
investigated PDK4 expression as a possible candidate for such purpose,
under conditions of metabolic adaptation driven by different regulatory
programs involving AMPK, PPARs and mTOR, which are relevant for
mechanisms of exercise, starving, obesity and contexts of defective
metabolism.
In rats that were treated with TTA for 50 weeks, we found sig-
nificantly increased expression of Pdk4 particularly in liver, and to
some extent in heart, but not in skeletal muscle and white adipose tissue
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(WAT). This parallels well with increased rates of mitochondrial fatty
acid oxidation especially in liver, and also in heart tissue, of TTA-
treated rats (Berge et al., 2005; Oie et al., 2013). In addition, we found a
pronounced increase in the muscle isoform Cpt1b in liver, yet only a
minor increase in heart, and no detectable effect in muscle and WAT.
TTA also caused significantly increased Me-1 expression in rat liver,
supporting that strengthened TCA anaplerotism contributes to the
adaptation of high mitochondrial fatty acid oxidation rates (Gibala
et al., 2000; Carley et al., 2015). These data underscore the importance
of context- and tissue-specific influences on gene regulation associated
with the fatty acid oxidation machinery. Interestingly, PDK4 upregu-
lation was consistently presented under conditions of increased fatty
acid oxidation in our studies, both in vivo and in vitro.
In cultured MDA-MB-231 cells, we found highly increased PDK4
expression accompanying enhanced mitochondrial fatty acid oxidation
upon PPARA-overexpression and after long-term treatment with TTA.
Congruently, PDK4-overexpression caused reduced pyruvate oxidation
simultaneously with increased fatty acid oxidation when the cells were
grown in high glucose. When transferred to low glucose conditions,
fatty acid oxidation in the parental cells increased to the same level as
the PDK4-overexpressing cells. This supports the theory that increased
PDK4 expression contributes to fasting/starving-type metabolism with
stimulated fatty acid oxidation (Wu et al., 2000), and our findings
suggest that this program is constitutively active in the PDK4–overex-
pressing cells. Hence, there is strong evidence for a tight regulatory and
functional relationship between PDK4 and the fatty acid oxidation
pathway. Direct activation of PPARα with WY-14,643 had no effect on
fatty acid oxidation in MDA-MB-231 cells, possibly due to a low en-
dogenous amount of this transcription factor, since overexpression
caused classical effects on cellular gene expression and metabolism. The
AMPK activator AICAR induced TFAM expression, suggestive of in-
creased mitochondrial biogenesis as previously observed in HeLa cells
(Hodneland Nilsson et al., 2015); however, there was no effect on mi-
tochondrial fatty acid oxidation. On the contrary, AICAR had a sup-
pressive effect on CPT1A and PDK4 expression. This is compatible with
previous findings in rat adipose tissue (Wan et al., 2010), but not in
skeletal muscle (Merrill et al., 1997). Interestingly, in addition to the
known function as panPPAR activator, TTA was found to act directly as
a mild mitochondrial uncoupler, which may contribute to the changed
energy state previously observed in rat liver (Grav et al., 2003). In that
study, reduced mitochondrial membrane potential was found in rat
liver after treatment with TTA, however, it remained unclear if this
could be a direct or indirect mechanism. Due to the acute effects in our
present cell culture study, it seems likely that TTA has a direct un-
coupling effect on the mitochondrial inner membrane.
Inhibition of mTOR by rapamycin did not induce fatty acid oxida-
tion or PDK4 expression in MDA-MB-231 cells, but it accentuated the
effects of TTA, suggesting that mTOR can act together with other
pathways of metabolic adaptation in a context-dependent manner. In
support, mTOR has been found to be regulated by the level of PDK4 in
Fig. 6. TTA exerts mild uncoupling activity.
Oxygen consumption rate (OCR) was measured in MDA-MB-231 cells immediately after administration palmitic acid (PA) or tetradecylthioacetic acid (TTA), at
concentrations of 30–200 μM. (A-B) Representative traces of OCR as % of initial rate (BASAL), in presence of PA or TTA. Specific modulators were added as indicated:
3 μM oligomycin to obtain leak respiration (LEAK), 1 μM CCCP to access uncoupled respiration (UNC), 1 μM rotenone to measure rotenone-resistant respiration
(ROT) and 1 μM antimycin A to measure residual oxygen consumption (ROX). (C) LEAK respiration and (D) UNCOUPLED respiration shown as % of basal OCR. (E)
Uncoupling activity mediated by PA and TTA, compared to complete uncoupler, CCCP (100%). The agent-induced LEAK rate (i.e. LEAKX - LEAKCTR) was calculated
relative to the CCCP-induced LEAK rate (i.e. UNCCCCP-LEAKCTR). Data are displayed as mean ± SD of 6–8 replicates, from one representative of three separate
experiments. Statistical analysis was performed by ANOVA. *p < .05, **p < .01, ***p < .001, ****p < .0001.
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cultured cells (Liu et al., 2014). In separate experiments, we found the
effects in HeLa cells to be similar to the observations in MDA-MB-231
cells.
A rather striking observation was the minor changes regarding mi-
tochondrial respiration and lactate production under basal cell culture
assay conditions, despite the pronounced changes in metabolic fuel
utilization indicated by increased fatty acid oxidation. This suggests
that the increase in fatty acid oxidation did not change the activity
balance between mitochondrial respiration and glycolysis, but rather a
change in substrate preference serving to maintain the supply of acetyl-
CoA for the TCA cycle. This type of cellular metabolic adaptation is
likely to affect properties of metabolic flexibility and associated stress
mechanisms, and therefore the susceptibility for changes in nutrient
supply. The present study primarily investigated metabolic effects
under standard cell culture conditions, which includes high glucose
concentration (normally 25mM in DMEM), and favorable effects on
glycolysis are expected to occur under such conditions. The dependency
on mitochondrial oxidative metabolism following relevant adaptations
of fuel utilization may be addressed further e.g. by reducing the amount
of glucose, or replacing glucose with galactose in the culture medium
(Arroyo et al., 2016).
Systemic and cellular nutrient-sensitive mechanisms in the body
Fig. 7. Synergistic effects of TTA and rapamycin on fatty acid oxidation.
MDA-MB-231 were treated for 6 days with TTA (30 μM) or rapamycin (50 nM, RAP), separately and in combination. (A) CPT1A and (B) PDK4 expression was
measured using real time quantitative PCR as mean ± SD of triplicate measurements. (C) Fatty acid oxidation was assessed by measuring 14CO2-production during
4 h incubation with [1-14C]palmitic acid (1 μCi/ml, 100 μM) in presence of L-carnitine (1mM) and glucose (0.5 mM), with and without an uncoupler (3 μM CCCP).
The oxidation data are normalized to cell protein content (mg). The pathway illustrations show the carbon flux fueled by the 14C-labeled palmitic acid. The filled and
open circles represent radiolabeled (filled, 14C) and non-labeled (open) carbons, released as CO2 under the respective conditions. (D) Correlation analysis (Spearman)
of data obtained from multiple conditions of metabolic adaptation. PDK4 mRNA expression was analyzed relative to fatty acid oxidation and CPT1A expression. The
oxidation data are shown as mean ± SD of 4–8 replicates, from one representative for three separate experiments. Statistical comparisons was performed by ANOVA.
*p < .05, **p < .01, ***p < .001, ****p < .0001.
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interact to mediate adaptations to changed metabolic needs or condi-
tions (e.g. due to activity or diet). For instance, increased release of free
fatty acids from adipose tissue under fasting would be expected to in-
fluence metabolism in relevant tissues, partly through ligand activation
of PPARs. The effects of such events will vary depending on tissue and
cell type. Therefore, it was interesting to find that increased PDK4 ex-
pression was a rather consistent sign of increased fatty acid oxidation
throughout this study. Measuring PDK4 may be relevant in clinical in-
vestigations, as exemplified by the finding that upregulated PDK4 ex-
pression in blood cells was associated with impaired PDH function in
ME/CFS patients (Fluge et al., 2016), which may involve adaptations of
fatty acid oxidation (Naviaux et al., 2016; Germain et al., 2017). Fur-
thermore, diurnal variation in PDK4 expression in blood cells was re-
cently reported to be associated with plasma free fatty acid levels,
supporting that this mirrors an important aspect of metabolic fuel
switching (Yamaguchi et al., 2018). Hence, based on these findings, and
supported by the current literature, upregulated PDK4 expression ap-
pears as a sensitive marker for metabolic adaptations involving in-
creased rates of mitochondrial fatty acid oxidation.
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Supplementary Fig. S1. Gene expression associated with fatty acid oxidation in TTA-treated rats.  
Gene expression was analyzed in liver, heart, skeletal muscle and white adipose tissue (WAT) from rats 
administered control (CTR) or TTA-supplemented diet for 50 weeks (Vigerust et al, 2012, J Nutr Biochem 23, 
1384-1393), using real time quantitative PCR. The data are shown as mRNA expression relative to the CTR group 
(ddCT method).Data are shown as mean ± SD (n = 8-10). Statistical analysis was performed by t-test. *p< .01 
 
 
Supplementary Fig. S2. PDK4 expression and fatty acid oxidation in contexts of metabolic adaptation.  
HeLa were treated for 6 days with AICAR (0.5 mM), WY 14,643 (10 µM) or TTA (30 µM or 60 µM). Control 
cultures were untreated (UNTR, for AICAR) or DMSO-treated (DMSO, for WY 14,643 and TTA). (A) Real time 
quantitative PCR analysis of TFAM, ACOX, CPT1A and PDK4. The diagrams show mRNA expression relative to 
the control group (ddCT method), as mean ± SD of triplicate measurements. (B-D) Substrate oxidation was 
assessed by measuring 14CO2-production during 2h incubation with the respective radiolabeled substrate, in the 
presence and absence of uncoupler (CCCP). (B) Fatty acid oxidation; with [1-14C]palmitic acid (1 µCi/ml, 100 
µM) in presence of L-carnitine (1 mM) and glucose (0.5 mM). (C) Glucose oxidation; with D-[14C(U)]glucose (4 
µCi/ml, 5 mM). (D) Pyruvate oxidation; with [1-14C]pyruvic acid (0.25 µCi/ml, 2 mM). CCCP concentrations 
were 1 μM for glucose and pyruvate, and 3 μM for palmitic acid oxidation. The oxidation data are normalized to 
cell protein content (mg), calculated relative to the respective control, and shown as mean ± SD of 4-8 replicates. 
The pathway illustrations show the carbon flux fueled by the 14C-labeled substrates. The filled and open circles 
represent radiolabeled (filled, 14C) and non-labeled (open) carbons, released as CO2 under the respective 
conditions. All figures display representative data as, mean ± SD, from one representative of three separate 




Supplementary Fig. S3. Analysis of mitochondrial respiration and glycolysis.  
Oxygen consumption rate (OCR) and extracellular acidification rates (ECAR) were measured in HeLa cells after 
6 days treatment with AICAR (0.5 mM), WY 14,643 (10 µM) and TTA (30 µM or 60 µM). Control cultures were 
untreated (UNTR, for AICAR) or DMSO-treated (DMSO, for WY 14,643 and TTA) cells. (A) Representative 
traces of OCR (pmol O2/min/µg protein). Following measurement of basal respiration (BASAL), specific 
modulators were added as indicated: 3 µM oligomycin to obtain leak respiration (LEAK), 1 µM CCCP to access 
uncoupled respiration (UNC), 1 µM rotenone to measure rotenone-resistant respiration (ROT) and 1 µM antimycin 
A to measure residual oxygen consumption (ROX). (B) Data extracted from the analyses in A, after subtraction of 
non-mitochondrial activity (ROX). (C) Analysis of functional integrity of mitochondria. Rates of interest 
calculated as % of basal OCR. (D) Representative traces of ECAR (mpH/min/µg protein). The specific modulators 
were added following measurement of endogenous activity (ENDOG), as indicated: 10 mM glucose (GLC) to 
obtain basal glycolysis (BASAL), 3 µM oligomycin to assess glycolytic capacity (CAP) and 100 mM 2-
deoxyglucose (2DG) to measure non-glycolytic activity (non-Glyc). (E) Data extracted from the analyses in D. 
(F) Analysis of glycolytic function. Rates of interest calculated as % of basal ECAR. Data are displayed as mean 
± SD of 6-8 replicates, from one representative of three separate experiments. Statistical analysis was performed 







Supplementary Fig. S4. TTA exerts mild uncoupling activity. 
Oxygen consumption rate (OCR) was measured in MDA-MB-231 cells immediately after administration palmitic 
acid (PA) or tetradecylthioacetic acid (TTA), at concentrations of 30 -200 µM. (A-B) Representative traces of 
OCR as % of initial rate (BASAL), in presence of PA or TTA. Specific modulators were added as indicated: 3 µM 
oligomycin to obtain leak respiration (LEAK), 1 µM CCCP to access uncoupled respiration (UNC), 1 µM rotenone 
to measure rotenone-resistant respiration (ROT) and 1 µM antimycin A to measure residual oxygen consumption 
(ROX). (C) LEAK respiration and (D) UNCOUPLED respiration shown as % of basal OCR. (E) Uncoupling 
activity mediated by PA and TTA, compared to complete uncoupler, CCCP (100 %). The agent-induced LEAK 
rate (i.e. LEAKX - LEAKCTR) was calculated relative to the CCCP-induced LEAK rate (i.e. UNCCCCP-LEAKCTR). 
Data are displayed as mean ± SD of 6-8 replicates, from one representative of three separate experiments. 
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